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Summary:  Endothelial Dysfunction in Insulin Resistance: The Role of 
EDHF and Gap Junction Communication 
 
Background: 
Endothelial dysfunction is a key factor in the development of vascular complications in 
insulin resistance and diabetes (De Vriese, Verbeuren et al. 2000) and recent studies have 
established that endothelium-derived hyperpolarising factor (EDHF) plays an important 
physiological role in endothelium-derived relaxation responses, especially in small arteries and 
arterioles (De Vriese, Verbeuren et al. 2000).  The nature of EDHF is not clearly understood, 
however evidence exists for a role for intercellular pathways provided by gap junctions (Edwards, 
Feletou et al. 1999; Hutcheson, Chaytor et al. 1999; Chaytor, Martin et al. 2001).   
There have been few studies investigating the effect of insulin resistance and type 2 diabetes 
on EDHF.  This project aims to identify the role of, and characterise, EDHF in animal models of 
insulin resistance, including the obese Zucker rat (OZR) as well as the fructose-fed (FF) Sprague-
Dawley rat.  It is hypothesised that endothelial dysfunction is present in small vascular arteries such 
as the third-order mesenteric artery and the lobar artery from these animal models of insulin 
resistance, and that this dysfunction can be linked with a reduction in EDHF function.  
Furthermore, this study aims to identify an integral role of gap junctions in EDHF-mediated 
vasodilatation that may be compromised in insulin resistance. 
   
Methods: 
Metabolic parameters of the OZRs, FF rats and their corresponding control rats were 
measured, including oral glucose tolerance, non-fasting glucose, urinary protein and plasma insulin 
and lipids, to establish if the OZRs or FF rats display characteristics associated with insulin 
resistance or type 2 diabetes.  
Table of Contents 
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Third-order mesenteric arteries from OZRs and control lean littermate Zucker rats (LZRs) 
were mounted on a pressure myograph, and the internal diameter was recorded by video 
microscopy.  Renal lobar arteries from the FF rats and the corresponding control rats (fed normal 
rat chow) were mounted on a wire myograph, and changes in isometric tension were recorded.  All 
experiments were carried out in the presence of the cyclo-oxygenase inhibitor indomethacin (10 
M). 
Endothelial function was determined by studying responses to the endothelium-dependent 
vasodilator acetylcholine (ACh, 1 nM–10 M) and the endothelium-independent vasodilator 
levcromakalim (10 nM–10 M).  The nitric oxide (NO) pathway was inhibited using the endothelial 
NO synthase inhibitor L-nitroarginine methyl ester (L-NAME, 100 M) and the guanylate cyclase 
inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 M).  The EDHF component 
was identified by inhibition using charybdotoxin (0.1 M) and apamin (1 M), or 1-[(2-
chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34, 1 M) and apamin (1 M), which block 
small- and intermediate-conductance calcium-activated potassium channels.  The contribution of 
gap junctions associated specifically with connexins 37, 40 or 43 was studied using the connexin-
mimetic peptides 40Gap27 (300 M), 43Gap26 (300 M) and 37,43Gap27 (300 M). 
The effect of insulin resistance on gap junctions was further assessed by measuring the 
protein and mRNA expression of vascular connexins.   Protein levels were determined by western 
blotting followed by semi-quantitative analysis of band intensity, whilst mRNA levels were 
quantified using real time PCR, in which β-actin was used as the housekeeping gene.  
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Results:   
Female Lean and Obese Zucker Rats 
 
The female OZRs displayed characteristics associated with insulin resistance, including 
urinary proteinuria, dyslipidaemia, hyperinsulinaemia and glucose intolerance.     
Relaxations to ACh were significantly smaller in third-order mesenteric arteries from the 
female OZR than the female LZR, whereas there was no difference in relaxations to 
levcromakalim, indicating endothelial dysfunction.  Responses to ACh were not altered by NO 
inhibitors, but were abolished by blockade of the EDHF component with charybdotoxin and 
apamin, or TRAM-34 and apamin, suggesting that relaxations are solely mediated by EDHF.  
40Gap27 significantly attenuated the response to ACh in mesenteric arteries from the LZR, but had 
no effect in the OZR.  Additionally, connexin 37 and 40 protein and mRNA levels in mesenteric 
vascular homogenates were significantly smaller in the OZR than in the LZR, with no difference in 
connexin 43 levels.  These latter results suggest that the defective EDHF is at least partly related to 
an impairment of connexin 40-associated gap junctions.  
 
Male vs. Female Lean and Obese Zucker Rats 
 
Metabolic parameter analysis showed that in contrast to the insulin-resistant female OZRs, 
male OZRs displayed characteristics associated with type 2 diabetes (i.e. non-fasting blood glucose 
>11.1 mM).  Additionally, male OZRs had significantly greater insulin and cholesterol levels than 
the female OZRs.   
Log concentration-response curves for ACh in mesenteric arteries from the male OZR 
showed a 2.8-fold rightward parallel shift compared to the male LZR, as well as a reduction in the 
maximal response.  In comparison, female OZR mesenteric arteries showed a 2.5-fold rightward 
parallel shift compared with the female LZR with no change in the maximal response, suggesting 
that type 2 diabetic male Zucker rats demonstrate a greater degree of endothelial dysfunction 
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compared to their insulin-resistant female counterparts.  There was no difference in endothelium-
independent responses to levcromakalim between mesenteric arteries from the female or male 
OZR and LZR.  As in female Zucker rats, responses to ACh in male rats were abolished by a 
combination of TRAM-34 and apamin and therefore attributed to EDHF.  
 
Fructose-Fed Rats 
 
The FF rats presented with glucose intolerance despite no change in non-fasting glucose 
levels compared with control rats on a normal chow diet.  Other characteristics of insulin resistance 
included significantly elevated triglyceride and insulin levels in the FF rats. There was no change in 
total cholesterol, HDL levels or urinary microalbumin in FF compared with control rats.  
Responses to ACh or levcromakalim were not significantly different between the FF and 
control rats in the lobar artery, suggesting normal endothelial function in the FF rats.  Responses to 
ACh in the lobar artery were mediated by NO only, since relaxations were abolished in the 
presence of L-NAME and ODQ in arteries from both groups.  
 
Conclusion:   
 
The findings presented in this thesis demonstrate that endothelial dysfunction is present in 
third-order mesenteric arteries from insulin-resistant female and type 2 diabetic male OZRs, and is 
associated with a defect in EDHF.  However, endothelial function was not compromised in the 
insulin-resistant FF rats.  Furthermore, the reduction in EDHF-mediated vasodilatation in the 
mesenteric arteries from female OZRs was associated with the functional absence of connexin 40-
related gap junctions as well as a reduction in connexin 40 protein and mRNA levels.  This novel 
finding suggests that gap junctions associated with connexin 40 may be a potential therapeutic 
target for diabetic vascular disease.  
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1.1 Endothelial Function 
The endothelium, a single layer of cells that lines the lumen of all blood vessels, acts not only as a 
selectively permeable barrier between the circulating blood components and the surrounding tissues of 
the body, but sustains numerous regulatory and homeostatic roles (Bell, Johns et al. 1998).  The dynamic 
vascular endothelium plays a crucial role in maintaining the physiology of blood vessels, including 
regulation of vascular tone, haemodynamics, and metabolic, thrombotic and inflammatory processes 
(Henrich 1991).  Vascular tone is regulated through the release of endothelium-derived relaxing factors 
including prostacyclin, nitric oxide (NO) and endothelium-derived hyperpolarising factor (EDHF)(Figure 
1.1), which counteract the actions of endothelium-dependent vasoconstrictors including endothelin-1 
and arachidonic metabolites (e.g. thromboxane A2).  Whilst in most cases, NO solely mediates 
endothelium-dependent vasodilatation in large conduit arteries such as the aorta, smaller arteries are 
modulated by various vasodilators including EDHF and prostacyclin and hence are more complex to 
study (Vanhoutte and Eber 1991; Edwards and Weston 1998).  The experiments detailed in this thesis 
are mainly focussed on the function of EDHF, however prostacyclin and NO are involved in the 
investigation. 
 
1.1.1 Prostacyclin 
Prostacyclin (also known as prostaglandin I2 or PGI2), discovered by Vane and colleagues in 
1976 (Moncada, Gryglewski et al. 1976), is formed from arachidonic acid by cyclo-oxygenase.   
Prostacyclin has vasorelaxant properties as well as an inhibitory action on platelet aggregation 
(Moncada, Gryglewski et al. 1976; Rubanyi 1991).  Prostacyclin initiates vascular relaxation via the 
stimulation of adenylate cyclase and the subsequent formation of cyclic 3‟ 5‟-adenosine 
monophosphate (cAMP) from adenosine triphosphate (ATP) (Vanhoutte, Boulanger et al. 
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1995)(Figure 1.1).  The release of prostacyclin can be stimulated by thrombin, bradykinin and shear 
stress (Shepherd and Katusic 1991).  Under most basal circumstances, prostacyclin does not play a 
major role in the regulation of vascular tone, and instead is more of an inducible vasorelaxing factor 
during certain disease states and inflammation (Parkington, Coleman et al. 2004). 
 
1.1.2 Nitric Oxide  
The release of NO is stimulated by chemical factors (e.g. acetylcholine (ACh), noradrenaline, 
thrombin, 5-hydroxytryptamine, bradykinin, substance P) as well as mechanical factors including shear 
stress and increased blood flow (Cooke and Dzau 1997).  Endothelial –derived relaxinf factor was 
initially identified by Furchgott and Zawadzki (Furchgott and Zawadzki 1980), which was subsequently 
identified as NO by Palmer and colleagues (Palmer, Ashton et al. 1988).  NO is synthesised by the 
catalysis of L-arginine to L-citrulline by nitric oxide synthase (NOS)(Figure 1.1).  There are three 
isoforms of NOS:  neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS).   
nNOS (type I) and eNOS (type III) are known as constitutive isoforms, in comparison to iNOS (type II), 
which is inducible by endotoxins and cytokines (Cooke and Dzau 1997).   
The conversion of L-arginine to L-citrulline by NOS requires calcium and calmodulin, oxygen 
and a variety of cofactors including dihydro-nicotinamide-adenine-dinucleotide phosphate (NADPH), 
flavin redox carriers 5'-phosphoriboflavin (FMN) and flavin-adenine dinucleotide (FAD), and 
tetrahydrobiopterin (BH4) (Andrew and Mayer 1999; Alderton, Cooper et al. 2001)(Figure 1.2).  NADPH 
donates electrons to the reductase domain of the enzyme, which proceed through to the oxygenase 
domain via FAD and FMN.  The electrons interact with the haem iron and BH4 at the active site to 
catalyse the reaction of oxygen with L-arginine, generating L-citrulline and NO as products (Alderton, 
Cooper et al. 2001).  NO acts as a labile intracellular messenger, which diffuses passively into adjacent 
smooth muscle cells where it stimulates intracellular soluble guanylate cyclase.  This leads to increased 
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levels of 3',5'-cyclic guanosine monophosphate (cGMP) from guanosine 5' triphosphate (GTP), resulting 
in decreased intracellular calcium, and in turn relaxation of the smooth muscle cell (Busse and Fleming 
1995)(Figure 1.1). 
eNOS is the vascular, calcium-dependent isoform, found in endothelial cells and platelets.  In the 
vasculature, NO assists in the regulation of vascular tone, through both basal and stimulated release, 
resulting in a constant level of vasodilatation, and acts as an inhibitor of platelet aggregation and smooth 
muscle cell proliferation (Salerno, Sorrenti et al. 2002).  Alterations in vascular NO have been associated 
with many cardiovascular disease states including atherosclerosis, hypertension and diabetes (Andrew and 
Mayer 1999).  
nNOS is found in the central nervous system and in non-adrenergic, non-cholinergic neurons in 
the peripheral nervous system and is calcium-dependent (Andrew and Mayer 1999).  Centrally, NO is 
important in learning and memory, whereas in the periphery, NO is involved in the relaxation of 
gastrointestinal tract sphincters and assistance in penile erection (eNOS is also involved).  Dysfunctions 
in nNOS action have been associated with erectile dysfunction, and acute (e.g. stroke) and chronic (e.g. 
Alzheimer‟s disease) neurodegenerative disorders (Salerno, Sorrenti et al. 2002). 
iNOS is the isoform involved in inflammatory processes, such as cytotoxicity and host defence, 
and releases NO in large amounts independently of intracellular calcium changes.  iNOS is expressed in 
many vascular cells, including endothelial cells, cardiac myocytes, smooth muscle cells and macrophages 
(Andrew and Mayer 1999).  iNOS acts as an anti-inflammatory agent through the release and degradation 
of NO, during which peroxynitrite (ONOO-) is produced which helps to fend off invading organisms.  
iNOS dysfunctions have been implicated in septic shock and autoimmune diseases (e.g. type 1 diabetes, 
rheumatoid arthritis)(Salerno, Sorrenti et al. 2002). 
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1.1.3 EDHF 
A large proportion of acetylcholine (ACh)-induced dilatation in the microcirculation is insensitive 
to the inhibition of NOS and cyclo-oxygenase (Yousif, Cherian et al. 2002), due to the increased 
contribution of EDHF (Cohen, Plane et al. 1997; De Vriese, Verbeuren et al. 2000; Ungvari, Csiszar et al. 
2002).   This is important as these smaller arteries are the vessels involved in the local control of blood 
flow and the regulation of blood pressure.  Despite its importance, the intra- and inter-cellular pathways 
for EDHF-mediated signal transduction are not well understood.  The target and identity of EDHF still 
remains controversial, and the literature concerning the nature and distribution of EDHF has been 
extensively reviewed (McGuire, Ding et al. 2001; Busse, Edwards et al. 2002; Sandow 2004; Vanhoutte 
2004).  As the identity and nature of EDHF is the primary focus of this thesis, EDHF will be reviewed 
here in detail. 
It is certainly possible that EDHF and NO are interrelated, either by sharing common 
mechanisms or by modulating the action of the other.  It appears that EDHF may also play a secondary 
“back-up” role to NO in some vessels, since under basal conditions, NO can exert negative feedback on 
EDHF production and activity (Cohen and Vanhoutte 1995; Bryan, You et al. 2005).  This negative 
feedback may come into play during times of disease processes, altering NO and EDHF contribution.  It 
has been shown that a lack of NO can be compensated by an upregulation of EDHF in skeletal muscle 
arterioles of eNOS knockout mice (Waldron, Ding et al. 1999; Huang, Sun et al. 2000).  NO has also 
been shown to exert feedback inhibition on EDHF in canine coronary arteries (Nishikawa, Stepp et al. 
1999; Oltman, Kane et al. 2001), rabbit carotid arteries and porcine coronary arteries (Bauersachs, Popp 
et al. 1996).  A recent study has examined EDHF and NO in the radial artery of humans, looking at 
arterial diameter, wall thickness, blood flow and pressure (Bellien, Joannides et al. 2005).  This study 
demonstrated that NO inhibition by NG-monomethyl-L-arginine (L-NMMA) led to decreased 
compliance, with no change in arterial diameter, however EDHF inhibition by the potassium channel 
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antagonist tetraethylammonium chloride (TEA) decreased arterial diameter and compliance.  When both 
NO and EDHF were inhibited, the reduction in arterial diameter and compliance was no different to 
that of EDHF inhibition alone.  The findings from this study suggest that EDHF was compensating for 
the loss in NO to maintain peripheral conduit arterial diameter and mechanics (Bellien, Joannides et al. 
2005).   
It is also interesting to note that in a number of studies EDHF-mediated relaxation has been 
shown to produce a more immediate action than the NO-second messenger-mediated pathway that 
produces a delayed but prolonged response (Bakker and Sipkema 1997).  This suggests that the 
endothelium-dependent hyperpolarisation and relaxation in resistance vessels evoked by ACh is likely to 
be complex, and is supported by the demonstration of the biphasic membrane hyperpolarisation, where 
an initial rapid transient hyperpolarisation, linked to EDHF activity, is followed by a slower component 
of longer duration (Bakker and Sipkema 1997; Oltman, Kane et al. 2001), the slower component being 
sensitive to NO inhibitors.  
Many studies have been conducted to study differences in endothelial function between male and 
female animal models.  Studies in non-diseased models have shown that the contributions of 
prostacyclin, NO and EDHF can differ with gender, as can the identity of EDHF.  Furthermore, the 
impact of disease on endothelial function can differ between male and female animals.  This issue is 
discussed in detail in Chapter 4, however, in general, female animals do show a larger EDHF component 
in comparison to their male age-matched controls (White, Rivera et al. 2000; Wu, Huang et al. 2001).  
Significant contributions of EDHF have been demonstrated in a wide variety of vascular beds, 
including renal arteries (Zygmunt, Ryman et al. 1995; Bussemaker, Wallner et al. 2002), mesenteric 
arteries and hepatic arteries (Zygmunt, Ryman et al. 1995), coronary arteries (Parkington, Tare et al. 
1993), carotid arteries (Quignard, Feletou et al. 2000), and gracilis arteries (Ungvari, Csiszar et al. 2002).  
Additionally, it has been demonstrated that EDHF is important in the human vasculature, including 
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mesenteric arteries (Matoba, Shimokawa et al. 2002), coronary arteries (Miura and Gutterman 1998; He 
2002), gastroepiploic arteries (Urakami-Harasawa, Shimokawa et al. 1997), interlobar arteries 
(Bussemaker, Popp et al. 2003), internal mammary arteries (He 2002; Archer, Gragasin et al. 2003) and 
human subcutaneous arteries (Coats, Johnston et al. 2001; Coleman, Tare et al. 2001; McIntyre, Buckley 
et al. 2001).  Studies of forearm blood flow have also identified a role for EDHF in the regulation of 
vascular tone (Honing, Smits et al. 2000; Halcox, Narayanan et al. 2001; Inokuchi, Hirooka et al. 2003; 
Schrage, Dietz et al. 2005). 
 
1.2 EDHF 
EDHF-mediated vasodilatation can be induced by a variety of mechanical and chemical factors.   
Pulsatile pressure has been shown to be a physiological stimulus (Cohen and Vanhoutte 1995), and 
EDHF has also been shown to mediate flow-induced (Huang, Sun et al. 2001) and shear stress-induced 
(Huang, Sun et al. 2005) vasodilatation in skeletal muscle arterioles from female eNOS-knockout mice.  
Additionally, EDHF has been demonstrated to mediate flow-induced vasodilatation in human coronary 
arteries (Miura, Bosnjak et al. 2003), hamster cremaster arteries (Watanabe, Yashiro et al. 2005) and rat 
coronary arteries (Ueda, Ohyanagi et al. 2005). 
In regards to chemical factors, ACh is the most common agonist used to induce EDHF-
mediated vasodilatation, including in rat mesenteric (Parkington, Chow et al. 2002), guinea-pig coronary 
arteries (Parkington, Tonta et al. 1995), bovine coronary arteries (Campbell, Falck et al. 2001) and human 
mammary and radial arteries (He 2002).  Bradykinin has also been used as an EDHF agonist, for instance 
in bovine pulmonary arteries (Tracey, MacDonald et al. 2002), porcine coronary arteries (Pomposiello, 
Rhaleb et al. 1999; Edwards, Feletou et al. 2001), renal afferent arterioles (Wang, Trottier et al. 2003) and 
human forearm resistance arteries (Honing, Smits et al. 2000).  Histamine has also been used to study 
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EDHF-mediated vasodilatation in the perfused mesenteric bed and kidney from diabetic rats (Yousif, 
Oriowo et al. 2002; Yousif 2005). 
Interestingly, the type of chemical agonist used can affect the relative contributions of NO and 
EDHF, particularly in human studies.  Bradykinin-induced vasodilatations of forearm resistance vessels 
have been attributed to EDHF using TEA (Honing, Smits et al. 2000; Inokuchi, Hirooka et al. 2003; 
Schrage, Dietz et al. 2005), however ACh-mediated vasodilatations in the same vessel have been 
attributed to NO (Schrage, Dietz et al. 2005), with little EDHF involvement (Inokuchi, Hirooka et al. 
2003).  In contrast, a comparison of bradykinin- and ACh-induced vasodilatation in rat mesenteric and 
hindlimb circulations, showed no significant difference (Parkington, Chow et al. 2002). 
Whilst the identity of EDHF remains controversial, it has been well established that EDHF-
induced hyperpolarisation and relaxation involves calcium-activated potassium channels (KCa) (Feletou 
and Vanhoutte 1996; Busse, Edwards et al. 2002) (Figure 1.3).  Initial studies used high potassium 
physiological salt solutions to saturate  KCa channels or TEA to block KCa channels to demonstrate that 
KCa channels were involved in EDHF-mediated vasodilatation (Campbell, Gebremedhin et al. 1996; 
Tanaka, Otsuka et al. 1999).  Inhibition of specific KCa channels has since been achieved using: apamin, 
an inhibitor of small-conductance KCa (SKCa) channels; charybdotoxin (ChTX), an inhibitor of 
intermediate- (IKCa) and large- (BKCa) conductance KCa channels; and iberiotoxin to inhibit BKCa 
channels.  Until recently, the combination of apamin and ChTX was the defining EDHF inhibitor in 
animal and human arteries, including rat mesenteric arteries (Doughty, Plane et al. 1999), canine coronary 
arteries (Nakashima, Toki et al. 1997), rat hepatic arteries (Zygmunt, Edwards et al. 1997), human 
mesenteric arteries (Batenburg, de Vries et al. 2004), human coronary arterioles (Petersson, Zygmunt et 
al. 1997) and human interlobar arteries (Bussemaker, Popp et al. 2003).  Furthermore, these apamin- and 
ChTX-sensitive responses are generally insensitive to iberiotoxin (Corriu, Feletou et al. 1996; Edwards, 
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Dora et al. 1998; Quignard, Feletou et al. 1999), confirming that the inhibitory action of ChTX is due to 
its effect on IKCa channels.   
More recently the availability of TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole), a 
specific inhibitor of IKCa channels, has helped to provide supportive data that activation of the IKCa 
channel is an important component of the EDHF-mediated responses, alongside SKCa channels.  
TRAM-34 has been demonstrated to attenuate vasodilatation in the rat caudal artery, alone and in 
combination with apamin (Eichler, Wibawa et al. 2003).  However, other studies have failed to show an 
effect with TRAM-34 by itself, although abolishment was demonstrated with the combination of TRAM-
34 and apamin (Crane, Gallagher et al. 2003; Gluais, Edwards et al. 2005).  This combination has also 
been used to block EDHF responses in rat saphenous arteries (Sandow, Goto et al. 2004).  TRAM-39 (2-
(2-chlorophenyl)-2,2-diphenyl acetonitrile), a similar compound to TRAM-34 has also been shown to be 
a potent IKCa inhibitor, effective in blocking EDHF responses, once again in combination with apamin 
(Hinton and Langton 2003; Weston, Feletou et al. 2005). 
IKCa and SKCa channels are expressed prominently by endothelial cells (Marchenko and Sage 
1996; Edwards, Dora et al. 1998; Burnham, Bychkov et al. 2002) whilst BKCa channels are prominently 
expressed by smooth muscle cells (Zygmunt, Edwards et al. 1997; Quignard, Feletou et al. 2000; 
Bychkov, Burnham et al. 2002), supporting proposals that the ChTX- and apamin-sensitive KCa channels 
activated in response to agonist stimulation are situated on endothelial cells rather than vascular smooth 
muscle cells.  This in turn supports suggestions that the activation and hyperpolarisation of endothelial 
cells are necessary for the EDHF-mediated hyperpolarisation and relaxation of smooth muscle cells, and 
that these KCa channels are involved in the initial propagation of endothelial cell hyperpolarisation 
(Baron, Frieden et al. 1996; Bychkov, Burnham et al. 2002).  Na+/K+-ATPase has also been 
demonstrated to be involved in some EDHF-mediated relaxations (Jiang, Li et al. 2000; Bussemaker, 
Wallner et al. 2002; Yousif, Cherian et al. 2002) (Figure 1.3).  It is possible that both KCa channels and  
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Na+/K+-ATPase are involved in the EDHF response; inhibitors of KCa channels, namely SKCa and IKCa,  
have been shown to specifically act on the endothelium (Edwards, Dora et al. 1998; Doughty, Plane et al. 
1999), whilst Na+/K+-ATPase inhibitors such as ouabain are working directly on vascular smooth muscle 
cells to inhibit hyperpolarisation (Dora and Garland 2001).  Other studies have failed to identify an 
involvement of Na+/K+-ATPase in EDHF responses (Bakker and Sipkema 1997; Quilley, Fulton et al. 
1997; Chaytor, Martin et al. 2001; Coleman, Tare et al. 2001).    
Studies which investigate potassium as a potential EDHF candidate (see section 1.2.1) use 
barium, alone or in combination with ouabain, to block inwardly rectifying potassium channels (KIR).  
Barium has been shown to attenuate EDHF-mediated vasodilatation in rat mesenteric arteries (Doughty, 
Boyle et al. 2001; Chauhan, Nilsson et al. 2003; Goto, Rummery et al. 2004) and mice gracilis arteries 
(Krummen, Falck et al. 2005).  Furthermore, the combination of barium and ouabain has been shown to 
inhibit EDHF-mediated responses in rat hepatic arteries (Edwards, Dora et al. 1998).  This combination 
also successfully reduced bradykinin-induced responses in porcine coronary arteries (Batenburg, de Vries 
et al. 2004), human coronary microarteries (Batenburg, Garrelds et al. 2004) and human thyroid arteries 
(Torondel, Vila et al. 2004).  In contrast, barium was shown to have no effect on EDHF-mediated 
vasodilatation in guinea-pig carotid and porcine coronary arteries, alone or in combination with ouabain 
(Quignard, Feletou et al. 1999).  Ouabain and barium also failed to inhibit responses in rat renal 
microvessels (Wang and Loutzenhiser 2002) and rat hepatic arteries (Andersson, Zygmunt et al. 2000).   
One hypothesis that has been put forward to explain these inconsistent findings is the „potassium 
cloud‟ theory.  Part of this theory suggests that preconstricting vasospastic agents, such as phenylephrine, 
can generate „potassium clouds‟ around smooth muscle cells by increasing the efflux of potassium ions 
through BKCa channels (Edwards and Weston 2004).  This in turn saturates the Na
+/K+-ATPase and KIR 
channels (Figure 1.3), potentially masking their involvement in EDHF-mediated vasodilatation.  The 
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heterogenous nature of EDHF must also be considered as a reason why certain potassium channels are 
involved in EDHF-mediated responses in certain vessels but not in others.   
 
1.2.1 The Identity of  EDHF 
It was initially suggested that EDHF is a soluble transferable factor, due to the success 
investigators had in passing a hyperpolarising factor between a vessel with endothelium to one that had 
been denuded of endothelium (Cohen and Vanhoutte 1995).   It is now considered that EDHF is likely 
to be more than one factor (Triggle, Dong et al. 1999; Triggle and Ding 2002; Sandow 2004) and the 
cellular basis for EDHF demonstrates substantial tissue and species heterogeneity, which has been 
extensively reviewed (Triggle, Dong et al. 1999; Triggle and Ding 2002; Sandow 2004).  Current 
hypotheses regarding the identity of EDHF, as illustrated in Figure 1.3, include: diffusible factors; 
arachidonic acid metabolite epoxyeicosatrienoic acids (EETs); anandamide (arachidonyl ethanolamine 
amide); potassium effluxing through KCa channels on endothelial cells (Quilley, Fulton et al. 1997; 
Triggle, Dong et al. 1999); reactive oxygen species (ROS) such as hydrogen peroxide; C-type natriuretic 
peptide (CNP); and cellular communication via gap junctions.  These hypotheses are discussed further 
below. 
 
1.2.1.1  Diffusible Factors 
Several studies have identified EDHF as a diffusible factor released from endothelial cells 
which then travels to surrounding smooth muscle cells.  This has been demonstrated in sandwich 
experiments following administration of the calcium ionophore A-23187, in the presence of the NOS 
inhibitor L-nitroarginine methyl ester (L-NAME) and the cyclo-oxygenase inhibitor indomethacin, in 
rabbit femoral (Plane, Pearson et al. 1995) and mesenteric (Hutcheson, Chaytor et al. 1999) arteries.  In 
these experiments, vessel rings were cut open, and small strips of endothelium-intact vessel were 
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sutured onto strips of endothelium-denuded artery, with their intimal surfaces in close apposition, to 
provide composite preparations (Hutcheson, Chaytor et al. 1999).  As the two sandwich preparations 
have no myo-endothelial connection, any endothelium-derived relaxations can be attributed to factors 
released by the endothelial cells which have diffused through to the smooth muscle cell layer.  
 
1.2.1.2  Arachidonic Acid Metabolites 
There is considerable support for an arachidonic acid metabolite to be an EDHF (Bauersachs, 
Hecker et al. 1994; Hecker, Bara et al. 1994; Campbell, Gebremedhin et al. 1996; Popp, Bauersachs et al. 
1996).  Numerous studies have provided evidence that epoxides, a class of arachidonic acid metabolites, 
act as an EDHF (Hecker, Bara et al. 1994; Campbell, Gebremedhin et al. 1996).  Epoxides or EETs are 
products of the cytochrome P450 (CYP) pathway, synthesised in the endothelium (Campbell, 
Gebremedhin et al. 1996), and reportedly activate BKCa channels on the vascular smooth muscle cell to 
cause relaxation (Quilley, Fulton et al. 1997; Edwards, Thollon et al. 2000).  CYP epoxygenases are not 
expressed in all endothelial cells and do not always play a major role in regulation of vascular tone in all 
arteries (Edwards, Dora et al. 1998; Heil, De Vriese et al. 2005).  For instance, EETs have been identified 
as putative EDHFs in human coronary arterioles (Larsen, Miura et al. 2006), human internal mammary 
arteries (Archer, Gragasin et al. 2003), rat and mouse gracilis arterioles (Huang, Sun et al. 2005), porcine 
(Fleming, Fisslthaler et al. 2001; Weston, Feletou et al. 2005) and bovine (Gauthier, Edwards et al. 2005) 
coronary arteries.  In contrast, other studies have shown that EETs do not contribute to EDHF 
responses in rat mesenteric arteries (Fukao, Hattori et al. 1997) and rat hepatic arteries (Zygmunt, 
Edwards et al. 1996). 
One factor that contradicts EET acting as an EDHF is that it is generally accepted that EET-
mediated vasodilatation involves smooth muscle BKCa channels, as demonstrated by the inhibitory 
effects of iberiotoxin on EET-mediated vasodilatation in bovine coronary  arteries (Campbell, Falck et al. 
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2001), porcine coronary arteries (Edwards, Thollon et al. 2000), swine coronary arteries (Weston, Feletou 
et al. 2005) and rat mesenteric arteries (Miller, Dimitropoulou et al. 2001).   It should be noted however 
that inhibitors of BKCa have failed to inhibit the EDHF response in vessels including the pig and guinea-
pig coronary arteries, and guinea-pig carotid artery (Corriu, Feletou et al. 1996; Zygmunt, Edwards et al. 
1996; Chataigneau, Feletou et al. 1998; Edwards, Thollon et al. 2000).   
It has also been proposed that EETs produced in the endothelial cells can act directly on smooth 
muscle cells via the closure of voltage-dependent calcium channels to cause hyperpolarisation and 
relaxation (Figure 1.3), as in some instances EETs are still able to produce relaxation in a denuded vessel 
(Fulton and Quilley 1998; Pratt, Li et al. 2001; Gauthier, Edwards et al. 2005).  Additionally, it has been 
suggested that EETs, which can be induced by shear stress (Huang, Sun et al. 2005), increase intracellular 
calcium levels within endothelial cells, activating SKCa and IKCa channels (Campbell, Gebremedhin et al. 
1996; Bakker and Sipkema 1997; Edwards, Thollon et al. 2000), and releasing K+ to cause smooth muscle 
cell relaxation and hyperpolarisation (Edwards, Dora et al. 1998; Hutcheson, Chaytor et al. 1999)(Figure 
1.3).   
The hypothesis of EET candidature as an EDHF has been questioned in several studies, 
culminating from problems with the limited specificity of the CYP inhibitors, including non-specific 
effects on K+ channels (Edwards, Zygmunt et al. 1996; Zygmunt, Edwards et al. 1996; Fukao, Hattori et 
al. 1997).   For example, clotrimazole is a non-specific CYP inhibitor that also blocks IKCa channels; it has 
been shown to significantly reduce EDHF-type dilatations in rat mesenteric (Fukao, Hattori et al. 1997) 
and hepatic arteries (Zygmunt, Edwards et al. 1996).  Other studies accepting the specificity of CYP 
inhibitors have had contradictory results:  17-octadecynoic acid (ODYA), a suicide inhibitor of some 
CYP enzymes, has no effect on EDHF-mediated relaxation in rat gracilis arteries (Ungvari and Koller 
2001), but does inhibit responses in human mammary arteries (Archer, Gragasin et al. 2003); SKF525a 
(also known as proadifen), an inhibitor of CYP monooxygenase, has no effect on EDHF-mediated 
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relaxations in human gastro-epiploic arteries (Urakami-Harasawa, Shimokawa et al. 1997), but has been 
shown to inhibit EDHF-mediated relaxation in the rat cremaster (Bakker and Sipkema 1997), hepatic 
artery (Zygmunt, Edwards et al. 1996) and bovine and porcine coronary arteries (Hecker, Bara et al. 
1994; Campbell, Gebremedhin et al. 1996), and the human forearm (Halcox, Narayanan et al. 2001).  The 
epoxygenase inhibitor miconazole has also been shown to inhibit EDHF-attributed vasodilatation in rat 
mesenteric arteries (Fukao, Hattori et al. 1997), hamster cheek pouch arterioles (Welsh and Segal 2000), 
rat perfused kidneys (Chen, Jiang et al. 2003) and bovine coronary arteries (Campbell, Gebremedhin et al. 
1996).  Fluconazole, an inhibitor of CYP2C29, has been used in humans in vivo to demonstrate CYP-
related EDHF in the radial artery (Bellien, Joannides et al. 2006).  Sulfaphenazole, a specific inhibitor of 
CYP2C3A, has confirmed the involvement of EETs in rat mesenteric arteries (Earley, Pastuszyn et al. 
2003) and swine coronary arteries (Fleming, Michaelis et al. 2001).  
There are four regioisomers of EETs (5,6-; 8,9-; 11,12-; 14,15) (Fulton and Quilley 1998), and 
initially the 5,6- isomer was found to be the most effective vasoactive agent (Fulton, McGiff et al. 1998; 
Hutcheson, Chaytor et al. 1999; Chaytor, Martin et al. 2001).  Recent studies have focused on 14,15-EET 
with the development of 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE) which is an analogue and antagonist 
of 14,15-EET, as well as having an attenuating affect on the other EET isomers, namely 5,6-EET 
(Gauthier, Deeter et al. 2002).  EEZE has been shown to inhibit EDHF-mediated dilatation in bovine 
coronary arteries (Gauthier, Deeter et al. 2002; Gauthier, Edwards et al. 2005), mice gracilis arteries 
(Krummen, Falck et al. 2005), rabbit renal afferent arterioles (Wang, Borrego-Conde et al. 2003) and 
porcine coronary arteries (Weston, Feletou et al. 2005).  14,15-epoxyeicosa-5(Z)-enoic-
methylsulfonylimide (EEZE-mSI) is another 14,15-EET analogue and antagonist of the 14,15- and 5,6-
EETs and has been shown to inhibit EDHF in bovine (Gauthier, Jagadeesh et al. 2003) and porcine 
(Weston, Feletou et al. 2005) coronary arteries.   
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In summary, EETs certainly appear to mediate EDHF-attributed relaxations in coronary arteries, 
however there isn‟t a clear consensus regarding other arteries.  The use of more specific inhibitors now 
available will enable more conclusive studies to be undertaken. 
 
1.2.1.3  Anandamide 
Anandamide, the ethanolamide of arachidonic acid and an endogenous ligand for cannabinoid 
receptors, has been considered to be an EDHF upon stimulation with ACh and bradykinin (Randall, 
Alexander et al. 1996).  It was proposed that anandamide was stored in phospholipids whereupon it 
could serve as a substrate for arachidonic acid to produce a vasodilator that activated K+ channels 
(Bornheim, Kim et al. 1993; Fulton and Quilley 1998).  However, studies using the cannabinoid receptor 
antagonist SR 141716A have shown no effect on responses to arachidonic acid, bradykinin or the 
potassium channel-opener cromakalim only an attenuation of responses directly stimulated by 
anandamide (Fulton and Quilley 1998).  The same study observed that ChTX abolished vasodilator 
responses to bradykinin, but had no effect on vasodilator responses to anandamide, suggesting 
bradykinin and anandamide and have different mechanisms of action.  In addition, anandamide and 
other cannabinoid agonists have been shown to interfere with EDHF generation by endothelial cells 
rather than having an effect on the smooth muscle cells (Fleming, Schermer et al. 1999).  Whilst 
anandamide may possess EDHF-like characteristics under certain experimental conditions, it is the 
opinion of this author that anandamide is not an endogenous EDHF. 
 
1.2.1.4  Potassium 
Potassium itself has been suggested as a possible EDHF in some vascular beds.   Edwards et al. 
(1998) concluded that EDHF was potassium in rat mesenteric and hepatic arteries, suggesting that 
potassium effluxed from endothelial cells and hyperpolarised the smooth muscle by opening KIR 
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channels and activating Na+/K+-ATPase channels (Figure 1.3); this is supported by studies showing the 
KIR channel inhibitor barium and the Na
+/K+ ATPase inhibitor ouabain are able to attenuate potassium-
induced hyperpolarisation (Edwards, Dora et al. 1998; Bussemaker, Wallner et al. 2002).  In contrast,  
ACh still evoked substantial hyperpolarisation and relaxation of the small intestine submucosal arteriole 
and guinea-pig internal carotid artery, in the presence of ouabain with or without barium (Quignard, 
Feletou et al. 1999; Coleman, Tare et al. 2001).  A recent study in rat middle cerebral arteries showed that 
EDHF-mediated smooth muscle vasodilatation and hyperpolarisation in response to the protease-
activated receptor 2 ligand SLIGRL, was inhibited by barium and ouabain, as well as being sensitive to 
IKCa inhibition, suggesting potassium ions act as an EDHF in this artery (McNeish, Dora et al. 2005).  As 
discussed earlier (section 1.1.3), the „potassium cloud‟ theory adds another level of debate, suggesting that 
there may be a build-up of vascular smooth muscle-derived K+ in the myoendothelial extracellular space, 
as can occur when agents such as phenylephrine, a BKCa opener, is used for preconstriction (Weston, 
Richards et al. 2002; Edwards and Weston 2004).  This may lead to the saturation of KIR and Na
+/K+ 
ATPase channels, thereby masking the contribution of endothelial-derived K+ to EDHF-mediated 
dilatation. 
EDHF-mediated relaxations in porcine interlobar arteries (Bussemaker, Wallner et al. 2002), rat 
mesenteric arteries (Ding, Kubes et al. 2000) and rat hepatic arteries (Edwards, Dora et al. 1998) can be 
mimicked by increasing the extracellular concentration of potassium using KCl (from 4 to 14 mM), and 
can be attenuated in the presence of a potassium chelator (Bussemaker, Wallner et al. 2002).  In contrast, 
studies in the porcine coronary artery have demonstrated that increases of 5 or 10 mM in extracellular 
potassium are unable to hyperpolarise the smooth muscle (Quignard, Feletou et al. 1999).  It has also 
been demonstrated that K+ causes hyperpolarisation and relaxation of smooth muscle in concentrations 
<14mM, but higher concentrations cause depolarisation and contraction of the smooth muscle; therefore 
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potassium only functions as an EDHF within the concentration window 4.8-14 mM (Campbell and 
Harder 2001).   
The general consensus now appears to be that whilst potassium is certainly involved in the 
EDHF pathway, it is not, under most circumstances, the initiating factor. 
 
1.2.1.5  Reactive Oxygen Species  
The generation of reactive oxygen species is illustrated in Figure 1.4. The vascular endothelium 
contains various superoxide (O2
.-)-producing oxidases including eNOS, cyclo-oxygenase, NADPH 
oxidases, xanthine oxidoreductase, CYP or via the mitochondrial electron transport chain.  The ROS 
generated remain confined within the endothelial cell as the extra charge impedes their passage across the 
cellular membrane (Ellis and Triggle 2003).   Within the endothelial cell, superoxide can be  degraded to 
hydrogen peroxide (H2O2) spontaneously or via dismutation catalysed by superoxide dismutase (SOD) 
(Matoba, Shimokawa et al. 2000; Katusic 2001; Miura, Bosnjak et al. 2003; Cai 2005).  Alternatively 
superoxide can react rapidly with NO to form peroxynitrite (OONO-).  H2O2 is able to permeate across 
the cellular membrane to act on adjacent cell targets; H2O2 can also react with metals or superoxide to 
form hydroxyl radicals (.OH).  H2O2 is then broken down by catalase or glutathione (GSH) peroxidase 
into water (Ellis and Triggle 2003).  
Several studies have suggested that H2O2 may function as an EDHF (Figure 1.3), which has now 
been recently reviewed (Shimokawa and Morikawa 2005).  Catalase, which dismutates H2O2 into water 
and oxygen, has been shown to inhibit EDHF-attributed relaxations and hyperpolarisations in small 
mesenteric arteries from eNOS knockout mice (Matoba, Shimokawa et al. 2000), canine small coronary 
arteries (Yada, Shimokawa et al. 2003), and human mesenteric and coronary arteries (Matoba, Shimokawa 
et al. 2002; Miura, Bosnjak et al. 2003; Yada, Shimokawa et al. 2003).  One study in rabbit ilio-femoral 
arteries demonstrated that catalase did inhibit A23187-induced vasodilatation, but had no effect on ACh-
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mediated vasodilatation.  This study also showed that whilst H2O2 may be an endothelium-dependent 
vasodilator, it is not responsible for the accompanying hyperpolarisation (Chaytor, Edwards et al. 2003).   
Tiron, a SOD mimetic has also been shown to significantly enhance EDHF-derived relaxations in 
human small mesenteric arteries, the effect of which was reversed with the addition of catalase 
(Morikawa, Fujiki et al. 2004).  Tempol, another SOD-mimetic has also been  used to demonstrate the 
involvement of oxidative stress in the development of endothelial dysfunction in STZ-treated diabetic 
rats (Nassar, Kadery et al. 2002).  Other studies using catalase or SOD have failed to identify H2O2 as an 
EDHF in porcine and canine coronary microvessels (Pomposiello, Rhaleb et al. 1999; Tanaka, Kanatsuka 
et al. 2003), rat aorta and small mesenteric arteries (Ellis, Pannirselvam et al. 2003), and human 
submucosal intestinal microvessels (Hatoum, Binion et al. 2005). 
There is no clear physiological role of H2O2 or other ROS as an EDHF under normal 
physiological conditions, although it has been suggested that H2O2 may play a role as an EDHF-like 
substance in certain disease states, where eNOS co-factors or substrates such as arginine or BH4 are 
depleted (Cohen and Vanhoutte 1995; Landmesser, Dikalov et al. 2003; Berka, Wu et al. 2004).  The 
depletion of eNOS co-factors is important as this causes the uncoupling of eNOS, resulting in decreased 
production of NO, and the subsequently increased production of O2
-.  Hence, the evidence so far 
suggests that H2O2 does not act an EDHF under normal physiological conditions, but may do so under 
certain pathophysiological conditions. 
 
1.2.1.6  C-Type Natriuretic Peptide (CNP) 
There have been a number of reviews published in the last few years highlighting C-Type 
Natriuretic Peptide (CNP) as a potential EDHF (Ahluwalia, MacAllister et al. 2004; Chauhan, Hobbs et 
al. 2004; Ahluwalia and Hobbs 2005; Scotland, Ahluwalia et al. 2005).  Initial indications that CNP may 
act as an EDHF came from studies showing that CNP can cause hyperpolarisation and relaxation in 
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isolated porcine coronary arteries (Barber, Burnett et al. 1998; Barton, Beny et al. 1998).  CNP is thought 
to act as an EDHF through the involvement of the natriuretic peptide receptor subtype C (NPR-
C)(Figure 1.3).  Whilst NPR-C was initially thought to be a clearance receptor for CNP (Matsukawa and 
Mano 1996), it has now been shown to induce smooth muscle and hyperpolarisation of the vascular 
smooth muscle cell via G-proteingated inwardly-rectifying K+ channels and Na+/K+ ATPase channels 
(Murthy, Teng et al. 2000; Ahluwalia and Hobbs 2005).  Further evidence has shown that CNP has 
EDHF-like vasoactive effects in mesenteric resistance arteries that are independent of guanylate cyclase, 
but do involve KIR and Na
+/K+ ATPase channels (Chauhan, Nilsson et al. 2003).  Whilst initial studies 
suggest that CNP may be an endogenous EDHF, further studies are clearly required with the use of 
specific antagonists, which are currently unavailable. 
 
1.2.1.7  Myoendothelial Gap Junctions 
Gap junctions are formed by the docking of two connexon subunits, each made up of 6 
connexin proteins arranged around a central core.  As illustrated in Figure 1.5, when two connexons 
dock together from adjacent cells, they create a channel allowing the direct exchange of ions and low-
molecular weight molecules, for instance K+, Ca2+, Cl2-, cyclic adenosine monophosphate (cAMP) and 
inositol phosphates (Quilley, Fulton et al. 1997), or spread of electrotonic signals (Segal and Duling 1989; 
Yamamoto, Klemm et al. 2001; Chaytor, Bakker et al. 2005).  In regards to the terminology, connexons 
formed from only one type of connexin are labelled homomeric, and connexons formed from two or 
more connexin types are labelled heteromeric.  When two identical connexons dock together to form a 
gap junction they are labelled homotypic, and if two different connexons dock they are labelled 
heterotypic (Cottrell and Burt 2001).  There are a number of comprehensive reviews which further 
discuss the structure and function of gap junctions and their connexin subunits (Yeager 1998; Yeager, 
Unger et al. 1998; de Wit 2004). 
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Gap junctions have been found to not only link adjacent endothelial cells and smooth muscle 
cells within each layer, but to also link the endothelial layer to the smooth muscle layer via 
myoendothelial connections (Beny and Pacicca 1994).  It has been suggested that EDHF-attributed 
hyperpolarisation activated by endothelial cells involves a current that spreads with negligible attenuation 
via these myoendothelial cell gap junctions to the smooth muscle cells (Edwards, Thollon et al. 2000; 
Emerson and Segal 2000). Recordings made from dye-identified  (using the fluorescent dye Lucifer 
yellow) smooth muscle and endothelial cells in the same segments of small intestine submucosal 
arterioles are consistent with electronic spread of current from the endothelial cells to the smooth muscle 
cells in the arterioles (Coleman, Tare et al. 2001).  Dye coupling has also been used to show gap junctions 
between smooth muscle cells (Beny and Connat 1992).  There is strong evidence that myoendothelial gap 
junctions are in operation, as membrane potential recordings have found action potentials from 
endothelial cells and smooth muscle cells to be indistinguishable, with hyperpolarisations associated with 
relaxations, suggesting strong electrical coupling, with the two essentially functioning as a single 
syncytium (Xia, Little et al. 1995; Coleman, Tare et al. 2001; Coleman, Tare et al. 2002). 
Four primary connexin subtypes (37, 40, 43 and 45) have been located in the vasculature (Severs 
1999).  Connexins 40 and 43 are the main constituents, both being rich in serines with a number of 
potential phosphorylating sites (Inoguchi, Ueda et al. 1995), which are important to the function and 
regulation of the gap junctions through mechanisms including protein kinase C (PKC) (Cruciani and 
Mikalsen 2002; Lampe and Lau 2004).  Connexins 37 and 45 are also present in the vasculature to a 
lesser extent (Pratt, Li et al. 2001).  A review of the literature demonstrates the clear heterogenous nature 
of connexin localisation, in regards to vessel type and vessel layer (Hill, Rummery et al. 2002; Griffith, 
Chaytor et al. 2004).  It has now been well established that connexins 37 and 40 are largely associated 
with endothelial and myoendothelial connections (Chaytor, Bakker et al. 2005), whereas connexin 43 is 
associated with the smooth muscle layers (Hill, Rummery et al. 2002; Chaytor, Bakker et al. 2005).  
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Confocal and electron microscopy of gap junctions have shown that connexons are grouped together 
into gap-junctional plaques, which can consist of any or all of the three connexin subtypes (Yeh, Rothery 
et al. 1998). 
Connexins 40 and 43 have been identified in a number of vascular beds, including rat renal 
arteries (Arensbak, Mikkelsen et al. 2001; Haefliger, Demotz et al. 2001), aorta (Hill, Rummery et al. 
2002), caudal arteries (Hill, Rummery et al. 2002), basilar arteries (Hill, Rummery et al. 2002), mesenteric 
vessels (Gustafsson, Mikkelsen et al. 2003), and bovine and rat retinal arteries (Matesic, Tillen et al. 2003).  
Several studies have shown that connexins 40 and 43 do form heteromeric connexons with unique gating 
and conductance properties (He, Jiang et al. 1999; Cottrell and Burt 2001).  Connexin 43 has also been 
shown to form heteromeric channels with connexin 37 (Brink, Cronin et al. 1997).  Connexin 37 has 
been located in mesenteric arterioles (Gustafsson, Mikkelsen et al. 2003), hepatic arteries (Chaytor, 
Martin et al. 2001), rabbit iliac arteries (Chaytor, Bakker et al. 2005), rat renal arterioles (Arensbak, 
Mikkelsen et al. 2001), rat aorta (Hill, Rummery et al. 2002), rat caudal arteries (Rummery, Hickey et al. 
2002), and rat basilar arteries (Hill, Rummery et al. 2002), and human aortae (Kwak, Mulhaupt et al. 
2002).  Connexin 45 has been identified in cerebral vascular smooth muscle cells (Li and Simard 2001). 
Whilst gap junctions are found in all vascular beds, it has been suggested that appreciable gap 
junction communication can only occur in the microcirculation where there is a limited number of 
smooth muscle cell layers (Shimokawa, Yasutake et al. 1996; Beny 1999).  Currents flowing through the 
endothelium would be expected to have a much larger effect on a single layer of smooth muscle of the 
microcirculation than a vessel where there are multiple layers of smooth muscle cells and a heavy 
electrical load (Coleman, Tare et al. 2002).  A recent study in rabbit iliac arteries however, showed only a 
15% decrement in hyperpolarisation through 10 smooth muscle layers (Chaytor, Bakker et al. 2005).    
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1.3 The Role of  Gap Junctions in EDHF-Mediated 
Relaxations 
Definitive evidence of the electrical conductance via gap junctions can be provided by agents 
that disrupt the conductance.  Early studies used the gap junction inhibitors heptanol, octanol and 
halothane, however these have a range of non-specific effects; for instance heptanol alters the activity of 
ion transport processes (Coleman, Tare et al. 2002). Further studies utilised the putative triterpenoid 
saponin gap junction inhibitors 18- and 18β-glycyrrhetinic acid, which alter gap junction aggregation 
and prevent connexon docking (Goldberg, Moreno et al. 1996; Guan, Wilson et al. 1996; Evans and 
Boitano 2001), however these inhibitors do not always appear to uncouple cells electrically to any great 
extent, and possess a range of non-specific effects including the inhibition of Na+/K+-ATPase, inhibition 
of hyperpolarisation and considerable depolarisation (Coleman, Tare et al. 2001).   
18α-Glycyrrhetinic acid has been shown to partially abolish responses to ACh in rat mesenteric 
arteries (Goto, 2002; Hill, 2000), rat middle cerebral arteries (Lagaud, Karicheti et al. 2002), and rabbit 
iliac arteries (Taylor, Chaytor et al. 1998) and human mesenteric arteries (Matoba, Shimokawa et al. 
2002).  18β-Glycyrrhetinic acid has also been shown to inhibit EDHF activity in the guinea-pig 
mesenteric artery (Yamamoto, Fukuta et al. 1998; Coleman, Tare et al. 2001).  It should also be noted 
however that 18α-glycyrrhetinic acid was found to be the more specific form for experimentation, as 
18β-glycyrrhetinic acid has inherent vasodilator effects (Coleman, Tare et al. 2001).  Carbenoxolone is a 
hemisuccinate water soluble salt of 18β-glycyrrhetinic acid (Coleman, Tare et al. 2002), which reduces gap 
junction connections by a mechanism which is probably related to connexin phosphorylation (Edwards, 
Feletou et al. 1999), and has also been shown to possess intrinsic vasorelaxant activity involving 
functional enhancement of NO, and causing additional effects on the vasculature (Chaytor, Marsh et al. 
2000). Carbenoxolone can also produce an endothelium-dependent depolarisation, which is probably not 
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the result of gap junction uncoupling, but rather due to inhibition of Na+/K+-ATPase, a secondary 
property of carbenoxolone (Edwards, Feletou et al. 1999).  Carbenoxolone has been shown to inhibit 
ACh-induced hyperpolarisations in the guinea-pig internal carotid artery (Edwards, Feletou et al. 1999) 
and rat superior mesenteric artery (Edwards, Feletou et al. 1999), but does not have an effect in human 
coronary microarteries (Batenburg, Garrelds et al. 2004). 
The non-specific effects of glycyrrhetinic acid and its derivatives limit the usefulness of these 
compounds in determining the role of gap junction communication in the actions of EDHF, however 
new peptides based on the extracellular structure of connexins may provide a more specific means of 
inhibiting gap junction communication.  The group of Gap 26 and Gap 27 connexin-mimetic peptides, 
as illustrated in Figure 1.6 , were first characterised by Chaytor in 1997 (Chaytor, Evans et al. 1997), and 
contain a motif  identical in sequence to a portion of the primary and secondary extracellular loops, 
respectively, of the specific connexin they are targeting (Figure 1.6).  The peptides are thought to 
interfere with both gap junction formation and stability (Edwards, Feletou et al. 1999; Hutcheson, 
Chaytor et al. 1999).  The specificity of these gap peptides has been studied recently, demonstrating that 
connexin-mimetic peptides block electrical signalling in rat mesenteric small arteries without exerting 
major non-junctional effects (Matchkov, Rahman et al. 2006).  Another study has demonstrated the 
effectiveness of the gap junction peptides in cultured rat aortic endothelial cells and A7r5 myocytes, 
showing that the peptides are able to reversibly block dye transfer without affecting plaque formation 
(Martin, Wall et al. 2005).   In contrast, a recent study in cerebral vessels using 37,43gap27 and 40gap27, 
showed non-junctional effects, with both peptides reducing [Ca2+]i oscillations in smooth muscles, and 
37,43gap27 also hyperpolarising the smooth muscle cell membrane (Haddock, Grayson et al. 2006).  
Peptide gap junction inhibitors targeting connexin 43 and connexin 40 have also been shown to inhibit 
the flow of lucifer yellow dye current through gap junctions (Dora, Martin et al. 1999; Berman, Martin et 
al. 2002).  However, inhibition of dye coupling is not necessarily a good indicator of inhibition of 
Chapter 1 
 
1-24 
electrical coupling, since dye coupling can be demonstrated in the absence of detectable gap junction 
coupling (Beny and Connat 1992; van Rijen, van Veen et al. 2000).   
37,43Gap 27 has been shown to abolish the hyperpolarisation to ACh and the IKCa activator 1-
ethyl-2-benzimidazolinone (1-EBIO) in internal carotid arteries from Duncan-Hartley guinea-pigs 
(Edwards, Feletou et al. 1999), and ACh responses in pig coronary arteries (Edwards, Thollon et al. 
2000).  In another study 37,43Gap 27 abolished carotid artery hyperpolarisation to ACh, with no non-
specific effects on the response to levcromakalim, a direct activator of KATP channels, suggesting that in 
the guinea-pig internal carotid artery, electronic propagation of endothelial cell hyperpolarisation via gap  
junctions may be the sole mechanism underlying the response attributed to EDHF (Edwards, Thollon et 
al. 2000).  37,43Gap 27 has also been shown to markedly attenuate the endothelium-dependent relaxation 
in the rabbit and rat mesenteric bed (Chaytor, Evans et al. 1998), and the rabbit central ear artery 
(Berman, Martin et al. 2002).    
Several studies have indicated that you may need a combination of gap peptides in order to cause 
significant attenuation of the relaxation (Chaytor, Martin et al. 2001), in which individual peptides have 
either no or negligible effects.  Chaytor et al. (2005) used gap peptide combinations to demonstrate that 
connexin 37 and connexin 40 are involved in the initial propagation of the hyperpolarisation from the 
endothelial cell layer to the subintimal media layers, whereas connexin 43 is involved in the further 
propagation of the electrical stimulus through to the subadventitial layers of the media (Chaytor, Bakker 
et al. 2005).   Gap peptides inhibiting connexin 40 have also been used to attenuate vasodilatation 
responses in rat renal arteries (Karagiannis, Rand et al. 2004) and mesenteric arteries (Mather, Dora et al. 
2005).    
Recently, a method was developed to selectively load gap peptides into endothelial cells, to study 
the importance of endothelial-endothelial and myoendothelial gap junctions.  This study also 
incorporated the use of newer gap peptides which are able to inhibit connexins by targeting the 
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intracellular carboxyl-terminal region, and this study demonstrated that connexin 40 plays a critical role in 
EDHF-mediated dilatation in pressurised rat third-order mesenteric arteries (Mather, Dora et al. 2005).   
The development of connexin-mimetic peptides has allowed studies to investigate what 
proportions of each connexin types are present in different vascular beds, and by using combinations of 
inhibitors intercellular communication can be studied in more depth (Chaytor, Martin et al. 2001).  It 
remains to be determined whether these inhibitors are affecting homocellular coupling or myoendothelial 
heterocellular coupling; this acknowledges a need to identify the specific connexins that form the 
heterocellular gap junctions between endothelial cells and smooth muscle cells in order to produce more 
specific inhibitors to such gap junctions (Hutcheson, Chaytor et al. 1999; Chaytor, Martin et al. 2001; 
Goto, Fujii et al. 2002).  What has become clear is that gap junction involvement in EDHF-mediated 
relaxations plays a varied role, depending on the vascular bed being studied.   
There has been recent suggestion that gap junctions may actually act in combination with EETs 
to mediate EDHF-derived vasodilatation.  Popp et al. demonstrated that bradykinin-induced 
vasodilatation in porcine coronary endothelial cells elicited a biphasic effect, with sulfaphenazole-
sensitive electrical coupling and the transfer of lucifer yellow dye (Popp, Brandes et al. 2002).  This dual 
effect was also seen in human endothelial cells following the administration of 11,12-EET (Popp, 
Brandes et al. 2002). 
 
1.3.1 The Physiological Role of  Gap Junctions 
The use of connexin knockout models has greatly advanced investigations into understanding the 
roles of specific connexins in vivo.  Connexin 37, 40 and 43 knockout mice have been made available, 
with most information pertaining to the connexin 40 knockout model.  Initial studies showed that 
connexin 40-deficient mice have an attenuated propagation of vasodilatation and vasoconstriction along 
the vessel (de Wit, Roos et al. 2000; Figueroa, Paul et al. 2003), and further studies went on to show that 
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these mice had  irregular vasomotion, associated with hypertension (de Wit, Roos et al. 2003).  
Interestingly, mice deficient in connexin 40 have been shown to have upregulated connexin 37 and 
connexin 43 levels in aortic endothelium, retaining intercellular communication (Kruger, Beny et al. 
2002).  Mice lacking both connexin 37 and connexin 40 have severe vascular abnormalities and die 
perinatally (Simon and McWhorter 2002), with pronounced vasodilatation.  As connexin 43 knockout 
mice do not survive, models which block tissue-specific connexin 43 subtypes have been bred.  A 
cardiac-restricted knockout model has been used to show that a lack of connexin 43 is associated with 
the development of fatal arrhythmias (Gutstein, Morley et al. 2001).  
Gap peptides have been used in in vivo rat experiments, which have demonstrated that ACh-
induced renal blood flow is abolished with 40Gap27, with only a small attenuation in the presence of 
37,43Gap27 (De Vriese, Van de Voorde et al. 2002).  Furthermore, the infusion of 40Gap27 or 37,43Gap27, 
led to a decrease in basal renal blood flow and a subsequent increase in mean arterial blood pressure, 
suggesting a basal role for EDHF in vascular resistance (De Vriese, Van de Voorde et al. 2002). 
 
1.3.2 The Role of  Gap Junctions in Vasomotor Conduction 
Recent studies have used gap junction inhibitors to study their effects on conducted 
vasodilatation and vasoconstriction, following the theory that gap junctions are thought to be involved in 
the propagation of the EDHF response along the vessel wall (Segal and Duling 1987; Segal and Duling 
1989; Edwards, Feletou et al. 1999).   These studies have established a role for gap junctions in the 
coordination of vascular behaviour and blood flow regulation (de Wit, Hoepfl et al. 2006).  This method 
involves using microiontophoresis to deliver ACh to a localised area of an arteriole, a defined distance 
from the membrane potential recording sites, up to 2000 m (Figueroa, Paul et al. 2003; Crane, Neild et 
al. 2004).  Transient hyperpolarisations have been recorded at these remote sites in response to ACh, 
which are attributed to EDHF in hamster cheek pouch arterioles (Crane, Neild et al. 2004) and mouse 
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cremaster arterioles (Looft-Wilson, Payne et al. 2004).  Studies using this technique have shown that 
vasodilatation is conducted along the endothelium of mouse cremaster arterioles (Looft-Wilson, Payne et 
al. 2004), and hamster feed arteries (Segal, Welsh et al. 1999; Emerson and Segal 2000) through gap 
junctions associated with connexins 37 and 40.  In contrast, the same technique has been used to 
demonstrate that both endothelial and smooth muscle layers are involved in vasodilatation conductance 
in hamster cheek pouch arterioles (Welsh and Segal 2000; Sandow, Looft-Wilson et al. 2003), associated 
with gap junctions consisting of connexins 37, 40 and 43 (Sandow, Looft-Wilson et al. 2003).    
Patch clamp conductance studies in guinea-pig mesenteric arteries, consisting of one smooth cell 
layer, showed that electrical conductance along endothelial cells, connected by gap junctions associated 
with connexins 40 and 43, demonstrates virtually no reduction over 25 m.  Conductance along the 
smooth cell layer, however, diminished steeply, and therefore electrotonic potential was spread from the 
endothelial cell layer to individual smooth muscle cells (Yamamoto, Klemm et al. 2001). 
The emerging studies of vasoconduction has initiated a whole new way of studying, not only gap 
junctions, but also EDHF, and allows a far more comprehensive understanding of the physiological role 
of gap junctions and EDHF.  These studies are also producing novel concepts regarding how gap 
junctions and EDHF can be affected by disease states. 
 
1.3.3 Regulation of  Connexin Expression 
Connexin expression in the vasculature has been shown to be altered in a number of 
pathophysiological states.  Decreases in connexin 43 levels have been demonstrated in type 1 diabetes 
(Zhang and Hill 2005) and heart failure (Severs 2002), whilst connexin 40 has been shown to be reduced 
in atherosclerosis (Kwak, Mulhaupt et al. 2002).  In contrast, connexin 43 levels have been demonstrated 
to be increased in early-atherosclerosis (Severs, Rothery et al. 2001).  Such findings raise questions about 
the regulation of connexin expression, either at the mRNA or protein level.  These questions appear to 
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have gained limited interest, however there are a number of studies that present possible mediators of 
connexin expression, including: all-trans retinoic acid, the tyrosine kinase pathway, tumour necrosis 
factor α (TNFα), homocysteine, the cAMP/protein kinase A (PKA) pathway and the protein kinase C 
(PKC) pathway. 
 
1.3.3.1 All-trans Retinoic Acid 
Early studies in 10T1/2 mouse cells showed that carotenoids upregulated connexin 43 mRNA 
levels (Zhang, Cooney et al. 1992), and further experiments in keratinocytes showed that retinoids had 
the same upregulatory effect (Guo, Acevedo et al. 1992).  All-trans retinoic acid has been shown to 
regulate connexin 43 mRNA levels by altering the stability of the 3‟ untranslated region (Clairmont and 
Sies 1997).   
 
1.3.3.2 Tyrosine Kinase Pathway 
More in depth studies in umbilical vein endothelial cells have demonstrated that hypoxia 
decreases connexin 43 function via  the activation of tyrosine kinase by vascular endothelial growth 
factor (VEGF) and enhanced phosphorylation of connexin 43 (Zhang, Morita et al. 1999), which was 
reversed with eicosapentaenoic acid (EPA) (Zhang, Yao et al. 2002).  The latter study also showed that 
SOD had no effect on connexin 43 regulation, suggesting ROS (or at least extracellular superoxide 
anions) were not involved (Zhang, Yao et al. 2002).   
 
1.3.3.3 TNFα 
Connexin 40 mRNA expression in HUVEC cells has been shown to be downregulated following 
the exposure to TNFα, which also decreased connexin 37 levels, with no effect on connexin 43. Dye 
coupling experiments showed that this decrease in mRNA was associated with a 40% decrease in dye 
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transfer (van Rijen, van Kempen et al. 1998).  Interestingly these effects were reversible 24 hr after the 
TNFα was removed (van Rijen, van Kempen et al. 1998).  TNFα also regulates connexin 43 in cultured 
HeLa cells and cardiac myocytes, by the p38 MAP kinase pathway, which is the same pathway involved 
in adenylyl cyclase (AC)/cAMP/protein kinase A (PKA), PKC pathways (Salameh, Polontchouk et al. 
2003; Salameh, Schneider et al. 2004).   This pathway has also been shown to involve activation of the 
tyrosine kinase pathways (Iwata, Haruta et al. 2001).   
 
1.3.3.4 Homocysteine 
Hyperhomocysteinaemia has been consistently implicated in the development of cardiovascular 
complications in diabetic patients (Hoogeveen, Kostense et al. 1998; Yeromenko, Lavie et al. 2001; 
Huijberts, Becker et al. 2005), however only a small number of studies have focussed on the affect of 
homocysteine on EDHF or gap junctions.  In one study, rat renal interlobar arteries pre-treated with 
homocysteine were demonstrated reduced EDHF activity (Li, Brodsky et al. 2002).  Homocysteine has 
been shown to upregulate connexin 43 in human umbilical vein endothelial cells (HUVEC)(Li, Brodsky 
et al. 2002), and this upregulation was associated with a redistribution of connexin 43 to intracellular 
compartments such as the mitochondria (Li, Brodsky et al. 2002).  In contrast, connexin 40 mRNA 
expression is downregulated in renal arteries from hyperhomocysteinaemic (HHcy) rats, which was 
accompanied by a decrease in EDHF-mediated vasodilatation (Heil, De Vriese et al. 2004).   
 
1.3.3.5 cAMP/Protein Kinase A Pathway 
Gap junctional communication in porcine coronary endothelial cells has also been shown to be 
sensitive to the PKA inhibitors Rp-cAMPS and KT5720 (Popp, Brandes et al. 2002).  This study, which 
also linked EETs with gap junctional communication, suggested that EETs are able to regulate gap 
junctional communication via the activation of cAMP-dependent PKA, which results in the 
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subsequent activation of extracellular signal-regulated kinase (ERK) 1/2  (Popp, Brandes et al. 2002).  
Additionally, cAMP has also been shown to regulate EDHF-mediated vasodilatation in isolated rabbit 
ear arteries (Taylor, Chaytor et al. 2001).  An important group of studies published by Matsumoto et al. 
have shown firstly that phosphodiesterase 3 (PDE3) activity is increased in mesenteric arteries from 
STZ-treated diabetic rats, which results in decreased cAMP activity (Matsumoto, Kobayashi et al. 
2003).  A follow-up study further showed that PKA activity is decreased in these same arteries 
(Matsumoto, Wakabayashi et al. 2004).  A third study demonstrated that treatment with cilostazol, a 
PDE3 inhibitor, improves EDHF-mediated vasodilatation in the mesenteric arteries from STZ-treated 
diabetic rats, which were significantly impaired without treatment (Matsumoto, Kobayashi et al. 2005).  
Most recently, this group has studied cAMP and PKA in the insulin resistant Otsuka Long-Evans 
Tokushima Fatty (OLETF) rat (discussed in section 1.7.5) in which EDHF vasodilatation has been 
shown to be impaired.  This study demonstrated that the cAMP/PDE3 inhibitor 3-isobutyl-1-
methylxanthine enhanced EDHF-mediated vasodilatation in OLETF mesenteric arteries to a lesser 
extent of that seen in the control mesenteric arteries, suggesting that the attenuated EDHF-mediated 
vasodilatation was partly attributable to a decrease in PKA activity (Matsumoto, Kobayashi et al. 2006). 
 
1.3.3.6 Protein Kinase C Pathway 
Gap junction activity has been shown to be reduced in cultured vascular smooth muscle cells 
exposed to 5.5 mM glucose, which could be mimicked by 12-O-tetradecanoylphorbol-13-acetate 
(TPA), was completely reversed following exposure to the PKC inhibitor calphostin C (Kuroki, 
Inoguchi et al. 1998).  Western blot analysis showed that both glucose and TPA resulted in excessive 
phosphorylation of connexin 43, which was restored to control levels by calphostin C (Kuroki, 
Inoguchi et al. 1998).  Similarly, gap junction activity has been shown to be reduced in cultured bovine 
aortic endothelial cells exposed to high glucose, which could be replicated by exposure to the PKC 
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activator 12-O-tetradecanoylphorbol-13-acetate.  Furthermore, gap junction activity was restored 
following exposure to the PKC inhibitor staurosporin (Inoguchi, Ueda et al. 1995).   
 
1.4 Insulin Resistance and Diabetes 
The World Health Organisation (WHO) estimates that there were 171 million people worldwide 
with diabetes in the year 2000, equivalent to approximately 3% of the population (Roglic, Unwin et al. 
2005).  The prevalence is expected to reach 366 million in 2030 (Roglic, Unwin et al. 2005), which will 
place an increasing burden on society, health wise and economically.  Furthermore, global diabetes-
related mortality is estimated at 2.9 million deaths, equivalent to 5.2% of all deaths worldwide per year 
(Roglic, Unwin et al. 2005).  In Australia, there were 20,908 diabetes-related deaths during the period 
between 2001-2003, representing 5.4% of all deaths (AIHW: Dixon T and Webbie K 2005). 
Type 1 (insulin-dependent) diabetes accounts for 5-10% of all diagnosed cases of diabetes (CDC 
2005).  Type 1 diabetes develops when the body's immune system destroys pancreatic beta cells, the only 
cells in the body that make the hormone insulin that regulates blood glucose.  To survive, people with 
type 1 diabetes must have insulin delivered by injection or a pump. This form of diabetes usually strikes 
children and young adults, although disease onset can occur at any age (CDC 2005).   
Type 2 (non insulin-dependent) diabetes accounts for approximately 90% of diagnosed cases of 
diabetes (Moller 2001).  This condition arises from an increased demand for insulin, accompanied by the 
gradual loss of insulin production.  Type 2 diabetes is associated with obesity, family history of 
diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and 
race/ethnicity (CDC 2005).  Type 2 diabetes is characterised by a state of hyperinsulinaemia and 
hyperglycaemia (De Vriese, Verbeuren et al. 2000), and is largely associated with the elderly, although 
type 2 diabetes in childhood and adolescence is also receiving increased attention.  Childhood type 2 
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diabetes has gone largely undetected, and an American study indicated that ~4% of obese children and 
adolescents have type 2 diabetes (Sinha, Fisch et al. 2002). 
The differences in the two types of diabetes contribute to the disparate endpoints seen between 
type 1 and 2 diabetic patients.  For instance, nephropathy develops in 35-45% of type 1 diabetic patients, 
and only 20% of type 2 diabetic patients (Nathan 1993).  Furthermore, nearly 60% of  type 2 diabetics 
die from ischaemic heart disease compared with 15% of type 1 diabetics (Jones and Gill 1997). 
Insulin resistance represents a pre-diabetic (type 2) stage, characterised initially by a 
normoglycaemic and hyperinsulinaemic state due to an impaired response of target tissues (liver, skeletal 
muscle and adipose tissue) to the action of insulin (Zimmet, Boyko et al. 1999).  Ultimately, through 
progressive insulin resistance or advanced impairment of  beta cell function in the pancreas, insulin levels 
plateau, and blood glucose levels rise, beginning with glucose intolerance, and leading to overt 
hyperglycaemia and type 2 diabetes (Jones and Gill 1997).  Insulin resistance is often accompanied by a 
combination of cardiovascular risk factors, including obesity, dyslipidaemia, glucose intolerance, 
hyperinsulinaemia and hypertension (Reaven and Laws 1994).  This combination of risk factors are now 
commonly referred to as the metabolic syndrome (Eckel, Grundy et al. 2005), and the International 
Diabetes Federation has recently defined the metabolic syndrome by the presence of raised fasting 
triglyceride and glucose levels, reduced high density lipoprotein (HDL) and raised blood pressure 
(Alberti, Zimmet et al. 2006).  It has been estimated that the prevalence of Americans with the metabolic 
syndrome is 41.3% of men and 32.7% of women between the ages of 40 and 74 (Ford, Abbasi et al. 
2005).  
The Centre for Disease Control and Prevention (CDC) National Health and Nutrition 
Examination surveys (NHANES) has estimated that approximately 40% of American adults have insulin 
resistance (CDC 2005).  The prevalence of type 2 diabetes in the United States is 6.5% for the total 
population over 20 years of age, 5.6% in non-Hispanic whites, 10.0% in non-Hispanic blacks and 6.5% 
Chapter 1 
 
1-33 
in Mexican Americans (Cowie, Rust et al. 2006).  Of increasing concern is the increasing prevalence of 
type 2 diabetes in children and adolescence, with 4% of overweight adolescents being diagnosed with 
type 2 diabetes (Sinha, Fisch et al. 2002).  Accompanying the increase in type 2 diabetes in children and 
adolescence, there is also an alarming increase seen in the prevalence of insulin resistance in these age 
groups.  A review of childhood diabetes studies has indicated that 3-13% of children or adolescents may 
have impaired glucose tolerance, depending on the population and age being studied (Bloomgarden 
2004; Williams, Cadwell et al. 2005). 
 
1.5 Long-term Complications of  Type 1 and 2 Diabetes 
Diabetic patients are at risk of developing numerous complications, including the 
microangiopathies (diabetic retinopathy, neuropathy, nephropathy) and macroangiopathies 
(atherosclerotic vascular disease in the heart, brain and legs) (Nathan 1993; Jones and Gill 1997).  
Hence, the risk of cardiovascular disease is much greater in patients with type 1 or 2 diabetes, with 
heart disease and stroke accounting for up to 65% of deaths in diabetics.  Diabetic retinopathy, 
neuropathy, and renal failure are also common complications, with diabetes being the leading cause of 
adult blindness, end stage renal failure and non-traumatic lower-limb amputations (CDC 2005).    
 
1.5.1 Microangiopathies 
Retinopathy refers to a series of changes, beginning with small lesions arising from retinal 
capillaries, leading to dot and blot haemorrhages, due to erythrocytes escaping from the extra-permeable 
retinal vessels.  This can be followed by a state of proliferative retinopathy which is characterised by 
neovascularisation of retinal capillaries, which are dysfunctional (King, Shiba et al. 1994).  If left 
untreated, retinopathy can result in impaired vision or complete blindness (Nathan 1993). 
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Neuropathies, which can be sensory or autonomic, mainly affect type 1 diabetic patients, as it is 
associated with a long duration of diabetes.  Sensory neuropathy is characterised by the loss of sensation 
in the extremities, which manifests clinically with conditions such as the “diabetic foot”, where the 
patient loses sensation in their feet, feeling numbness and weakness (Nathan 1993).  Autonomic 
neuropathies are associated with a collection of clinical disorders, including postural hypotension, 
“diabetic diarrhoea” and impotence (Comi and Corbo 1998).  Whilst neuropathy refers primarily to 
neural dysfunctions, it has been suggested that these dysfunctions stem from microvascular defects 
associated with the metabolic changes of diabetes (Cameron, Eaton et al. 2001). 
Nephropathy is a microvascular complication associated with the development of 
microalbuminuria, reflective of glomerular damage.  Nephropathy can lead to glomerular fibrosis, 
resulting in end-stage renal failure, which is a leading cause of mortality in diabetes (King, Shiba et al. 
1994). 
It is important to note that several large clinical trials have highlighted the importance of 
intensive glycaemic control in decreasing the onset and progression of microangiopathies.  The UK 
Prospective Diabetes Study (UKPDS) showed that glycaemic control in overweight patients with type 
2 diabetes, through the administration of Metformin, decreases the risk of diabetes-related endpoints 
(UKPDS 1998).  The Diabetes Control and Complications Trial (DCCT) also showed that intensive 
treatment of insulin in insulin-dependent type 1 diabetic patients reduces the progression of diabetic 
retinopathy, nephropathy, and neuropathy (DCCT 1993).  In addition, the Kumamoto study showed 
that intensive glycaemic control can delay the onset and progression of microvascular complication in 
Japanese patients with type 2 diabetes (Shichiri, Kishikawa et al. 2000).    
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1.5.2 Macroangiopathies 
The macroangiopathies refer to a collection of disorders affecting the macrovasculature, 
leading to an increased risk of stroke, coronary artery disease and peripheral gangrene (Nathan 1993).  
The UKPDS followed 4000 newly diagnosed type 2 diabetics over a ten year period, and found that 15% 
of patients had a myocardial infarction, 6% had a stroke and amputations were necessary in 1% of 
patients (Strojek 2003). These macrovascular complications have also been associated with an increased 
progression of atherosclerotic lesions (King, Shiba et al. 1994; Skrha 2003).   
 
1.6 Endothelial dysfunction as a cause of  long-term 
diabetic complications 
Loss of modulatory control in the cardiovascular system, such as the lost balance between 
endothelium-derived vasodilators and vasoconstrictors, may be a critical factor in the development of 
vascular disease in type 2 diabetes (Goligorsky, Chen et al. 2001).   The onset of angiopathy, due to 
endothelial dysfunction, has been highly correlated with morbidity and mortality in insulin-resistant and 
type 2 diabetic patients (Stehouwer, Lambert et al. 1997; Calles-Escandon and Cipolla 2001).  
Hyperglycaemia has consistently been implicated in the development of endothelial dysfunction (Pieper, 
Meier et al. 1995; Triggle, Howarth et al. 2005; Varma, Lal et al. 2005; Yu and Lyons 2005).  A series of 
metabolic disturbances displayed throughout the pre-diabetic and diabetic phases have been implicated in 
the development of endothelial dysfunction and diabetic complications, these include hyperactivity of the 
polyol pathway,  activation of PKC, accelerated formation of advanced glycation end products (AGEs) 
and oxidative stress (Brownlee 2001).  It is ultimately a complex interaction between all of these pathways 
that leads to the development of endothelial dysfunction and diabetes-related complications. 
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1.6.1 Polyol Pathway 
Although glucose levels in type 2 diabetes do not reach the extreme levels found in type 1 
diabetes, they are still high enough to saturate the hexokinase pathway by which glucose is degraded to 
glucose-6-phosphate.  With this pathway saturated, aldose reductase also begins to break down glucose 
via the polyol pathway, resulting in the production of sorbitol, in which NADPH is converted to 
nicotinamide-adenine-dinucleotide phosphate (NADP+).  Sorbitol is then converted to fructose, and 
nicotinamide-adenine-dinucleotide (NAD+) is converted to dihydro-nicotinamide-adenine-dinucleotide 
(NADH) (Cohen 1993).  Activation of the polyol pathway therefore leads to a decreased availability of 
NADPH, a cofactor required for  eNOS activity and glutathione antioxidant activity (Cohen 1993).  The 
altered NADH/NAD+ ratio may also decrease BH4 levels, a cofactor for eNOS activity, resulting in 
decreased eNOS activity (Honing, Morrison et al. 1998).   
 
1.6.2 Protein Kinase C 
It has been shown that hyperglycaemia also induces the diacylglycerol-PKC pathway (Honing, 
Morrison et al. 1998); the de novo synthesis of diacylglycerol from glycolytic intermediates results in an 
increased NADH/NAD+ ratio, leading to further activation of the PKC pathway cyclic adenosine 
monophosphate.  PKC has been proposed to directly phosphorylate eNOS, ensuing a reduction in 
catalytic activity (Hirata, Kuroda et al. 1995), and may also inhibit insulin-stimulated eNOS activity 
(Kuboki, Jiang et al. 2000).  Stimulation of PKC has also been shown to reduce NO-mediated relaxation 
responses in the Wistar rat mesenteric bed (Taylor, Chaytor et al. 2001). 
Aside from the obvious effects hyperglycaemia has on NO function, it has also been shown to 
affect EDHF function.  As discussed above, hyperglycaemia can lead to a decrease in BH4 levels, which 
can affect not only eNOS activity; it has also been associated with endothelial function in vessels where 
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EDHF is the primary mediator of vasodilatation (Griffith, Chaytor et al. 2005).  Furthermore, as 
discussed in detail further on in this chapter (Section 1.6.7.3), the changes in the PKC pathway can also 
have deleterious affects on EDHF function, via its effect on gap junctions (Salameh, Polontchouk et al. 
2003).   
 
1.6.3 Oxidative Stress 
Oxidative stress describes a state in which there is an excessive production of ROS, leading to a 
compromised protective mechanism (Jay, Hitomi et al. 2006).  Oxidative stress may also arise from 
reduced anti-oxidant defence mechanisms, such as impaired glutathione peroxidase and glutathione 
reductase activity (Maritim, Sanders et al. 2003).  These alterations have been consistently implicated in 
the development of endothelial dysfunction in diabetes (Ting, Timimi et al. 1996; Anderson 1999; 
Ammar, Gutterman et al. 2000; Watts, Playford et al. 2002).  The role of ROS in the development of 
endothelial dysfunction has been extensively reviewed (Mezzetti, Cipollone et al. 2000; Maritim, Sanders 
et al. 2003; Son, Whalin et al. 2004; Ceriello 2006; Jay, Hitomi et al. 2006).  The increased production of 
ROS in diabetes, largely due to an increase in endothelium-derived ROS (Figure 1.4),  attributed to the 
hyperglycaemic state, is often suggested to be a primary event in the activation of the other pathways 
which lead to the development of endothelial dysfunction  For instance, the increased generation of 
superoxide alters the activity of eNOS, thereby leading to the increased production of peroxynitrite in the 
endothelium, which in turn activates the pathogenic pathways that lead to diabetes-related complications 
(Ceriello 2006).  The polyol pathway discussed in the section above also contributes to the oxidative 
environment seen in diabetic patients (Jay, Hitomi et al. 2006).  Firstly, NADPH levels are reduced as a 
result of aldose reductase reducing glucose to sorbitol.  Secondly, NADH levels are increased due to 
sorbitol dehydrogenase oxidising sorbitol to fructose.  The decreased NADPH reduces antioxidant 
activity, as it attenuates glutathione regeneration and NO˙ synthase activity, whilst the increased NADH 
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fuels NAD(P)H oxidases to produce superoxide. The exact role of ROS in diabetes is complex, but is 
certainly an important therapeutic target.  
 
1.6.4 Advanced Glycation End Products 
Another mechanism implicated in the development of diabetic complications is the increased 
production of AGEs.   AGEs are formed from the chemical modification and cross-linking of tissue 
proteins and their formation contributes to the gradual decline in tissue function and to the 
pathogenesis of diabetic complications.   
AGEs have been found to be increased in blood vessels of diabetic patients (Brownlee 2001), 
resulting in increased NO scavenging (Bucala, Tracey et al. 1991), thereby compromising endothelial 
vasodilatory function.  AGEs bind to the receptors for AGEs (RAGE), commonly found on vascular 
cells, which in turn stimulates the production of ROS, resulting in increased oxidative stress (Wautier, 
Chappey et al. 2001; Jay, Hitomi et al. 2006).  AGEs also increase vascular permeability, and enhance 
subintimal protein lipoprotein deposition, contributing to atherosclerotic lesion development (Honing, 
Morrison et al. 1998).  The AGE mode of action has been attributed to changes made by the AGEs to 
collagen cross-linking and tissue rigidity (Goligorsky, Chen et al. 2001), as well as AGE precursor 
modification to intracellular and extracellular proteins (Brownlee 2001; Jay, Hitomi et al. 2006).  Bucala 
et al. (1991) have demonstrated that inhibition of AGE production with aminoguanidine prevents the 
quenching of NO, returning endothelium-dependent vasodilatory function.   
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1.7 Endothelial Dysfunction in Diabetic Patients and 
Animal Models 
Endothelial dysfunction has been widely reported in both type 1 and 2 diabetes, and in both 
humans and animal models of diabetes mellitus.  As early studies investigated responses to endothelium-
dependent vasodilators without distinguishing between an effect on NO or EDHF, an impairment in 
endothelium-dependent relaxation was often interpreted as an impairment in the endothelial NO 
pathway, without knowledge about the relative contributions of different factors (De Vriese, Verbeuren 
et al. 2000).   
Only a limited number of studies have focused on the contribution of EDHF to endothelial 
dysfunction in insulin resistance and type 2 diabetes, and has been recently reviewed (Triggle, Hollenberg 
et al. 2003; Triggle, Ding et al. 2004; Fitzgerald, Kemp-Harper et al. 2005).  The effects of insulin 
resistance, type 1 and type 2 diabetes on endothelial dysfunction, specifically relating to EDHF, are 
discussed further below. 
 
1.7.1 Diabetic Patients 
Endothelial dysfunction has been demonstrated in conduit (Lekakis, Papamichael et al. 1997) 
and resistance arteries (Zenere, Arcaro et al. 1995; Carmines and Fujiwara 2002) from type 1 diabetic 
patients, where these patients have also been shown to have decreased brachial (Clarkson, Celermajer et 
al. 1996) and femoral artery flow-mediated vasodilatation (Jorgensen, Russo et al. 1988; Zenere, Arcaro et 
al. 1995).  Endothelial dysfunction in type 2 diabetic patients has been extensively reviewed (Cosentino 
and Luscher 1998; Makimattila and Yki-Jarvinen 2002; Dandona and Aljada 2004; Yu and Lyons 2005; 
Avogaro, Fadini et al. 2006), for instance, endothelial function has been shown to be impaired in the 
forearm vasculature (McVeigh, Brennan et al. 1992; Ting, Timimi et al. 1996), leg circulation (Steinberg, 
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Chaker et al. 1996), and coronary circulation (Nitenberg, Valensi et al. 1993).  An attenuation of flow-
mediated dilatation in the brachial artery has also been reported in type 2 diabetic patients (Enderle, 
Benda et al. 1998).  Whilst it is now clear that endothelial dysfunction is present in diabetic patients, and 
is inexplicably linked with the development of diabetes-related complications, the best therapeutic target 
to combat endothelial dysfunction is still under much debate (Bell, Johns et al. 1998; Anderson 1999; 
Calles-Escandon and Cipolla 2001).  
 
1.7.2 Streptozotocin-Induced Type 1 Diabetic Rats 
Type 1 diabetes can be induced in animal models following chronic treatment with 
streptozotocin (STZ) which destroys beta cells in the pancreas, thereby preventing insulin release 
(Tomlinson, Gardiner et al. 1992).  These rats develop many of the features associated with type 1 
diabetes, including hyperglycaemia, polyuria and  weight loss (Igarashi, Takeda et al. 1997).  Studies in 
STZ-treated diabetic rats have demonstrated endothelial dysfunction in the perfused kidney (Fulton, 
Balazy et al. 1996; Kamata and Hosokawa 1997) and the perfused mesenteric bed (Taylor, Wickenden et 
al. 1994; Makino, Ohuchi et al. 2000).  STZ-treated  rats have also been shown to exhibit endothelial 
dysfunction, associated with reduced NO activity, in the thoracic aorta (Hattori, Kawasaki et al. 1991; 
Shimizu, Muramatsu et al. 1993; Pieper, Langenstroer et al. 1997), mesenteric artery (Taylor, McCarthy et 
al. 1992; Fukao, Hattori et al. 1997; Palmer, Gopaul et al. 1998), interlobar artery (Dai, Diedrich et al. 
1993) and coronary artery (Koltai, Hadhazy et al. 1997).  In studies where the EDHF component has 
been isolated, EDHF-mediated relaxations to ACh have been found to be attenuated in perfused kidneys 
(Kamata and Hosokawa 1997) and mesenteric arteries (Fukao, Hattori et al. 1997; Makino, Ohuchi et al. 
2000; Wigg, Tare et al. 2001; Matsumoto, Kobayashi et al. 2003) from STZ-treated rats.   Similarly, small 
mesenteric arteries from STZ-treated diabetic ApoE-deficient mice, were found to demonstrate a 
decrease in EDHF-mediated vasodilatation, compared with the citrate-treated control ApoE-deficient 
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mice (Ding, Hashem et al. 2005; Morikawa, Matoba et al. 2005).  This impairment was associated with a 
decrease in EDHF-mediated dilatation, partly compensated by an increase in NO-mediated 
vasodilatation (Ding, Hashem et al. 2005; Morikawa, Matoba et al. 2005).  In contrast, histamine-induced 
dilatation in STZ-treated rats was recently demonstrated to be impaired, associated with a decrease in 
NO, with no alteration in EDHF activity (Yousif 2005).  
 
1.7.3 Obese Zucker Rat 
The genetically insulin-resistant obese Zucker rat (OZR: fa/?) can be characterised by the 
presence of hyperinsulinaemia, mild hyperglycaemia, enlarged fat cells, hyperphagia, insulin resistance, 
hypertension, hyperlipidaemia and proteinuria (McCaleb and Sredy 1992).  Age-based studies have 
shown that the onset of clinical manifestations is progressive, with metabolic and haemodynamic 
abnormalities fully developed at 24-25 weeks of age (Cox and Kikta 1992), and this has been confirmed 
in studies carried out in our laboratory (Lau and Reid 2000).   Endothelial dysfunction has been 
consistently reported in aortae from 10 to 14 week male OZRs (Duarte, Martinez et al. 1999; Brooks-
Asplund, Shoukas et al. 2002; Laight, Anggard et al. 2002) and the mesenteric arteries from 12 to 14  and 
25 to 30 week male OZRs (Zanchi, Delacretaz et al. 1995; Wu, Makynen et al. 1996; Walker, Dores et al. 
1997).  Endothelial dysfunction has also been reported in the renal artery (Hayashi, Kanda et al. 2002), 
basilar arteries  (Karagiannis, Reid et al. 2003) and skeletal muscle arteries (Frisbee and Stepp 2001) in 
this animal model.   
The breeding of two obese Zucker rats has seen the development of the diabetic fatty Zucker 
rat (ZDF: fa/fa), which is a model of overt type 2 diabetes.  Studies in the ZDF have demonstrated 
impaired flow-mediated dilatation in the mesenteric bed (Jin and Bohlen 1997) and impaired responses to 
ACh in isolated mesenteric arteries (Schafer, Steioff et al. 2004).  Additionally EDHF has shown to be 
impaired in ZDF epineurial arterioles (Coppey, Gellett et al. 2003). 
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1.7.4 Diet-Induced Insulin-Resistant Rat 
The feeding of fructose to Sprague-Dawley rats results in the development of hyperinsulinaemia, 
hyperlipidaemia, hypertension and insulin resistance, consistent with the insulin resistance syndrome 
(Hwang, Ho et al. 1987; Verma, Bhanot et al. 1996).  Studies using fructose-fed insulin-resistant rats have 
demonstrated endothelial dysfunction in coronary arteries (Miller, Katakam et al. 1999), renal arteries 
(Kamata and Yamashita 1999), middle cerebral arteries (Erdos, Miller et al. 2002) and superior (Verma, 
Bhanot et al. 1996) and third-order (Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999) 
mesenteric arteries.  In some studies, these impaired endothelium-dependent relaxations were related to a 
defect in EDHF-mediated relaxations in coronary (Miller, Katakam et al. 1999; Katakam, Ujhelyi et al. 
2000) and small mesenteric arteries (Miller, Hoenig et al. 1998; Katakam, Hoenig et al. 2000).  The 
decreased EDHF activity in the small mesenteric artery has also been associated with a compensatory 
increase in NO (Miller, Hoenig et al. 1998).   In comparison, a reduction in the cyclo-oxygenase-mediated 
pathway, alongside the altered function of KCa and KATP channels, was demonstrated in the middle 
cerebral artery (Erdos, Miller et al. 2002; Erdos, Miller et al. 2002).  A follow-up study showed that this 
endothelial impairment was associated with an increase in ROS production (Erdos, Simandle et al. 2004).  
Impaired KATP activity has also been reported in mesenteric arteries from fructose-fed rats (Katakam, 
Ujhelyi et al. 1999), and impaired KCa activity has been demonstrated in coronary arteries, which was 
reversible with the reductase inhibitor rosuvastatin (Miller, Tulbert et al. 2004). 
 
1.7.5 Otsuka Long-Evans Tokushima Fatty (OLETF) Rat 
The OLETF rat model was developed by the Tokushima Research Institute (Otsuka 
Pharmaceutical, Tokushima, Japan) (Kawano, Hirashima et al. 1992), and demonstrates hyperglycaemia 
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at 18 weeks, accompanied by the onset of hyperinsulinaemia, mild obesity, insulin resistance and renal 
complications (Kawano, Hirashima et al. 1992; Sakamoto, Minami et al. 1998).  Using this animal model, 
endothelial dysfunction has been demonstrated in renal arteries (Kagota, Yamaguchi et al. 2000) and 
aortae (Kagota, Yamaguchi et al. 2000; Kim, Lee et al. 2002); aortae from the OLETF rats have a 
significant EDHF component, and this is reduced in the diabetic state resulting in endothelial 
dysfunction (Minami, Ishimura et al. 2002).   
 
1.7.6 Type 2 Diabetic Mouse Models 
Studies in mice models of type 2 diabetes, such as the C57BL/KsJ-db/db mouse  have also 
demonstrated endothelial dysfunction in the aorta (Ellis, Pannirselvam et al. 2003) and small mesenteric 
arteries (Lagaud, Masih-Khan et al. 2001; Ellis, Pannirselvam et al. 2003), however the mechanisms 
underlying the dysfunction appear to differ from these commonly found in rat models of type 1 or type 2 
diabetes.  Superoxide-mediated impairment has been demonstrated in cerebral arteries (Didion, Lynch et 
al. 2005) and small mesenteric arteries (Pannirselvam, Wiehler et al. 2005), and increased vasoconstrictor 
activity has also been suggested to play a role in endothelial dysfunction in aortae (Kamata and Kojima 
1997; Kanie and Kamata 2000) and mesenteric arteries (Lagaud, Masih-Khan et al. 2001).   Endothelial 
dysfunction in the small mesenteric artery has also been associated with a decrease in NO, not EDHF, 
which was reversed using the NOS co-factor BH4 (Pannirselvam, Verma et al. 2002). 
An alternative model, the Tally Ho mouse has recently been developed as a multi-genic model 
of type 2 diabetes (Kim, Sen et al. 2001), however only gene and leptin characterisation studies have been 
undertaken (Brown, Olver et al. 2005; Kim, Stewart et al. 2005; Sung, Lee et al. 2005), and no 
information is available regarding the state of endothelial function. 
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1.8 The Effect of  Insulin Resistance and Diabetes on Gap 
Junctions 
As detailed in the previous section, many studies suggest that EDHF is impaired in insulin 
resistance and type 2 diabetes.  The importance of gap junctions in EDHF activity has also been 
previously discussed (section 1.3),  which leads to the question of  whether  impaired EDHF-mediated 
responses in diabetes are associated with abnormalities in either the structure or function of gap 
junctions (Goto, Fujii et al. 2002). 
There have been a number of reviews outlining gap junction and connexin changes in disease 
(Brink, Ricotta et al. 2000; Severs, Rothery et al. 2001; Kansui, Fujii et al. 2004; Rummery and Hill 2004), 
however there is little information pertaining to changes in gap junctions in animal models of insulin 
resistance and diabetes.  Down-regulation of connexin protein expression has been reported in studies in 
cells cultured in high glucose solution (Inoguchi, Yu et al. 2001; Li, Sato et al. 2003).  Inoguchi et al. 
(1995) determined that increased PKC levels were associated with attenuated gap junction activity in 
aortic endothelial cells exposed to high glucose levels and similar results were obtained in aortic smooth 
muscle cells, in which the attenuation was directly linked to an increase in the phosphorylation of 
connexin 43 (Kuroki, Inoguchi et al. 1998; Inoguchi, Yu et al. 2001).  Gap junctions have also been 
studied in microvascular endothelial cells cultured from rat epididymal fat pads, in which gap junction 
activity was reduced by exposure to high glucose,  with the reduction being associated with increased 
phosphorylation of connexin 43  and reduced connexin 43 protein and mRNA expression (Sato, 
Haimovici et al. 2002).  Fluorescent dye experiments, in cultured corporeal myocytes isolated from STZ-
treated rats, revealed that connexin 43-mediated junctional permeability was increased 3-fold, with no 
changes in connexin 43 expression, gating or conductance (Brink, Valiunas et al. 2006).  This study is the 
first to suggest that diabetes-related changes in intercellular permselectivity, a term used to define the 
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preferential permeation of certain ionic species through ion-exchange membranes, may have important 
implications in vascular intra-cellular communication. 
The most direct evidence for changes in gap junction activity related to diabetes comes from a 
study by Oku et al. (2001), which demonstrated that extensive cell-to-cell coupling in rat retinal 
microvessels was substantially reduced within days of the onset of STZ-induced diabetes.  In this study, 
cell-to-cell coupling was assessed using the gap junction-permeant tracer, Neurobiotin, which was 
delivered via patch pipettes into pericytes located on microvessels.   Immunohistochemical methods 
were then used to reveal the extent of the intercellular spread of the tracer.  In addition to this study, 
EDHF responses in superior mesenteric arteries from control and STZ-treated rats have been 
demonstrated to involve gap junctions using 18α-glycyrrhetinic acid; however, in this study the 
contribution of gap junctions did not differ between the control and STZ-treated rats (Matsumoto, 
Kobayashi et al. 2003).  
Overall, emerging studies suggest that EDHF-associated endothelial dysfunction may be 
related to defects in gap junctions, and invites further investigation. 
 
1.9 Aims of  the Thesis 
This project aims to identify the role of, and characterise, EDHF in animal models of insulin 
resistance, including the obese Zucker rat as well as the fructose-fed Sprague-Dawley rat.  It is 
hypothesised that endothelial dysfunction is present in small vascular arteries such as the third-order 
mesenteric artery and the lobar artery from these animal models of insulin resistance, and that this 
dysfunction can be linked with a reduction in EDHF function.  Furthermore, this study aims to identify 
an integral role of gap junctions in EDHF-mediated vasodilatation that may be compromised in insulin 
resistance. 
The specific aims of this project are as follows: 
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1) The aim of the experiments described in chapter 2 was to develop a pressure myograph 
protocol for the study of third-order mesenteric artery vasodilatation in male Sprague Dawley 
rats.  This included determining the optimal conditions required for the mesenteric artery to 
develop myogenic tone.  This was deemed necessary in order to assess endothelial function in 
resistance arteries (diameter <200 m), which are too small for wire myography.  Third-order 
mesenteric arteries were chosen as these resistance arteries are accessible for experimentation, 
and endothelial dysfunction has been consistently reported in the vessel, as discussed throughout 
this chapter. 
2) The aim of the experiments described in chapter 3 was to establish the role of EDHF in 
third-order mesenteric arteries from the lean (control) and obese (insulin-resistant) female Zucker 
rats.  Furthermore, this study aimed to characterise the EDHF-mediated response, in regards to 
the involvement of gap junctions and EETs.  Whilst other EDHF candidates also require 
investigation, our laboratory has focussed on gap junctions, although we also wanted to do 
preliminary studies into the role of EETs in EDHF-mediated vasodilatation, due to the increased 
interest EETs has received over the last few years.  Studies in our laboratory, in the renal artery 
from the lean and obese Zucker rats have suggested that whilst gap junctions do contribute to 
EDHF responses, there is a residual component resistant to gap junction inhibitors, which may 
be attributable to EETs. 
3) The aim of the experiments discussed in chapter 4 was to establish the role of EDHF in 
third-order mesenteric arteries from male lean and obese male Zucker rats, and compare these 
results with those obtained in the female Zucker rats.  A gender comparison study allows us to 
compare any differences in the degree of endothelial dysfunction, and any altered contributions 
of NO and EDHF. 
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4) The aim of the experiments described in chapter 5 was to compare connexin protein and 
mRNA levels in mesenteric and renal arteries from lean and obese female Zucker rats.  
Biochemical analysis of both protein and mRNA levels are important, as they contribute to the 
overall understanding of the effect of insulin resistance on gap junction function.  The hypothesis 
being that an impairment in gap junction function will be associated with a decrease in connexin 
protein and mRNA expression. 
5) The aim of the experiments described in chapter 6 was to establish the role of EDHF in 
lobar arteries from control and insulin-resistant fructose-fed Sprague-Dawley rats.  In order to 
determine that endothelial dysfunction in the female OZR is due to the state of insulin resistance, 
and not due to factors specific to this animal model, it is important to reproduce the findings in 
an alternative model of insulin resistance, such as the fructose-fed model. 
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Figure 1.1: Endothelium-derived relaxing factors  
Receptor-induced increases in intracellular calcium can result in vascular relaxation via the production of 
PGI2, NO or EDHF. 
 
Abbreviations:  (AA) arachidonic acid; (ATP) adenosine triphosphate; (cAMP) cyclic adenosine monophosphate; (cGMP) 
3′,5′-cyclic guanosine monophosphate; (EDHF) endothelium-derived hyperpolarizing factor; (GTP) guanosine 5′ 
triphosphate; (IP3) inositol phosphate; (NOS) nitric oxide synthase; (PGI2) prostacyclin; (R) endothelial receptor; (SR) 
sarcoplasmic reticulum. 
(Reproduced from Boulanger and Vanhoutte (Boulanger and Vanhoutte 1997)) 
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Figure 1.2: NOS conversion of arginine to citrulline 
NOS activity requires a series of cofactors to convert arginine to citrulline. 
 
Abbreviations:  (BH4) tetrahydrobiopterin; (e-)  electrons; (FAD) flavin adenine dinucleotide; (FE) haem iron; 
(FMN) flavin mononucleotide; (NADPH) nicotinamide adenine dinucleotide phosphate hydrogen; (NOS) nitric 
oxide synthase.  
 
Reproduced from  Alderton et al. (Alderton, Cooper et al. 2001). 
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Figure 1.3:  EDHF Candidates  
(1) A receptor-induced increase in intracellular calcium causes release of C-type natriuretic peptide 
(CNP) from the endothelium which activates the CNP receptor (NPR-C) on the smooth muscle 
cells; this stimulates G-protein gated inwardly rectifying potassium channels (GIRK) and the 
sodium potassium ATPase pump (Na+/K+ ATPase), (2) A receptor-induced increase in 
intracellular calcium results in potassium effluxing through small and intermediate KCa (SKCa and 
IKCa respectively) and/or stimulation of gap junctions (GJ);  increased levels of extracellular K
+ 
activates inwardly rectifying potassium channels (KIR) and Na
+/K+ ATPase (3) hydrogen peroxide 
(H2O2) activating a via a similar pathway to (2), (4) epoxyeicosatrienoic acids (EETs) produced by 
the arachidonic acid (AA)-cytochrome P450 (CYP) pathway opens BKCa channels, which closes 
vascular voltage operated calcium channels (VOCC).  
Note:  Pathways may vary in different vessels. 
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Figure 1.4:  Endothelium-Derived Reactive Oxygen Species 
Superoxide anions (reactive oxygen species (ROS)) generated within the endothelium can react with 
NO. to form OONO˙, or react with SOD to form H2O2 which can act on adjacent cells. 
 
Abbreviations: (NADPH) nicotinamide adenine dinucleotide; (XO) xanthine oxidoreductase; (eNOS) endothelial 
nitric oxide synthase; (CYP) cytochrome P450; (O2˙
-
) superoxide; (SOD) superoxide dismutase; (H2O2) hydrogen 
peroxide; (OONO˙) peroxynitrite; (˙OH) hydroxyl radicals; (GSH) glutathione. 
 
Derived from Ellis and Triggle (Ellis and Triggle 2003) 
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Figure 1.5:  Gap Junctions  
Gap junctions are formed between two adjoining cells.  Gap junctions are formed by two 
connexons, each consisting of six connexin subunits, docking together to create coupling between 
cells.  Gap junctions allow low molecular weight molecules (e.g. K+, Cl-, cyclic adenosine 
monophosphate (cAMP)) to diffuse through to an adjoining cell; gap junctions also allow 
transmission of electrotonic responses (membrane potential (mp)) between two cells.  Such 
communication may allow EDHF-mediated increases in endothelial cell intracellular calcium to 
stimulate hyperpolarisation and relaxation in adjoining cells via these mechanisms. 
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∆mp
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Factors
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Figure 1.6:  Connexin-mimetic Peptides 
Each connexin possesses four transmembrane segments (M1–4). Also highlighted are the Gap 26 and Gap 27 domains of the first and second extracellular 
connexin loops which are conserved in man, rat and mouse. Differences in the amino-acid sequences of the Gap 26 and Gap 27 domains of the three major 
vascular connexins allow designation as 37,40Gap26, 43Gap26, 37,43Gap27 and 40Gap27.  Synthetic peptides possessing these sequences inhibit direct 
intercellular communication in a connexin-specific fashion.  Reproduced from Griffith (Griffith 2004) 
 Gap 26 Gap 27 
Connexin 37 VCYDQAFPISHIR SRPTEKTIFII 
Connexin 40 VCYDQAFPISHIR SRPTEKNVFIV 
Connexin 43 VCYDKSFPISHVR SRPTEKTIFII 
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2. Characterisation of Vasodilatation in 
the Sprague-Dawley Rat Mesenteric 
Artery 
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2.1 Introduction 
As discussed in the introductory chapter (see section 1.4), nitric oxide (NO) solely 
mediates endothelium-dependent vasodilatation in conduit arteries such as the aorta, whereas 
vasodilatation in smaller arteries is predominantly modulated by endothelium-derived 
hyperpolarising factor (EDHF) (Vanhoutte and Eber 1991; Edwards and Weston 1998).  
Therefore, in order to study and characterise EDHF, the smaller resistance arteries, such as those 
located in the mesenteric arterial system, must be the primary level of investigation. 
Rat mesenteric endothelial function has been studied using a variety of methods, 
including the perfused mesenteric bed  (Adeagbo and Triggle 1993; Kamata, Umeda et al. 1996; 
Randall, Alexander et al. 1996; Harris, Martin et al. 2000; Makino, Ohuchi et al. 2000; Misurski, 
Tatchum-Talom et al. 2000; McNeish, Wilson et al. 2002), wire myography (Doughty, Plane et al. 
1999; Kimura, Tsuda et al. 1999; Chauhan, Rahman et al. 2003; Hinton and Langton 2003; Cao, 
Zheng et al. 2005) and pressure myography (Intengan, He et al. 1998; Tribe, Thomas et al. 1998; 
Doughty, Plane et al. 1999; Lagaud, Skarsgard et al. 1999; Scotland, Chauhan et al. 2001).  The 
perfused mesenteric bed is distinctively different to the wire and pressure myograph techniques, as 
the technique involves studying endothelial function in a complex interactive system consisting of 
all levels of mesenteric arteries, whereas the wire and pressure myograph in vitro systems are based 
on studying isolated single vessel function.  In distinguishing between the wire and pressure 
myograph techniques, it has been demonstrated that results obtained from wire and pressure 
myography can be vastly different using the same arterial section (Doughty, Plane et al. 1999), 
which has important implications for the study of small artery responses in vitro (Falloon, Stephens 
et al. 1995).  It has been suggested that in vivo behaviour is better reproduced in pressurised vessels 
than in wire-mounted vessels (VanBavel, Mooij et al. 1990; VanBavel, Giezeman et al. 1991).  
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Studies comparing the two techniques have demonstrated that pressurised rat small mesenteric 
arteries are significantly more sensitive to the vasoconstrictor noradrenaline in comparison to the 
wire-mounted artery (Buus, VanBavel et al. 1994; Falloon, Stephens et al. 1995).  Wall tension has 
been suggested as an influence in determining vascular sensitivity, since wall tension is lower in the 
pressurised preparation compared with a wire-mounted preparation (Schubert, Wesselman et al. 
1996).  Membrane potential has also been shown to be important in determining the reactivity of 
the resistance vasculature, as pressurised (isobaric) potentials mimic those in vivo, and wire-mounted 
(isometric) potentials can also mimic those in vivo if the vessels are partially depolarised (Dunn, 
Wellman et al. 1994).  Interestingly, one study has shown that acetylcholine (ACh)-induced 
relaxations are not significantly different between the wire and pressure myograph techniques, 
suggesting that agonist-induced endothelium-dependent relaxation is not influenced by the in vitro 
technique employed (Falloon, Stephens et al. 1995).   
In setting up the mesenteric artery using a pressurised set-up, there appears to be a lack of 
consensus in the literature regarding the optimal conditions required for mesenteric arteries to 
develop myogenic tone.  Myogenic tone refers to the intrinsic response of vascular smooth muscle 
to changes in transmural pressure or stretch; myogenic responsiveness is inversely related to vessel 
size (Schubert and Mulvany 1999).  The conditions used to obtain myogenic tone in the pressurised 
mesenteric arteries differ between laboratories in regards to the intraluminal pressure and 
equilibration times.  Intraluminal pressures employed include: 40 mmHg (Katakam, Ujhelyi et al. 
1999); 45 mmHg (Intengan, He et al. 1998); 50 mmHg, (Mather, Dora et al. 2005); 55 mmHg 
(Parkington, Dodd et al. 2004); 60 mmHg (Arenas, Xu et al. 2006); and 80 mmHg (Tribe, Thomas 
et al. 1998; Doughty, Plane et al. 1999; Lagaud, Skarsgard et al. 1999; Scotland, Chauhan et al. 
2001).  Equilibration times of 30 min (Katakam, Ujhelyi et al. 1999; Mather, Dora et al. 2005; 
Arenas, Xu et al. 2006), 40 min (Tribe, Thomas et al. 1998), 60 min (Intengan, He et al. 1998; 
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Lagaud, Skarsgard et al. 1999), and 90 min (Kenny, Baker et al. 2002) have been cited.  Another 
factor that differs between laboratories using pressurised myography is the buffer solution used, 
where most laboratories use a bicarbonate-buffered physiological salt solution (PSS) (Intengan, He 
et al. 1998; Doughty, Plane et al. 1999; Katakam, Ujhelyi et al. 1999; Scotland, Chauhan et al. 2001; 
Parkington, Dodd et al. 2004), however other laboratories use an organic  HEPES (2-N-
hydroxyethylpiperazine-N‟-2-ethansulfonic)-buffered PSS (Hill, Zou et al. 2000; Arenas, Xu et al. 
2006).  HEPES-based buffer was used for all of the pressure myograph experiments described 
during this project.  This decision was based on previous unpublished findings, which established 
that a HEPES-based buffer does not require constant oxygenation, and provides extra „buffering‟.   
Given the different protocols cited, characterisation of the pressurised mesenteric artery 
needed to be carried out in our laboratory in order to determine the optimal conditions for 
developing myogenic tone in the rat third-order mesenteric artery.  The specific aim of the 
experiments described in this chapter was to investigate the optimal conditions for developing 
myogenic tone in third-order mesenteric arteries from 8-wk Sprague-Dawley rats. This included 
studying the optimal intraluminal pressure, the incubation period required for the development of 
myogenic tone, and time-control experiments to determine the number of concentration-response 
curves achievable in an individual preparation before vascular function becomes compromised.  
This study provided a sound basis for subsequent pressure myograph experimental protocols. 
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2.2 Methods 
 
2.2.1 Animals 
Mesenteric beds from 8-wk male Sprague-Dawley (SD) rats (198 ± 15g) were used to 
characterise the optimal conditions for mesenteric pressure myography.  Their use was approved by 
the RMIT Animal Experimentation Ethics Committee (AEEC #0301, #0105 and #0403), and 
conformed to the Australian National Health and Medical Research Council Code of Practice for 
the Care and Use of Animals for Scientific Purposes.  The rats were killed by asphyxiation with 
carbon dioxide followed by decapitation.   
 
2.2.2 Rat Tissue collection 
The entire mesenteric bed was removed from the body cavity and placed in a HEPES-
buffered PSS: 111 mM NaCl, 11.5 mM glucose, 10 mM HEPES, 25.7 mM NaHCO3, 1.2 mM 
MgSO4, 2 mM CaCl2, 1.2 mM KH2PO4, 4.9 mM KCl (pH 7.4 at 37
oC, gassed with 95%N, 
5%CO2).   
 
2.2.3 Pressure Myography 
2.2.3.1 Isolation and Cannulation 
The pressure myograph technique used was based on the methodology for isolated and 
cannulated arterioles as used for a number of tissues (Kuo, Davis et al. 1988; Hill and Ege 1994).   
A portion of the mesenteric bed was placed in dissecting buffer (3 mM 3-N-morpholino 
propanesulfonic acid (MOPS), 1 mM NaH2PO4, 5 mM glucose, 2 mM pyruvate, 0.02 mM ethylene 
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diamine tetra-acetic acid (EDTA), 145 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1 mM MgSO4, 1% 
fatty-acid free albumin) in a cooled dissecting chamber (4oC), which is lined with a silicone gel 
allowing the tissue to be pinned out (Figure 2.1a).  Fibre-optic lighting was used to illuminate the 
tissue without heating it.  Fine forceps and scissors were used to clear away layers of fat and 
connective tissue under a dissecting microscope (Olympus SZX12, Olympus, Australia), isolating 
the third-order mesenteric artery (Figure 2.1b), without touching the vessel itself.  Care was taken to 
select a length of mesenteric artery (approx. 2-3 mm) with no branches; any unavoidable branches 
were tied off using suture fibres (10-0 monofilament).   
The vessel was then transferred to the arteriole chamber (5 ml) which sits inside a „pipette 
holder stage‟, complete with two, 3-dimensional micromanipulators (Figure 2.1c).  The 
microvessel was cannulated onto two opposing glass pipettes (formed using a Sachs-Flaming 
micropipette puller and Stoelting microforge from custom glass tubing (Drummond Scientific 
Company, USA)) and secured using suture fibres (10-0 monofilament)(Figure 2.1d).   The 
chamber was then placed on an inverted microscope (Olympus CK40 or IX70, Olympus, 
Australia) coupled to a charged-coupled device (CCD) camera and video monitor (Figure 2.2).   
 
2.2.3.2 Pressurisation and Equilibration 
Pressurisation of the vessel was achieved either via a height-adjustable water reservoir, or 
via a pressure servo control (Living System Instrumentation, Burlington, Vermont, USA) 
connected to a peristaltic pump (Living System Instrumentation, Burlington, Vermont, USA).  
The vessel was first connected at 50 mmHg, and then pressurised to 120 mmHg.  This step allows 
the vessel to be lengthened such that the vessel is taut, and the vessel can also be checked for 
leaks and untied branches by directly measuring the pressure in the vessel.  The vessel was then 
returned to 50 mmHg.  The chamber was superfused with PSS solution at a rate of 4 ml/min, 
Chapter 2 
 
2-7 
gradually warmed to 37°C, and the vessel was pressurised to 80 mmHg over 30 min, by increasing 
the pressure by 10 mmHg every 10 min.  The vessel was then further equilibrated until a stable 
level of myogenic tone was achieved.  Vessels were determined to have a viable level of myogenic 
tone if the internal diameter was 40-60% of the initial diameter (taken after returning the pressure 
to 50 mmHg following the single pressure step to 120 mmHg).   
Pressure and intraluminal diameter measurements were recorded on a MacLab system 
(MacLab/4 Chart Software, model MKIIII, AD Instruments Pty Ltd, Australia, Figure 2.2).  A 
temperature thermo-coupler was also attached to monitor the bath temperature, which was 
maintained at 37  0.5 oC.   
 
2.2.3.3 Pressure Curve  
Active (calcium-dependent) and passive (calcium-free) diameters were recorded as the 
pressure was changed between 30-130 mmHg in 10 mmHg units, and in a random order (e.g. 30, 
90, 70, 110, etc.) to obtain pressure curves.  After each change in pressure, the vessel was left to 
stabilise for 5-10 min.  The pressure at which the vessel showed a consistent level of tone 
approximately half way within the active tone range was identified to be the optimal pressure for 
experimentation. 
 
2.2.3.4 Vasodilatation Characterisation 
Endothelial function was determined by studying responses to the endothelium-
dependent vasodilator ACh (1 nM–3 µM) and the endothelium-independent vasodilator 
levcromakalim (LK, 1 nM–3 µM).  Concentration-response curves were obtained by the 
cumulative addition of the drug directly into the chamber.  All responses were obtained in the 
presence of 10 µM indomethacin to block prostanoid production.  Superfusion of the chamber 
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was stopped during concentration-response curves, and drugs were added directly to the arteriole 
chamber. 
A total of 3 sets of concentration-response curves for both ACh and LK, alternating 
between the agonists ACh and LK, were obtained in the same preparation (i.e. ACh, LK, ACh, 
LK, ACh, LK).  The time-line of these events are detailed in Figure 2.3.   
The second stage involved superfusing the vessels with PSS containing nitro-l-arginine 
methylester (L-NAME, 100 µM) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 µM) 
for 30 min, which remained present whilst a concentration-response curve for ACh was repeated.  
A 20-min washout period, followed by superfusion with L-NAME and ODQ, was repeated prior 
to a second concentration-response curve for LK (Figure 2.3a).   
The third stage involved incubation with 0.1 µM charybdotoxin (ChTx) and 1 µM apamin 
added as well as 100 µM L-NAME and 1 µM ODQ (Figure 2.3a) for 30 min.  For this set of 
concentration-curves, superfusion of the chamber was stopped and the drugs were added directly 
to the chamber. 
At the end of all experiments, the vessels were superfused with calcium-free PSS buffer 
for 20 min and the maximal (passive) diameter was measured and recorded.   
 
2.2.3.5 Time-Control Experiments  
Time-control experiments were carried out in mesenteric arteries from SD rats as 
described above (2.2.3.4) without the addition of inhibitor drugs (Figure 2.3b).    
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2.2.4 Data & Statistical Analysis 
The graphic and statistical software package GraphPad Prism version 4.00 for Windows 
(GraphPad, San Diego, California USA) was used to construct figures showing the data and 
analyses of the results.  Typical traces were obtained using MacLab. 
Data were presented as mean and standard error of the mean (SEM) with n indicating the 
number of experimental animals.  Student‟s t-test (paired) or a two-way analysis of variance (two-
way ANOVA) followed by Student-Newman-Keuls test was used to compare data sets.  A value 
of p<0.05 was regarded as statistically significant.  A two-way repeated measures ANOVA 
followed by Student-Newman-Keuls test was used when comparing concentration-curves 
obtained in the same vessel. 
GraphPad Prism (V.4 for Windows, GraphPad, San Diego, California USA) was used to 
fit regression lines to the linear portions of the log concentration-response curves by the method 
of least squares.  EC50 values were interpolated from the regression lines, and correspond to a 
concentration producing 50% of the maximal response.  EC50 values are shown with the 95 % 
confidence interval (CI) ranges, and were considered to be significant if the ranges did not 
overlap. 
 GraphPad Prism was also used to construct figures showing the data and analyses of 
the results. 
 Relaxations were measured as a percentage of the maximal (passive) diameter. 
 
 Diameter (% of max.) = 100-(R/M x 100) 
 
where R is the absolute diameter at a given drug concentration and M is the maximal diameter of 
the vessel as determined by superfusing the vessel with calcium-free PSS. 
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2.2.5 Drugs and Chemicals 
All drugs were purchased from Sigma Chemicals unless otherwise stated.  All drugs were 
dissolved in distilled water with several exceptions: indomethacin was dissolved in 0.1 M Na2CO3 
to give stock solutions of 0.01 M; LK was dissolved in 70% ethanol to give a stock solution of 0.01 
M.  All stock solutions were diluted on the day using PSS. 
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Figure 2.1:  Isolation and Cannulation of the Mesenteric Artery 
a) The mesenteric bed is pinned out flat; b) The third-order mesenteric artery is identified and 
cleared of surrounding fat and connective tissue; c) The vessel is placed in a cannulating chamber 
with two opposing glass pipettes submerged in physiological salt solution; d) The isolated vessel is 
cannulated between the two pipettes.  Suture is used to tie each end of the vessel to the glass 
pipette, and to tie off any branches. 
3rd order 
2nd order 
Chapter 2 
 
2-12 
 
Figure 2.2:  Pressure Myography Methodology 
Pressure (e.g. 80 mmHg) was maintained in the vessel via a height-adjustable water reservoir.  In 
some experiments, a pressure servo control connected to a peristaltic pump was used to maintain 
pressure.  The bath was superfused with physiological salt solution (containing 10μM 
indomethacin), allowing the vessel to develop myogenic tone.  Vessel diameter was measured using 
a charge-coupled device (CCD) video camera linked to a dimension analyser. 
Illustration based on (Duling, Gore et al. 1981)  
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Figure 2.3: Pressure Myograph Protocols 
A) Time-line detailing concentration-response curves to acetylcholine (ACh) and levcromakalim (LK) in the presence nitro-l-arginine methylester (L-NAME, 
100 µM) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 µM), or 100 µM L-NAME, 1 µM ODQ, charybdotoxin (ChTx, 0.1 µM) and apamin (1 µM)  
B) Time-line detailing concentration-response curves to acetylcholine (ACh) and levcromakalim (LK) in the absence of inhibitors. 
 
All experiments end with a washout period in zero calcium physiological salt solution (0 Ca).
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2.3 Results 
Vessels obtained a steady state of myogenic tone following an equilibration period of 50-60 
min, including the time to step from 50 mmHg to 80 mmHg.   
2.3.1 Pressure Curves 
The active and passive diameters at various pressures between 30 and 130 mmHg were 
recorded in third-order mesenteric arteries from SD rats (Figure 2.4).  From this graph, 80 mmHg 
was chosen as an appropriate pressure to study vasodilatation in third-order mesenteric arteries, as 
vessels at 80 mmHg consistently developed tone, without lying too close to either end of the active 
tone range (60-130 mmHg).   
 
2.3.2 Vasodilatation Characterisation 
All results have been normalized against the maximal (passive) diameter (181 ± 14 µm, 
n=9).  The active level of myogenic tone achieved was 60.7 ± 2.7% (n=9) of the maximal passive 
diameter.  Figure 2.5 illustrates a typical trace obtained for vasodilatation to ACh and LK.  
Responses to ACh, were not significantly (p>0.05, two-way ANOVA) altered in the presence of 
L-NAME and ODQ, but were abolished in the presence of L-NAME, ODQ, ChTX and apamin 
(Figure 2.6). It should be noted that incubation with the latter combination resulted in significant 
constriction (p<0.05, paired Student‟s t-test); the level of myogenic tone was decreased to 32.1  
3.0% of the maximal passive diameter.   
Responses to LK were not significantly (p>0.05, two-way ANOVA) altered in the 
presence of L-NAME and ODQ.  Although there was a significant change in the basal level of 
myogenic tone in the presence of L-NAME, ODQ, ChTX and apamin, the maximum response 
to LK was not altered, but there was a significant change in the EC50 (no inhibitors: 61.9 nM, 
Chapter 2 
2-15 
95% CI 40.0 – 96.1 nM; L-NAME, ODQ, ChTX, apamin: 17.5 nM, 95% CI 10.5 – 29.3 nM, 
Figure 2.6). 
 
 
2.3.3 Time-Control Experiments 
Time-control experiments are shown in Figure 2.7.  Responses to ACh and LK did not 
change (p>0.05, ANOVA, n=4) when 3 sets of concentration-response curves (alternating ACh, 
LK) were obtained in the same mesenteric artery preparation without addition of inhibitor drugs.    
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Figure 2.4:  Pressure Myography: Pressure Curves 
Active (●, calcium-present) and passive (●, calcium-free) pressure curves were obtained in third-
order mesenteric arteries from Sprague-Dawley rats, obtained using pressure myography.  Values 
are shown as mean ± SEM (n=4).   
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Figure 2.5:  Representative Acetylcholine- and Levcromakalim-Induced 
Relaxations 
Typical traces illustrating the relaxations induced by a) acetylcholine (10-9 to 3x10-6M cumulative 
additions indicated by arrows) and b) levcromakalim (10-9 to 3x10-6M, cumulative additions 
indicated by arrows) in third-order mesenteric arteries from 8-wk Sprague-Dawley rats.   
A.  Acetylcholine 
B.  Levcromakalim 
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Figure 2.6: Acetylcholine and Levcromakalim Response Curves 
Concentration-response curves for relaxations to a) acetylcholine (ACh) and b) levcromakalim (LK) 
in mesenteric arteries from 8-wk Sprague-Dawley rats in the presence of 10 µM indomethacin with 
or without nitro-l-arginine methylester (L-NAME, 100 µM) and 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ, 1 µM), or L-NAME (100 µM), ODQ (1 µM), charybdotoxin (ChTX, 0.1 
µM) and apamin (1 µM).  Values are shown as mean ± SEM (n=4).  Note that in some instances 
error bars are smaller than the size of the symbols. 
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Figure 2.7:  Time-Control Experiments 
Responses to a) acetylcholine (ACh) and b) levcromakalim (LK) were obtained in third-order 
mesenteric arteries from 8-wk Sprague-Dawley rats, by alternating ACh, LK over 6 concentration-
response curves (i.e. 3 pairs of curves):  1 refers to the first pair of curves for ACh and LK; 2 refers 
to the second pair of curves; and 3 refers to the third pair of curves.  Values are shown as mean ± 
SEM (n=3-4).  Note that in some instances error bars are smaller than the size of the symbols. 
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2.4 Discussion 
The functional experiments described in this chapter served several purposes, which 
contributed to the understanding of the optimal conditions required to achieve myogenic tone in 
pressurised third-order mesenteric arteries.  This included determining the optimal intraluminal 
pressure, equilibration period, and determining how many concentration-response curves can be 
obtained in an individual preparation, without compromising the vasodilator function of the vessel. 
The optimal intraluminal pressure is determined by the pressure at which the vessel 
demonstrates a consistent level of tone which lies midway within the active tone range, so that both 
vasoconstriction and vasodilatation can be detected.   The active tone range for the third-order 
mesenteric artery, as determined by the pressure curves in this experimental set (Figure 2.4), was 
60-130 mmHg.  80 mmHg was chosen as the optimal intraluminal pressure within this range; at this 
pressure, the vessels displayed consistent tone of ~55% of the maximal passive diameter.  This 
finding is in agreement with the majority of other laboratories (Doughty, Plane et al. 1999; Lagaud, 
Skarsgard et al. 1999; Scotland, Chauhan et al. 2001).  It should be noted that the experiments 
described in the following chapters are in 25-week Zucker rats, and the optimal intraluminal 
pressure may therefore be influenced by gender and/or age.  Vessels with a myogenic tone of 40-
60% of the maximal passive diameter were identified as viable vessels, and as the average level of 
tone was ~50% (please refer to chapter 3, 4 and 6), the 80 mmHg was considered to be optimal in 
these arteries, although there were not enough animals to run specific pressure curves for the 
different ages and animal models. 
In order to determine the equilibration period required for the vessels to develop 
myogenic tone, the experimental vessels were left to equilibrate after being set to 80 mmHg, until 
a steady state of tone was achieved.  Taking into account the 30-min period during which the 
vessel was taken from 50 mmHg to 80 mmHg, a total equilibration time of 50-60 min was 
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required, which was also in consensus with other laboratory findings (Intengan, He et al. 1998; 
Lagaud, Skarsgard et al. 1999). 
With the third-order mesenteric arteries pressurised at 80 mmHg and equilibrated to a 
steady myogenic state, vasodilatation was studied by conducting concentration-response curves 
to the endothelium-dependent vasodilator ACh and the endothelium-independent vasodilator LK 
(Figure 2.6).  These responses were studied in the presence of 10 M indomethacin to block any 
contributing prostacyclin-mediated relaxation, allowing the specific study of NO and EDHF 
contributions.   
To assess the contribution of NO to the ACh-induced vasodilatation, responses were 
obtained in the presence of L-NAME and ODQ, which inhibit nitric oxide synthase (NOS) and 
guanylate cyclase respectively.  Whilst many studies block the NO component with L-NAME only 
(Plane, Pearson et al. 1995; Tare, Parkington et al. 2000; Hayashi, Kanda et al. 2002), ODQ was 
used to provide additional inhibition, as stored NO can be released from intracellular stores to 
contribute to ACh-mediated relaxations and is not inhibited by L-NAME (Chauhan, Rahman et al. 
2003; Triggle, Hollenberg et al. 2003).  Other studies have also found that 100 M L-NAME is 
insufficient to fully block NO-mediated responses, and that higher concentrations such as 300 M 
are necessary (Taylor, Chaytor et al. 1998; Scotland, Chauhan et al. 2001).  Inhibition with L-
NAME and ODQ, was found to have no significant effect on ACh- or LK-induced responses, 
suggesting that NO does not play a role in third-order mesenteric arteries from Sprague-Dawley 
rats.  This finding is in agreement with other studies which have also failed to identify a role of NO 
in this vessel (Parsons, Hill et al. 1994; Doughty, Plane et al. 1999; Izzard and Heagerty 1999; Iida, 
Taguchi et al. 2001; Takagawa, Berger et al. 2002).  In contrast, studies in first- and second-order 
mesenteric arteries from Sprague-Dawley rats show a significant NO component (Sofola, Knill et 
al. 2002; Chauhan, Rahman et al. 2003; Mitsumizo, Nakashima et al. 2004). 
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The effect of ChTX and apamin on responses to ACh was examined in order to demonstrate 
whether the non-NO, non-prostacyclin component was EDHF.  As discussed in the introduction, 
ChTX blocks the intermediate and large calcium-activated potassium channels, whilst apamin 
blocks the small calcium-activated potassium channels (see section 1.5).  Responses to ACh, in the 
presence of L-NAME, ODQ, ChTX and apamin, were completely abolished, indicating that ACh-
induced relaxation was mediated solely by EDHF, with NO playing no significant role.   
Whilst L-NAME and ODQ had no significant effect on the basal level of myogenic tone, 
incubation with apamin and ChTX did result in a significant increase in basal myogenic tone.  The 
increased tone resulted in an altered response to the endothelium-independent vasodilator LK; 
however the maximum response was not significantly changed, indicating that smooth muscle 
vasodilator function was not compromised by the ChTX.  This may be due to the inhibitory effect 
of ChTX on large-conductance calcium-activated potassium channels.  As mentioned in Chapter 1 
(see section 1.8), the problems that arise from using ChTX to block EDHF can be overcome by 
using TRAM-34 (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole) (Wulff, Miller et al. 2000).  Due 
to a kind donation of TRAM-34 from Dr Wulff (Wulff, Miller et al. 2000) towards the end of my 
candidature, experiments with TRAM-34 and apamin were conducted in female (see chapter 3) and 
male (see chapter 4) Zucker rats, in which there was no change in basal constriction.   
One possible concern of the work presented here relates to the incubation times used for 
the various inhibitors, particularly the charybdotoxin and apamin.  Whilst the 30-min incubation 
times were substantially less than some incubation times used by other research groups to inhibit 
EDHF responses in  pressurised setups (Doughty, Plane et al. 1999), this incubation time was 
found to be sufficient in this vessel as well as the pressurised third-order mesenteric arteries of 
the same diameter from Sprague-Dawley rats (Chapter 2.2.3.4); the 30-min incubation period 
with ChTX and apamin was sufficient to abolish ACh-induced responses.  It should be noted 
that longer incubation times are required for other tissues in the Zucker rat, such as the gracilis 
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artery, which is a larger artery than the third-order mesenteric artery (Hannan et al., unpublished 
finding).   
An additional concern is the possible inhibitory effect of the HEPES buffer on the 
contribution of EDHF, as identified in porcine coronary arteries (Edwards, Feletou et al. 2001). 
Although EDHF-mediated relaxation achieved maximal dilation it is possible that the HEPES-
based buffer caused a significant rightward shift in the concentration-response curve.  It may be 
beneficial to study vascular function in an alternative buffer, such as a MOPS based buffer, which 
also requires low oxygenation. 
Time-control experiments (Figure 2.7) demonstrated that 3 sets of curves for ACh and LK 
can be obtained in an individual preparation without altering vasodilatation function; this suggests 
that time had no effect on relaxations, at least over the time period studied, and vascular function 
was not compromised.  
This set of experiments provided valuable information regarding the conditions required for 
optimal development of myogenic tone in the third-order mesenteric artery, and the results of this 
study were used to develop future pressure-myograph protocols.  This study also demonstrated 
which endothelium-derived relaxing factors contribute to ACh-induced vasodilatation in this vessel, 
i.e. relaxation was solely mediated by EDHF. 
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3.1 Introduction 
There have been few studies investigating the effect of insulin resistance and type 2 
diabetes on endothelium-derived hyperpolarising factor (EDHF).  Studies using insulin-resistant 
fructose-fed rats have demonstrated that impaired endothelium-dependent relaxation is associated 
with a defect in EDHF-mediated relaxations in coronary (Miller, Katakam et al. 1999; Katakam, 
Ujhelyi et al. 2000) and small mesenteric (Miller, Hoenig et al. 1998; Katakam, Hoenig et al. 2000) 
arteries.  Furthermore, the EDHF component of acetylcholine (ACh)-induced relaxations in 
epineurial arterioles from the sciatic nerve were impaired in type 2 diabetic Zucker fatty (ZDF) rats 
(Coppey, Gellett et al. 2003).   
A series of studies have suggested that diabetes-induced impaired EDHF-mediated 
dilatation may be linked with defects in gap junctions involved in the spread of relaxation and 
hyperpolarisation.  Cell cultures exposed to high glucose levels have been used to study gap 
junctions and specific connexins in isolation, with results showing an attenuation in gap junction 
activity in bovine aortic endothelial and smooth muscle cells, associated with connexin 43 
(Inoguchi, Ueda et al. 1995; Kuroki, Inoguchi et al. 1998; Inoguchi, Yu et al. 2001).  Additionally, 
investigations using animal models of type 1 diabetes have shown an attenuation in EDHF-
mediated responses (Wigg, Tare et al. 2001) and gap junction activity in mesenteric arteries from 
streptozotocin (STZ)-treated diabetic rats (Matsumoto, Kobayashi et al. 2003).  Gap junction 
electrophysiology has also been shown to be altered in the STZ-induced diabetic rat heart 
(Howarth and Qureshi 2006).  To our knowledge no studies in insulin-resistant or type 2 diabetic 
animal models have studied changes in vascular gap junction and connexin activity.  
The effect of insulin resistance or type 2 diabetes on other EDHF candidates, most 
importantly epoxyeicosatrienoic acids (EETs), is also poorly understood.   One study in mesenteric 
arteries from insulin-resistant fructose-fed rats demonstrated that whilst control Sprague-Dawley rat 
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vessels were sensitive to the cytochrome P450 (CYP) inhibitor miconazole, mesenteric arteries 
from insulin-resistant fructose-fed Sprague-Dawley rats were not attenuated by miconazole.  This 
study, which also demonstrated endothelial dysfunction in mesenteric arteries from the insulin-
resistant rats, showed that CYP induction corrected endothelial function, as well as normalising the 
mean arterial blood pressure that was increased (Katakam, Hoenig et al. 2000).   A follow-up study 
showed that in the same animal model, control mesenteric arteries relaxed in response to 11,12-
EET and 14,15-EET, however the insulin-resistant rat vessels did not relax in response to the 
EETs (Miller, Dimitropoulou et al. 2001).  These two studies suggest that EETs are involved in 
control, but not insulin-resistant, relaxation in the mesenteric artery, and that the absence of 
EETs in the insulin-resistant rat may contribute to the endothelial dysfunction demonstrated in 
this vessel.  The patch-clamp experiments of the latter study suggested that the impaired 
relaxation to EETs was due to altered regulatory mechanisms of the large-conductance calcium-
activated potassium (BKCa) channels (Miller, Dimitropoulou et al. 2001), involved in EET-
mediated dilatation (Gauthier, Jagadeesh et al. 2003). 
Studies in our laboratory have demonstrated endothelial dysfunction in renal arteries 
from female obese Zucker rats (OZR), as compared with lean (LZR) littermate controls, associated 
with impaired EDHF vasodilatation responses (Reid, Roche et al. 2003).  Follow-up studies were 
conducted to identify the role of gap junctions in the EDHF responses; 40gap27, a specific inhibitor 
of connexin 40, significantly inhibited the relaxation response to ACh in the LZR and OZR 
(p<0.05, ANOVA) to the same maximal response; 43gap27, a specific inhibitor of connexin 43, did 
not show any significant effect on ACh responses in LZR or OZR.; these two gap27 inhibitors 
combined showed a significant inhibition in the LZR, with no change in the OZR (Reid and Lau 
2003).  These results demonstrated that endothelial dysfunction in renal arteries from OZRs 
involved impaired EHDF responses associated with decreased connexin 40-related gap junctions.  
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The main objective of the experiments described in this chapter was to investigate 
EDHF-mediated endothelial function in the third-order mesenteric artery from the obese Zucker 
rat (OZR), a well established model of insulin resistance at 25 weeks of age (Kasiske, O'Donnell et 
al. 1992).  More specifically these experiments served to answer the following questions: 
 
1. What role does EDHF play in the third-order mesenteric artery of the 25-wk Zucker rat? 
2. Is endothelial function reduced in the third-order mesenteric artery of the OZR, compared 
with the corresponding LZR control? 
3. Do gap junctions contribute to EDHF-mediated vasodilatation in the third-order 
mesenteric artery of the 25-wk Zucker rat?   
4. Do EETs contribute to EDHF-mediated vasodilatation in the third-order mesenteric artery 
of the 25-wk Zucker rat? 
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3.2 Methods and Materials 
3.2.1 Animals  
Female LZR and OZR of 25 wk of age were obtained from Monash Animal Services, 
Victoria, Australia.  All procedures involved were approved by the Animal Experimentation 
Ethics Committee (AEEC #0217 and #0530), and conformed to the Australian National Health 
and Medical Research Council Code of Practice for the Care and Use of Animals for Scientific 
Purposes.    
The rats were killed by asphyxiation with carbon dioxide followed by decapitation.  All 
animals were weighed prior to culling.  Blood samples, collected in vials containing 50 units/ml 
heparin, were taken by exsanguination at the time of killing for determination of glucose levels. 
 
3.2.2 Rat Tissue collection 
The entire mesenteric bed was removed from the body cavity and placed in a HEPES-
based physiological salt solution (PSS): 111 mM NaCl, 11.5 mM glucose, 10 mM 2-N-
hydroxyethylpiperazine-N‟-2-ethansulfonic (HEPES), 25.7 mM NaHCO3, 1.2 mM MgSO4, 2 mM 
CaCl2, 1.2 mM KH2PO4, 4.9 mM KCl (pH 7.4 at 37
oC, gassed with 95%N, 5%CO2).   
 
3.2.3 Metabolic Parameters 
Glucose analysis of blood taken at the time of killing was conducted using the 
MediSense

2 glucometer with Precision Plus

 blood glucose electrodes (MediSense, Australia).   
The following parameters were measured by a colleague, Winnie Lau, to assess the 
haemodynamic and metabolic status of the rats.  Although not measured in all experiments, it was 
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important to establish that the obese Zucker rat was an acceptable model of insulin resistance, 
demonstrating hypertension, glucose intolerance, dyslipidaemia, hyperinsulinaemia and 
proteinuria.  These experiments are included here as they were vital in establishing the female 
OZR as an acceptable model of insulin resistance: 
a. Oral glucose tolerance test:  Rats (non-fasted) were administered a 70% glucose 
solution (2.5 mg/kg) by oral gavage.  Blood from the tail vein was then sampled over 
90 mins (baseline, followed by 15, 30, 60 and 90 min post-gavage).  The glucose levels 
were measured as described above.    
b. Systolic blood pressure:  Measured using a blood pressure tail cuff (sphygmometer).     
c. Fasting glucose:  Rats were fasted overnight, allowing fasting glucose levels to be 
measured from these rats at the time of culling.  Glucose levels were measured as 
described above. 
d. Non-fasting glucose:  Glucose levels were collected from non-fasting rats at the 
time of culling by exsanguination.  Glucose levels were measured as described above. 
e. Plasma insulin:  Plasma was obtained by centrifugation of blood, taken by 
exsanguination at time of killing, and stored at –20oC until assayed.  Plasma insulin 
levels were determined using an enzyme immunoassay kit (Ultrasensitive Rat Insulin 
ELISA, Mercodia AB, Uppsala, Sweden).  
f. Plasma lipids:  Plasma was obtained by centrifugation of blood (1-2 ml), taken by 
exsanguination at time of killing, and stored at -20oC until assayed.  Plasma levels of 
total cholesterol and triglycerides were measured using enzymatic assay kits (CHOD-
PAP and GPO-PAP respectively, Roche, Basel, Switzerland) which were carried out by 
the Cell Biology of Diabetes Laboratory at the Baker Medical Research Institute 
(Victoria, Australia). 
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g. Urinary protein:  Urine was collected from rats placed in a metabolic cage for a 24-h 
period; protein levels were determined with the Bio-Rad protein assay kit (Bio-Rad 
Laboratories, CA, USA) based on the Lowry method. 
 
3.2.4 Pressure Myography 
3.2.4.1 Set-Up, Pressurisation and Equilibration 
Mesenteric arteries were isolated, cannulated and pressurised as previously described in 
Chapter 2 (2.2.3.1).   
Briefly, vessels, superfused with PSS, were pressurised from 50 mmHg to 80 mmHg over 
30 min, after which the vessel was further equilibrated for 30 min, or until acceptable myogenic 
tone was achieved.  Vessels were determined to have a viable level of myogenic tone if the 
internal diameter was 40-60% of the initial diameter. 
Pressure and intraluminal diameter (measured using video microscopy) were recorded on 
a MacLab system (MacLab/4 Chart Software, model MKIIII, AD Instruments Pty Ltd, 
Australia).  A temperature thermo-coupler was also attached to monitor the bath temperature, 
which was maintained at 37o  0.5 oC.   
 
3.2.4.2 Vasodilatation Characterisation 
All responses were obtained in the presence of 10 µM indomethacin to block prostanoid 
production.   
Endothelial function was determined by studying responses to the endothelium-
dependent dilator ACh (1 nM–3 µM) and the endothelium-independent dilator levcromakalim 
(LK: 10 nM–10 µM).  Concentration-response curves were obtained by the cumulative addition 
of the drug directly into the chamber.  Up to 3 sets of concentration-response curves for both 
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ACh and LK, alternating between the two agonists, were obtained in the same preparation (i.e. 
ACh, LK, ACh, LK, ACh, LK), as detailed in Chapter 2 (2.2.3.4).  Although time-control 
experiments were not carried-out for this set of experiments (due to the limited availability of 
rats), 3 sets of concentration-response curves was considered to be viable in this artery, following 
the analysis of the time-control experiments detailed in third-order arteries from Sprague-Dawley 
rats (see section 2.3.3). 
Specific inhibitors were added to the chamber 20-30 min before, and remained present 
during the concentration-response curve to ACh or LK.  The contribution of NO to the 
vasodilator response was examined by incubation with nitro-l-arginine methylester (L-NAME, 
100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 M) for 30 min, which 
remained present whilst a concentration-response curve for ACh was repeated.  A 20-min wash-
out period, followed by incubation with L-NAME and ODQ, was repeated prior to a second 
concentration-response curve for LK.   
 The EDHF component was investigated following incubation with 100 M  L-NAME, 1 
M ODQ as well as either a combination of charybdotoxin (ChTX, 0.1 M) and apamin (1 M), 
or 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34, 1 M, donated by Dr Wulff, 
University of California) and apamin (1 M).   
The contribution of gap junctions associated specifically with connexins 37, 40 or 43 was 
studied using 40Gap27 (300 M: H-SRPTEKNVFIV-NH2, Auspep, Melbourne, Australia), 
43Gap26 (300 M: H-VCYDKSFPISHVR-NH2, Auspep, Melbourne, Australia) and 
37,43Gap27 
(300 M: H- SRPTEKTIFII -NH2, Auspep, Melbourne, Australia), in the presence of 10 M 
indomethacin only.  Due to the loss of myogenic tone following incubation with 40Gap27, vessels 
were preconstricted with 0.1-1 M phenylephrine (PE) to achieve the same level of tone 
demonstrated prior to incubation with the peptide.  
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The contribution of EETs was assessed using the CYP epoxygenase 2C/3A inhibitor 
sulfaphenazole (1 M), in the presence of 10 M indomethacin only.   
At the end of all experiments, the arterioles were superfused with calcium-free PSS buffer 
for 20 min and the maximal passive diameter was measured and recorded.   
 
3.2.5 Data & Statistical Analysis 
Data were presented as mean and standard error of the mean (SEM) with n indicating the 
number of experimental animals.  Results were analysed and compared using the Student‟s t-test 
(unpaired, unless otherwise stated) or two-way analysis of variance (two-way ANOVA) followed 
by a Student-Newman-Keuls test.  A value of p<0.05 was regarded as statistically significant.  A 
two-way repeated measures ANOVA followed by Student-Newman-Keuls test was used when 
comparing concentration-curves obtained in the same vessel. 
GraphPad Prism (V.4 for Windows, GraphPad, San Diego, California USA) was used to 
fit regression lines to the linear portions of the log concentration-response curves by the method 
of least squares.  EC50 values were interpolated from the regression lines, and correspond to a 
concentration producing 50% of the maximal response.  EC50 values are shown with the 95 % 
confidence interval (CI) ranges, and were considered to be significant if the ranges did not 
overlap. 
 GraphPad Prism was also used to construct figures showing the data and analyses of 
the results. 
 
Relaxations were measured as a percentage of the maximal diameter. 
 
 Diameter (% of max.) = R/M x 100 
Chapter 3 
3-10 
 
where R is absolute diameter at a given drug concentration and M is the maximal diameter of the 
vessel, determined by superfusing the vessel with calcium-free PSS. 
     
3.2.6 Drugs and Chemicals 
All drugs were purchased from Sigma Chemicals unless otherwise stated.  All drugs were 
dissolved in distilled water with several exceptions: indomethacin was dissolved in 0.1 M Na2CO3 
to give stock solutions of 0.01 M; LK was dissolved in 70% ethanol to give a stock solution of   
0.01 M; the gap peptides were dissolved in dimethyl sulfoxide (DMSO) to give stock solutions of 
0.03 M.   All stock solutions were diluted on the day using PSS. 
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3.3 Results 
3.3.1 Metabolic Parameters 
The average body weight of the female OZRs (397 ± 3 g, n=22) was approximately double 
that of the lean littermate controls (230 ± 4 g, n=20) (p<0.05, Student‟s t-test).  Non-fasting blood 
glucose levels were found to be significantly (p<0.5, Student‟s t-test) higher in the female OZR (6.9 
± 0.3 mM, n=22) than the female LZR (5.9 ± 0.2 mM, n=20). 
The metabolic and haemodynamic characteristics monitored in the lean and obese Zucker 
rat are shown in Table 3.1. The obese rats, compared to the lean controls, showed significantly 
(p<0.05, Student‟s t-test) increased body weights, systolic blood pressure, non-fasting blood glucose 
levels and urinary protein excretion. Similarly, plasma levels of insulin, total cholesterol and 
triglycerides were all significantly (p<0.05, Student‟s t-test) higher in obese than in lean rats. The 
oral glucose tolerance test, as illustrated in Figure 3.1, demonstrated that the obese rats displayed 
significantly (p<0.05, 2-way ANOVA) elevated blood glucose levels compared to the lean rats after 
an oral gavage of glucose. 
 
3.3.2 Vasodilatation Characterisation 
All results have been normalised against the maximal (passive) diameters, which were not 
significantly different (p>0.05, Student‟s t-test) between LZR (146 ± 8 m, n=27) and OZR (143 
± 7 m, n=30).  There was no significant difference (p>0.05, Student‟s t-test) in the absolute 
active diameters (LZR: 81 ± 6 µm, n=27; OZR: 75 ± 4 m, n=30), or in the percentage of 
myogenic tone achieved by mesenteric arteries from the LZR (53.1 ± 2.2% of maximal diameter, 
n=14) and OZR (50.8 ± 0.9% of maximal diameter, n=21).   
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Figure 3.2 and Figure 3.3 illustrate typical traces obtained for vasodilatation to ACh and 
LK respectively.  Concentration-response curves to ACh for the OZR (EC50 86.0 nM, 95% CI 
62.8-117.8 nM, n=18) showed a significant 2.5-fold rightward parallel shift compared to the LZR 
(EC50 33.8 nM, 95% CI 23.5-48.8 nM, n=14)(Figure 3.4A).  There was no significant difference 
(p>0.05, Student‟s t-test) in the maximal dilatation caused by ACh between LZRs (96.6 ± 0.7% of 
maximal diameter, n=14) and OZRs (95.0 ± 1.4% of maximal diameter, n=18).  Relaxation 
responses to LK were not significantly different between the LZR and OZR (Figure 3.4B).   
Responses to ACh were not altered (p>0.05, ANOVA) by L-NAME and ODQ in the 
LZR (n=6-7, Figure 3.5A) or OZR (n=6-7, Figure 3.5B), but were abolished (p<0.05, ANOVA) 
by a combination of either: L-NAME, ODQ, ChTX and apamin (Figure 3.5, n=5) or ChTX and 
apamin alone (Figure 3.5, n=3-4).  Furthermore, responses in the presence of ChTX and apamin 
were not significantly different, alone or in the additional presence of L-NAME and ODQ 
(Figure 3.5, n=3-4).  The addition of ChTX and apamin (in the absence or presence of L-NAME 
and ODQ) produced a significant (p<0.05, paired Student‟s t-test) basal constriction in both LZR 
mesenteric arteries (before 51.0 ± 2.8% of maximal diameter; after 24.7 ± 3.4%; n=10) and OZR 
arteries (before 47.3 ± 3.1%; after 29.6 ± 2.2%; n=18).  This effect was not seen after incubation 
with TRAM-34 and apamin, with no change in myogenic tone in the LZR (before 53.5 ± 2.3% of 
maximal diameter; after 55.1 ± 1.5%; n=3) or OZR (before 48.7 ± 1.1%; after 50.6 ± 1.5%; n=3).  
Responses to ACh in the presence of TRAM-34 and apamin (in the absence of L-NAME and 
ODQ) were abolished (Figure 3.6). 
Responses to LK were not altered (p>0.05, ANOVA) in the presence of L-NAME and 
ODQ (Figure 3.5, n=3-4), nor were they altered (p>0.05, ANOVA) by the addition of TRAM-34 
and apamin (Figure 3.6, n=3).  Whilst there was a change in basal myogenic tone after incubation 
with ChTX and apamin, or L-NAME, ODQ, ChTX and apamin, maximal responses to LK were 
not altered (Figure 3.5). 
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3.3.3 EDHF Characterisation 
40Gap27 abolished myogenic tone in both LZR and OZR rat preparations, and hence 
vessels were preconstricted with PE (0.1-1 M) to achieve a similar level of tone to that in the 
absence of 40Gap27.  The maximal response to ACh was significantly attenuated (p<0.05, 
Student‟s t-test) by 54% in the presence of 300 M 40Gap27 in the LZR (n=5), but was not 
changed in the OZR (n=5) (Figure 3.7).  Responses to LK were not altered by 40Gap27 (n=3) in 
either the LZR or OZR preparations.   
37,43Gap27 had no effect on ACh or LK responses in the LZR or OZR preparations 
(Figure 3.8).  Similarly, 43Gap26 had no significant effect on ACh or LK responses in either LZR or 
OZR preparations (Figure 3.9).  
Responses to ACh or LK were not significantly changed by sulfaphenazole in third-order 
mesenteric arteries from either LZR or OZR preparations (p<0.05, ANOVA, n=4, Figure 3.10). 
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 n LZR OZR 
Body weight (g) 39-41 218 ± 3 391 ± 5* 
Systolic blood pressure (mmHg) 9 137 ± 6 166 ± 4* 
Blood glucose (mM) 
Fasting 
Non-fasting 
 
9 
28-30 
 
4.72 ± 0.29 
5.51 ± 0.18 
 
4.97 ± 0.18 
6.56 ± 0.31* 
Plasma insulin (pM) 11-12 56   33 1386  388* 
Plasma cholesterol (mM) 8 1.36  0.09 2.07  0.33* 
Plasma triglycerides (mM) 8 0.48  0.06 7.4  1.06* 
Urinary protein excretion (mg/day) 9-10 27.6 ± 2.5 63.4 ± 6.7* 
 
 
 
Table 3.1: Metabolic and haemodynamic characteristics 
Metabolic and haemodynamic characteristics of lean Zucker rat (LZR) and obese Zucker 
rat (OZR) at 25 wk (Lau and Reid, unpublished data).  All data are expressed as mean ± SEM and 
n = number of animals.   
* Significantly different from corresponding lean control rats (p<0.05, Student‟s unpaired t-tests). 
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Figure 3.1:  Oral glucose tolerance test. 
Blood glucose levels of 25 wk lean Zucker rats (LZR, , n=8) and obese Zucker rats (OZR, , 
n=8) measured over 90 min, following administration of an oral glucose load of 2.5 g/kg. 
*p<0.05, ANOVA 
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Figure 3.2:  Representative Acetylcholine–Induced Dilatations 
Typical traces illustrating responses to acetylcholine (10-9 to 3x10-6 M, cumulative additions 
indicated by arrows) in pressurised third-order mesenteric arteries from a female lean Zucker rat 
(LZR, A) and a female obese Zucker rat (OZR, B). 
 


80
100
120
140
160
180

10-9
3x10-9
10-8
3x10-8
10-7
3x10-7
10-6
3x10-6
D
ia
m
et
er
 (

m
)
2 min





A.     LZR
D
ia
m
et
er
 (

m
)
B.    OZR
80
120
160
180
140
100
3x10-9
10-8
3x10-8
10-7
3x10-7
10-6
3x10-6







10-9
 2 min
D
ia
m
et
er
 (

m
)
D
ia
m
et
er
 (

m
)
D
ia
m
et
er
 (

m
)
 
Chapter 3 
3-17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:  Representative Levcromakalim–Induced Dilatations 
 Typical traces illustrating responses to levcromakalim (10-8 to 10-5 M, cumulative additions 
indicated by arrows) in pressurised third-order mesenteric arteries from a female lean Zucker rat 
(LZR, A) and a female obese Zucker rat (OZR, B). 
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Figure 3.4:  ACh- and Levcromakalim-Induced Dilatations 
Concentration-response curves for relaxations to acetylcholine (ACh, A) and levcromakalim (LK, 
B) in pressurised third-order mesenteric arteries from lean (●, n=11-14) and obese (●, n=12-18) 
female Zucker rats, in the presence of indomethacin (10 M).  Values are means ± SEM.  Note 
that in some cases error bars are smaller than the size of the symbols.   
*no overlap of confidence intervals when comparing EC50 values  
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Figure 3.5:  Vasodilatation Characterisation 
Concentration-response curves for relaxations to acetylcholine (ACh, A&B) and 
levcromakalim (LK, C&D) in pressurised third-order mesenteric arteries from lean (LZR, n=3-7, 
A&C) and obese (OZR, n=3-7, B&D) female Zucker rats before (● LZR, ● OZR) and after 
treatment with:  
 Nitro-L-arginine methyl ester (L-NAME, 100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ, 1 M) (● LZR, ● OZR);  
 L-NAME (100 M), ODQ (1 M), Charybdotoxin (1 M) and apamin (1 M) (● LZR, ● 
OZR);  
 Charybdotoxin (1 M) and apamin (1 M) (● LZR, ● OZR). 
Values are means ± SEM.  Note that in some instances error bars are smaller than the size of the 
symbols.   
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Figure 3.6:  Tram-34 and Apamin 
Concentration-response curves for relaxations to acetylcholine (ACh, A) and 
levcromakalim (LK, B) in pressurised third-order mesenteric arteries from lean (LZR, n=3-7) and 
obese (OZR, n=3-7) female Zucker rats before (● LZR, ● OZR) and after treatment with 
TRAM-34 (1 M) and apamin (1 M) (● LZR, ● OZR).  Values are means ± SEM.  Note that in 
some instances error bars are smaller than the size of the symbols.   
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Figure 3.7:  40Gap27 
Concentration-response curves for relaxations to acetylcholine (ACh, A&B) and 
levcromakalim (LK, C&D) in third-order mesenteric arteries from female lean Zucker rats (LZR, 
n=3-5) and obese Zucker rats (OZR, n=3-5) before (● LZR, ● OZR) and after (● LZR, ● OZR)   
treatment with 40Gap27 (300 M) in the presence of 10 M indomethacin.  Values are means ± 
SEM.  Note that in some instances error bars are smaller than the size of the symbols.   
*p<0.05, paired student’s t-test, comparison of maximal responses . 
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Figure 3.8:  37,43Gap27 
Concentration-response curves for relaxations to acetylcholine (ACh, A&B) and 
levcromakalim (LK, C&D) in third-order mesenteric arteries from female lean Zucker rats (LZR, 
n=3-5) and obese Zucker rats (OZR, n=3-5) before (● LZR, ● OZR) and after (● LZR, ● OZR)   
treatment with 37,43Gap27 (300 M) in the presence of 10 M indomethacin.  Values are means ± 
SEM.  Note that in some instances error bars are smaller than the size of the symbols.   
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Figure 3.9:  43Gap26 
Concentration-response curves for relaxations to acetylcholine (ACh, A&B) and 
levcromakalim (LK, C&D) in third-order mesenteric arteries from female lean Zucker rats (LZR, 
n=3-5) and obese Zucker rats (OZR, n=3-5) before (● LZR, ● OZR) and after (● LZR, ● OZR)   
treatment with 43Gap26 (300 M) in the presence of 10 M indomethacin.  Values are means ± 
SEM.  Note that in some instances error bars are smaller than the size of the symbols.   
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Figure 3.10:  Sulfaphenazole 
Concentration-response curves for relaxations to acetylcholine (ACh, A&B) and 
levcromakalim (LK, C&D) in third-order mesenteric arteries from female lean Zucker rats (LZR, 
n=3-5) and obese Zucker rats (OZR, n=3-5) before (● LZR, ● OZR) and after (● LZR, ● OZR)   
treatment with sulfaphenazole (300 M) in the presence of 10 M indomethacin.  Values are 
means ± SEM.  Note that in some instances error bars are smaller than the size of the symbols.   
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3.4 Discussion 
The metabolic parameters studied in the 25-wk female LZR and OZR confirms that the 
female OZR is an acceptable animal model of insulin resistance.  The OZRs weighed nearly 
double the LZR, with a significantly increased random glucose, glucose intolerance, an elevated 
systemic blood pressure, proteinuria, as well as elevated lipid and insulin levels.  These results are 
consistent with previous characterisation of the OZR which have demonstrated 
hyperinsulinaemia, mild hyperglycaemia, glucose intolerance, hypertension, hyperlipidaemia and 
proteinuria (Cox and Kikta 1992; McCaleb and Sredy 1992).  Furthermore these  characteristics 
are consistent with those observed in people with insulin resistance and the metabolic syndrome, 
including obesity, dyslipidaemia, glucose intolerance, hyperinsulinaemia and hypertension (Moller 
and Flier 1991; Lebovitz 2001).   
The findings from this study provide evidence that there is a decrease in the EDHF-
mediated relaxation response to the endothelium-dependent dilator ACh in third-order 
mesenteric arteries from the 25-wk female OZR.  As responses to the endothelium-independent 
dilator LK were not altered, this attenuated response can be identified as endothelial dysfunction, 
a well established complication in animal models of insulin resistance and diabetes (De Vriese, 
Verbeuren et al. 2000).   
The NO component of the ACh-induced vasodilatations was identified by using L-
NAME to inhibit endothelial nitric oxide synthase (eNOS) and ODQ which inhibits guanylate 
cyclase.  A combination of inhibitors was used, as opposed to using L-NAME alone, to ensure 
that the NO component was completely inhibited.  Responses to ACh were not affected by the 
NO inhibitors L-NAME and ODQ in either LZR or OZRs.  Therefore, it can be concluded that 
NO does not contribute to ACh-induced vasodilatation in the third-order mesenteric artery from 
LZR and OZR, in the presence of indomethacin.   
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 Most early studies identified the EDHF component of vasodilatation by using the small-
conductance calcium-activated potassium channel (SKCa) inhibitor apamin and ChTX, an inhibitor 
of intermediate-conductance KCa (IKCa) and BKCa-conductance calcium-activated potassium 
channels (Kagota, Yamaguchi et al. 1999; Brandes, Schmitz-Winnenthal et al. 2000; Scotland, 
Chauhan et al. 2001; Chaytor, Taylor et al. 2002).  The development of TRAM-34 which is a 
specific inhibitor of IKca (Wulff, Miller et al. 2000) is now commonly used with apamin to 
specifically block EDHF-mediated dilatation (Crane, Gallagher et al. 2003; Eichler, Wibawa et al. 
2003; Sandow, Goto et al. 2004; Ding, Hashem et al. 2005; Gluais, Edwards et al. 2005).  Both 
combinations have been used during this project due to the initial unavailability of TRAM-34, 
which was kindly donated towards the end of my candidature by Dr Wulff (University of 
California). 
The indomethacin/L-NAME/ODQ-resistant responses to ACh were identified as 
EDHF, following inhibition with either: L-NAME, ODQ, ChTX and apamin; ChTX and apamin; 
or TRAM-34 and apamin. Hence, EDHF was shown to be the predominant endothelium-
dependent vasodilator mechanism present in pressurised third-order mesenteric arteries from 
both the LZR and OZRs, in agreement with other studies in pressurised rat mesenteric arteries 
(Doughty, Plane et al. 1999; Lagaud, Skarsgard et al. 1999; Mather, Dora et al. 2005; Liu, Ngai et 
al. 2006).  ChTX and apamin, in the absence and presence of L-NAME and ODQ, caused a 
significant basal constriction in both LZR and OZR preparations, which was not seen after 
incubation with TRAM-34 and apamin.  The constriction seen with the former combination may 
be due to the inhibitory action of ChTX on BKCa channels, which are known to be involved in 
the regulation of myogenic tone (Miller, Moczydlowski et al. 1985; Brayden and Nelson 1992; 
Nelson and Brayden 1993).  
It is important to note that ACh-induced responses, in the presence of ChTX and apamin 
were not significantly different from ACh-induced responses in the presence of L-NAME, ODQ, 
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ChTX and apamin.  The two different combinations were investigated as it has been 
demonstrated that NO can exert negative feedback on EDHF (Bauersachs, Popp et al. 1996; 
Nishikawa, Stepp et al. 2000; Oltman, Kane et al. 2001), and hence it could be suggested that the 
EDHF component will be greater if the NO component is inhibited, as opposed to the EDHF 
component present if NO is not inhibited.  However, flow-mediated dilatation in hamster 
cremaster arterioles was found to be 50% mediated by CYP-mediated EDHF, whether the 
general CYP inhibitor 17-octadecynoic acid (17-ODYA) was added before or after incubation 
with L-NAME to inhibit the NO component (Watanabe, Yashiro et al. 2005).  Similarly, the 
findings from this set of experiments demonstrated that ACh-induced relaxation in third-order 
mesenteric arteries from Zucker rats are solely mediated by EDHF, in the presence or absence of 
NO inhibitors. 
The endothelial dysfunction demonstrated in this set of experiments is consistent with 
the work of Coppey et al. (Coppey, Gellett et al. 2003), who demonstrated impaired EDHF-
mediated responses to ACh in epineurial arterioles from the ZDF rat.  Studies using insulin-
resistant fructose-fed rats have also shown that EDHF function is attenuated in pressurised  
mesenteric (Katakam, Ujhelyi et al. 1999) and coronary (Miller, Katakam et al. 1999) arteries in 
this animal model.  Our laboratory has also demonstrated impaired EDHF-mediated relaxation in 
wire-mounted lobar arteries from the OZR; interestingly, endothelial function appears to be 
compensated by an upregulation in NO in this vessel (Reid, Roche et al. 2003).   In contrast, 
some studies have demonstrated that endothelial dysfunction is not due to an alteration in either 
EDHF or NO function.   One study, in aortae and renal arteries from Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, showed that endothelial dysfunction was due to an increase in 
contractile factors (Kagota, Yamaguchi et al. 2000).  A second study, in middle cerebral arteries, 
showed that an impairment of cyclo-oxygenase-dependent dilatation, which accounted for 40% 
of bradykinin-induced relaxation in the control rats, was responsible for the endothelial 
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dysfunction seen in the fructose-fed insulin-resistant rats (Erdos, Miller et al. 2002).  Many 
factors may contribute to the disparate findings, as EDHF is known to be heterogenous in 
nature, and it‟s role can change in different species, different vessels, different disease states, and 
the experimental conditions that differ between laboratories. 
A recent study in mesenteric arteries from STZ-induced type 1 diabetic mice 
demonstrated that endothelial dysfunction in this vessel is largely attributable to reduced EDHF 
signalling (Matsumoto, Miyamori et al. 2006), which is accompanied by an increase in NO (Ding, 
Hashem et al. 2005).  In contrast, studies in mesenteric arteries from STZ-treated type 1 diabetic 
rats demonstrated a loss of NO function, accompanied by a compensatory increase in EDHF 
activity (Matsumoto, Wakabayashi et al. 2004; Shi, Ku et al. 2006).  The contradiction in findings 
may be related to the factors mentioned above, particularly given the different species used. 
This set of experiments additionally showed that EDHF responses to ACh were 
significantly attenuated by 40Gap27 in mesenteric arteries from the LZR, with no effect in arteries 
from the OZR.  43Gap26 and 37,43Gap27 had no effect in either LZR or OZR.  These results suggest 
that gap junctions associated with connexin 40, but not connexins 37 or 43, are involved in EDHF-
mediated vasodilatation in the third-order mesenteric arteries from the LZR, but do not play a role 
in mesenteric arteries from the OZR.  This is consistent with our laboratory‟s findings in the 
Zucker lobar arteries, which also demonstrated that connexin 40 is involved in EDHF-mediated 
responses in the LZR, but not the OZR (Reid and Lau 2003).   
One possible concern regarding this work is that the incubation periods may not be 
sufficient to allow maximal inhibition with the gap peptides.  However, 40Gap27 had a significant 
inhibitory effect on ACh-induced responses in third-order mesenteric arteries from LZRs, 
demonstrating that 30-min was sufficient to demonstrate blockade.  Furthermore, 30-min 
incubation times have been used by other laboratories (Dora, Martin et al. 1999; Griffith, Chaytor 
et al. 2002), although 40- (Chaytor, Bakker et al. 2005; Griffith, Chaytor et al. 2005) and 60-min 
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(Sandow, Goto et al. 2004; Sokoya, Burns et al. 2006) incubation periods have also been reported.  
It is possible that further incubation may allow further inhibition, however as superfusion of PSS is 
stopped during this period, the viability of the vessels will be reduced; an incubation period longer 
than 30-min would require the inhibitor to be added to the PSS, which in the case of gap peptides 
would be far too expensive. 
The concentration of the gap peptides used in this study (300 M) may also be regarded 
as being too low to achieve full inhibition.  A review of the literature shows that 100 M  (Sandow, 
Goto et al. 2004), 300 M (Dora, Martin et al. 1999; Sokoya, Burns et al. 2006) and 600 M 
(Griffith, Chaytor et al. 2002; Chaytor, Bakker et al. 2005) are the concentrations most widely used.  
One study actually found that 100 M 43gap26 inhibited EDHF responses as effectively as the  600 
M (Griffith, Chaytor et al. 2005).  In the experiments detailed in this chapter, 300 M 40gap27 was 
effective in partially inhibiting ACh-induced responses in the LZR, suggesting that this 
concentration is sufficient. 
It is important to recognise that 40Gap27 resulted in a striking loss of myogenic tone, 
which may be due to a non-junctional effect of this peptide, or alternatively may identify a non-
EDHF related role of gap junctions, involved in the maintenance of myogenic tone.  Due to this 
lack of tone, responses to ACh in the presence of 40Gap27 were obtained in the presence of PE, 
which has been demonstrated to increase the gap junction component of an EDHF response, 
whilst decreasing any contribution being made by endothelium-derived potassium to the EDHF 
response by increasing extracellular potassium levels (Dora and Garland 2001; Richards, Weston et 
al. 2001).  However, given that the 40Gap27 did not have an inhibitory effect in the OZR 
preparations, it could be suggested that the PE concentrations used were not sufficient to inhibit 
any endothelium-derived potassium contribution to the EDHF response.  One way of overcoming 
the effects of PE would be to use a vasoconstrictor which does not increase extracellular potassium 
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levels.  It may also be beneficial to study this effect in the absence of 40Gap27 by obtaining control 
concentration-response curves to ACh in the presence of PE.  However, because we only accept 
preparations which demonstrate myogenic tone, adding PE would alter the baseline, and further 
complicate interpretation of the results.  It should also be noted that the HEPES-buffered PSS 
solution may have had an inhibitory effect on the gap junctions (Bevans and Harris 1999; Edwards, 
Feletou et al. 2001), which would affect gap junctions in both LZR and OZR, and may have had an 
impact on the experimental findings. 
The other significant factor to consider when interpreting the gap peptide results is that it 
remains to be determined whether these inhibitors are affecting homocellular coupling or 
myoendothelial heterocellular coupling.  This acknowledges a need to identify the specific 
connexins that form the heterocellular gap junctions between endothelial cells and smooth muscle 
cells in order to produce more specific inhibitors to such gap junctions.  It should also be noted 
that the effect of non-selective gap junction inhibitors such as 18α-glycyrrhetinic acid and 
carbenoxolone were tested for their effect on EDHF-mediated responses, however responses to 
18α-glycyrrhetinic acid were very inconsistent and carbenoxolone resulted in potent vasodilatation, 
consistent with previous findings (Chaytor, Marsh et al. 2000).  
Given the non-specific effects of general gap junction inhibitors (Edwards, Feletou et al. 
1999; Chaytor, Marsh et al. 2000), the specificity of the connexin-mimetic peptides should also be 
questioned; a recent study has demonstrated that connexin-mimetic peptides block electrical 
signalling in rat mesenteric small arteries without exerting major non-junctional effects (Matchkov, 
Rahman et al. 2006).  Furthermore, 40Gap27 had a discriminatory effect in this set of experiments, 
only inhibiting responses in the LZR, suggesting a specific inhibition of connexin 40-gap junctions. 
Gap peptides have been shown to abolish the hyperpolarisation to endothelium-
dependent vasodilators in guinea-pig internal carotid arteries (Edwards, Feletou et al. 1999), porcine 
coronary arteries (Edwards, Thollon et al. 2000) and rat mesenteric arteries (Goto, Fujii et al. 2002; 
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Sandow, Tare et al. 2002).  Gap peptides have also been used to inhibit relaxations to ACh in rabbit 
mesenteric arteries (Chaytor, Evans et al. 1998) and the rabbit central ear artery (Berman, Martin et 
al. 2002).  Studies have also shown that some vessels require a combination of gap peptides to 
cause significant attenuation of the relaxation response (Chaytor, Martin et al. 2001), in which 
individual peptides have either no or negligible effects.  An important application of this concept 
was highlighted in a recent study which demonstrated that connexin 37 and connexin 40 are 
involved in the initial propagation of the hyperpolarisation response from the subintimal media 
layers to the smooth muscle layer, whereas connexin 43 is involved in the further propagation of 
the electrical stimulus through to the subadventitial layers of the media (Chaytor, Bakker et al. 
2005).    
The use of connexin-mimetic peptides in this study has highlighted the importance of 
connexin 40 gap junctions in EDHF responses in the third-order mesenteric artery from female 
LZR and OZRs.  The physiological importance of connexin 40 has been identified in a number of 
studies, where it has been shown that a loss of connexin 40 (either through genetic mutation or 
connexin 40 inhibitors) results in an increase in blood pressure, and a loss of vasocontrol (de Wit, 
Roos et al. 2000; De Vriese, Van de Voorde et al. 2002; de Wit, Roos et al. 2003).  The inhibition of 
gap junction communication with connexin-mimetic peptides 40Gap27 or 43Gap27 has been shown 
to block EDHF-mediated signal transmission in vivo, indicated by the abolition of L-NAME- and 
indomethacin-resistant renal vasodilatation (De Vriese, Van de Voorde et al. 2002).  In the latter 
study, the gap peptides were also found to cause a decrease in basal renal blood flow, which 
possibly contributed to the increase in blood pressure noted in that study (De Vriese, Van de 
Voorde et al. 2002).  This was one of the first studies to support a role for tonic EDHF release in 
the control of tissue perfusion and vascular resistance, and to show the importance of gap junctions 
in the EDHF response.   
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Studies conducted using connexin 40-deficient mice have also emphasised the importance 
of gap junctions, specifically those associated with connexin 40, in normal physiological 
transmission of endothelium-dependent vasodilatation (de Wit, Roos et al. 2000; de Wit, Roos et al. 
2003; de Wit 2004).  This set of studies showed that a lack of connexin 40 leads to the development 
of hypertension, and to irregular vasomotion in resistance arteries (de Wit, Roos et al. 2003).  
Another important outcome of these studies was the finding that the vessels needed to be locally 
stimulated with ACh for the attenuated propagation along the endothelium to become apparent.  
This is in contrast to most studies, including this one, where responses to ACh are studied in 
chambers where ACh is administered along the whole vessel, hence disguising any defects in 
propagation. 
Whilst there has been considerable work carried out on the nature of gap junctions under 
normal physiological conditions, the effect of insulin resistance and diabetes on connexins is less 
understood.  Gap junction pathways in retinal arteries (Oku, Kodama et al. 2001) and gap junction 
activity in mesenteric arteries (Matsumoto, Kobayashi et al. 2003) from type 1-diabetic STZ-treated 
rats have been shown to be reduced.  In addition, Ding et al. (Ding, Hashem et al. 2005) showed 
that endothelial dysfunction in small mesenteric arteries from STZ-induced diabetic apoE-/- mice 
is associated with a decrease in connexin 37 mRNA expression, as compared with non-diabetic 
apoE-/- control mice.   
The final set of experiments detailed in this chapter looked at the effects of 
sulfaphenazole, an inhibitor of CYP2C/3A, sometimes found to be involved in EET-mediated 
EDHF relaxations (Fleming, Michaelis et al. 2001; Hoepfl, Rodenwaldt et al. 2002; Morio, Carter et 
al. 2003; Taniguchi, Honda et al. 2005).  In this set of experiments, sulfaphenazole was shown to 
have no effect in either the LZR or OZR preparations, suggesting that EETs are not involved in 
EDHF responses in the third-order mesenteric artery from lean and obese Zucker rats.  EETs have 
consistently been shown to contribute to EDHF-mediated vasodilatation in rat mesenteric arteries 
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(Huang, Sun et al. 2005), rat skeletal muscle arterioles (Ungvari and Koller 2001), bovine coronary 
arteries (Campbell, Gebremedhin et al. 1996; Campbell, Falck et al. 2001; Pratt, Li et al. 2001), rat 
afferent arterioles (Wang, Borrego-Conde et al. 2003) and human mammary arteries (Archer, 
Gragasin et al. 2003).  However studies in isolated mesenteric arteries in humans (Matoba, 
Shimokawa et al. 2002) and rats (Fukao, Hattori et al. 1997), and rat perfused mesenteric beds 
(Adeagbo 1997) have shown no effect of sulfaphenazole on endothelium-dependent vasodilatation.  
It should be noted that in the latter study, an alternative CYP inhibitor clotrimazole did attenuate 
responses to ACh, suggesting that an array of EET inhibitors, such as CYP inhibitors proadifen 
(Campbell, Gebremedhin et al. 1996), miconazole (Campbell, Gebremedhin et al. 1996) and 
clotrimazole (Eckman, Hopkins et al. 1998), or EET-antagonists such as 14,15-epoxyeicosa-5(Z)-
enoic acid (EEZE) and 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (EEZE-mSI)(Weston, 
Feletou et al. 2005), may need to be studied to ascertain the involvement of EETs in EDHF-
mediated relaxation.  The limited availability of Zucker rats towards the end of my candidature 
precluded me from doing these experiments. 
The findings from the experiments described in this chapter are the first, to the author‟s 
knowledge, to study the effect of insulin resistance on EDHF and gap junctions in the female LZR 
and OZRs.  This set of experiments has established that EDHF-mediated endothelial 
vasodilatation is reduced in pressurised third-order mesenteric arteries from female OZRs.  
Furthermore, this attenuation in endothelial function was shown to be associated with a 
dysfunction in gap junction activity.  More specifically, connexin 40-associated gap junctions 
contribute to EDHF-derived responses to ACh in third-order mesenteric arteries from the LZR, 
but not the OZR.  Further studies need to be conducted to elucidate the other pathways involved 
in the EDHF-responses, and whilst the EET inhibitor sulfaphenazole had no effect on ACh-
induced vasodilatation, it would be beneficial to study the effect of other CYP inhibitors or EET 
antagonists.   
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4. Gender Comparison of vasodilatation 
responses in Zucker mesenteric arteries 
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4.1 Introduction 
 
Many studies have been conducted to study differences in endothelial function between 
male and female animal models.  Studies in non-diseased models have shown that the contributions 
of prostacyclin, NO and EDHF can differ with gender, as can the identity of EDHF.  
Furthermore, the impact of disease on endothelial function can differ between male and female 
animals. 
A comparison of male and female pressurised mesenteric arteries from Sprague-Dawley 
rats has shown that the EDHF component of ACh-induced responses is greater in the females 
(White, Rivera et al. 2000).    Vasodilatation has also been studied in male and female Wistar 
pressurised gracilis muscle arterioles which have been treated with N(omega)-nitro-L-arginine 
methyl ester (L-NAME) to block NO synthesis.  This study showed that endothelial 
prostaglandins mediate flow-induced dilatation in male preparations, whereas female arterioles are 
mediated by EDHF, and more specifically cytochrome P450 (CYP) metabolites (Wu, Huang et al. 
2001).   Additionally, a recent study has compared male and female endothelial nitric oxide synthase 
(eNOS) and cyclo-oxygenase (COX) knockout mice (eNOS-/-/COX-/-) with male and female 
WT mice.  The results of this study indicated that EDHF is the predominant endothelium-derived 
relaxing factor in female mice, with NO and prostacyclin being the predominant mediators in male 
mice (Scotland, Madhani et al. 2005).  In contrast, renal arteries from male and female Wistar rats 
have been demonstrated to show similar contributions of NO and EDHF (Wangensteen, Moreno 
et al. 2004).  Additionally, this study showed that the female renal vasculature has a decreased 
responsiveness to vasoconstrictors (Wangensteen, Moreno et al. 2004). 
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The degree of endothelial dysfunction in animal models of diabetes can also differ with 
gender.  For instance, male diabetic Zucker fatty (ZDF) rats have been shown to demonstrate a 
more impaired response to acetylcholine (ACh) than the females (Ajayi, Hercule et al. 2003).  This 
study suggested that these findings were related to the testosterone-induced increased production 
of thromboxane A2 in males, and the oestrogen-induced increase in NO production (Ajayi, Hercule 
et al. 2003).  This is an important study that suggests that gender can play a large role in the 
development of disease and complications, and warrants further investigation. 
Another area still to be more thoroughly explored is the gender differences in relation to 
the mechanisms underlying the EDHF response, has also received little attention.  One study has 
shown that C-natriuretic peptide (CNP) plays a more significant role in female Yorkshire pig 
coronary arteries compared with the males (Barber, Burnett et al. 1998).   Another study has 
demonstrated that male rats fed a high-fat diet develop high blood pressure and reduced eicosanoid 
(EET)-mediated vasodilatation in the kidneys; whereas no changes in blood pressure or EET 
production were observed in the female high-fat fed rats (Zhou, Lin et al. 2005).  As an increase in 
blood pressure and a reduction in EET production could be induced in the female rats by 
treatment with 5α-dihydrotestosterone, the gender difference was attributed to differing androgen 
levels (Zhou, Lin et al. 2005). 
Many of the differences described in the paragraphs above have been attributed to the 
actions of oestrogen in the female animals, which can affect the relative contributions of NO and 
EDHF, as well as affecting overall endothelial function.  A study in rat mesenteric arteries has 
shown that females demonstrate an enhanced EDHF contribution compared to the males, which 
was equalised by ovariectomisation of the females (Sakuma, Liu et al. 2002).   EDHF-mediated 
relaxations to acetylcholine have been shown to be reduced in mesenteric arteries from 
ovariectomisation rats compared with the control female rats (Liu, Hattori et al. 2001; Nawate, 
Fukao et al. 2005).  This impairment was reversed following treatment with 17β-estradiol (Liu, 
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Hattori et al. 2001).  A study of ATP-induced dilations in middle cerebral arteries has shown that 
the EDHF component is lower in female rats compared with male rats and ovariectomised rats 
(Golding and Kepler 2001).  Treating the ovariectomised rats with oestrogen reduced the EDHF 
contribution to that of the control female rats (Golding and Kepler 2001).  Another important 
study showed that chronic treatment with 17β-estradiol stimulates EDHF activity in male rat 
aortae, normally entirely mediated by NO. 
Oestrogen may also affect the degree of endothelial dysfunction caused by disease states 
such as insulin resistance and type 2 diabetes, as oestrogen has been shown to play a 
cardioprotective role via its ability to improve lipid metabolism and stimulate production of NO 
and possibly EDHF (Hishikawa, Nakaki et al. 1995; Rahimian, Chan et al. 2004; Chataigneau and 
Schini-Kerth 2005).  Despite this cardioprotective effect, the administration of oestrogen in post-
menopausal women in order to reduce the onset of cardiovascular disease is still under debate.  
Some studies have found that chronic oestrogen treatment can reduce the onset of diabetes 
(Smith 2003; Song, Arikawa et al. 2005) and other cardiovascular events (Newton, LaCroix et al. 
2003), and can improve endothelial function in post-menopausal women with type 2 diabetes 
(Lee, Lee et al. 2001).  Another study has shown that chronic oestrogen treatment can actually 
increase the risk of type 2 diabetes in American Indian post-menopausal women (Zhang, Howard 
et al. 2002).  The Heart and Estrogen/progestin Replacement Study (HERS) and the HERS II 
follow-up study failed to show a reduction in cardiovascular events following hormone therapy 
(Barrett-Connor and Stuenkel 1999; Grady, Herrington et al. 2002). 
The studies outlined in chapter 3 were completed in female lean (LZR) and obese (OZR) 
Zucker rats due to the limited availability of male Zucker rats.   A great opportunity arose when a 
small number of male LZRs and OZRs became available.  The aim of the experiments presented in 
this chapter was to conduct a gender comparison study between the female and male lean (LZR) 
and obese (OZR) Zucker rats.  As mentioned in chapter 3, no studies have been reported in Zucker 
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rats with regards to the characterisation of EDHF.  Therefore, this gender comparison study not 
only serves to compare the differences in endothelial dysfunction between the male and female 
Zucker rat, it will also define the role of EDHF in third-order mesenteric arteries from the male 
LZRs and OZRs.  More specifically, the experiments described in this chapter served to answer the 
following questions: 
 
1. What role does EDHF play in the pressurised third-order mesenteric artery of the 25-wk 
male Zucker rat? 
2. Is endothelial function reduced in the pressurised third-order mesenteric artery of the male 
OZR, compared with the corresponding LZR control? 
3. Is there a difference in either the contributions of NO and EDHF or the level of dysfunction 
seen in the pressurised third-order mesenteric arteries from male and female Zucker rats? 
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4.2 Methods and Materials 
4.2.1 Animals  
Male Lean Zucker Rats (LZR) and Obese Zucker Rats (OZR) of 25 wk of age were 
obtained from Monash Animal Services, Victoria, Australia.  All procedures involved were 
approved by the Animal Experimentation Ethics Committee (AEEC #0530), and conformed to 
the Australian National Health and Medical Research Council Code of Practice for the Care and 
Use of Animals for Scientific Purposes.    
The rats were killed by asphyxiation with carbon dioxide followed by decapitation.  All 
animals were weighed prior to culling.  Heparinised blood samples were taken by exsanguination 
at the time of killing for determination of glucose levels. 
 
4.2.2 Rat Tissue collection 
The entire mesenteric bed was removed from the body cavity and placed in a HEPES-
based physiological salt solution (PSS): 111 mM NaCl, 11.5 mM glucose, 10 mM 2-N-
hydroxyethylpiperazine-N‟-2-ethansulfonic (HEPES), 25.7 mM NaHCO3, 1.2 mM MgSO4, 2 mM 
CaCl2, 1.2 mM KH2PO4, 4.9 mM KCl (pH 7.4 at 37
oC, gassed with 95%N, 5%CO2).   
 
4.2.3 Metabolic Parameters 
Plasma for glucose, lipid and insulin analysis of male Zucker rats was obtained by 
centrifugation of blood (1-2 ml), taken by exsanguination at the time of killing, and stored at -
20oC until assayed.  Glucose levels were analysed using the MediSense

2 glucometer with 
Precision Plus

 blood glucose electrodes (MediSense, Australia).  Insulin levels were assayed using 
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an Ultra-sensitive Rat Insulin ELISA (Mercodia AB, Uppsala, Sweden).  Lipid levels (triglyceride, 
cholesterol and HDL) were measured on a Roche Modular analyser (Roche, Sydney, Australia).  
 
4.2.4 Pressure Myography 
4.2.4.1  Set-Up, Pressurisation and Equilibration 
Mesenteric arteries were isolated, cannulated and pressurised as previously described in 
Chapter 2 (2.2.3.1).   
Briefly, vessels, superfused with PSS, were pressurised from 50 mmHg to 80 mmHg over 
30 min, after which the vessel was further equilibrated for 30 min, or until acceptable myogenic 
tone was achieved.  Vessels were determined to have a viable level of myogenic tone if the 
internal diameter was 40-60% of the initial diameter. 
Pressure and intraluminal diameter measurements were recorded on a MacLab system 
(MacLab/4 Chart Software, model MKIIII, AD Instruments Pty Ltd, Australia).  A temperature 
thermo-coupler was also attached to monitor the bath temperature, which was maintained at 37  
0.5 oC (see chapter 2, section 2.2.3.2).   
 
4.2.4.2 Vasodilatation Characterisation 
All responses were obtained in the presence of 10 µM indomethacin to block prostanoid 
production.   
Endothelial function was determined by studying responses to the endothelium-
dependent dilator acetylcholine (ACh: 1 nM–10 µM) and the endothelium-independent dilator 
levcromakalim (LK: 10 nM–10 µM).  Concentration-response curves were obtained by the 
cumulative addition of the drug directly into the chamber.  Up to 3 sets of concentration-response 
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curves for both ACh and LK, alternating between the agonists ACh and LK, were obtained in the 
same preparation (i.e. ACh, LK, ACh, LK, ACh, LK), as detailed in Chapter 2 (2.2.3.4). 
Specific inhibitors were used to study the contributions of NO and EDHF, as outlined in 
chapter 3 (3.2.4.2); please note that the EDHF component was investigated following incubation 
with 100 M  L-NAME, 1 M ODQ, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-
34, 1 M, donated by Dr Wulff, University of California) and apamin (1 M).   
The contribution of EETs was assessed using the cytochrome P450 (CYP) epoxygenase 
2C/3A inhibitor sulfaphenazole (1 M), in the presence of 10 M indomethacin only.   
At the end of all experiments, the arterioles were superfused with calcium-free PSS buffer 
for 20 min and the maximal passive diameter was measured and recorded.   
 
  
4.2.5 Data & Statistical Analysis 
Data were presented as mean and standard error of the mean (SEM) with n indicating the 
number of experimental animals.  Results were analysed and compared using the Student‟s t-test  
(unpaired unless otherwise stated) or two-way analysis of variance (two-way ANOVA) followed 
by a Student-Newman-Keuls test.  A value of p<0.05 was regarded as statistically significant.  A 
two-way repeated measures ANOVA followed by Student-Newman-Keuls test was used when 
comparing concentration-curves obtained in the same vessel.  A one-way ANOVA followed by a 
Student-Newman-Keuls test was used to compare metabolic parameters.  
GraphPad Prism (V.4 for Windows, GraphPad, San Diego, California USA) was used to 
fit regression lines to the linear portions of the log concentration-response curves by the method 
of least squares.  EC50 values were interpolated from the regression lines, and correspond to a 
concentration producing 50% of the maximal response.  EC50 values are shown with the 95 % 
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confidence interval (CI) ranges, and were considered to be significantly different if the ranges did 
not overlap. 
 GraphPad Prism was used to construct figures showing the data and analyses of the 
results. 
 
Relaxations were measured as a percentage of the maximal diameter. 
 
 Diameter (% of max.) = R/M x 100 
 
where R is absolute diameter at a given drug concentration or pressure step and M is the maximal 
diameter of the vessel as determined by superfusing the vessel with calcium-free PSS. 
    
4.2.6 Drugs and Chemicals 
All drugs were purchased from Sigma Chemicals unless otherwise stated.  All drugs were 
dissolved in distilled water with several exceptions: indomethacin was dissolved in 0.1 M Na2CO3 
to give stock solution of 0.01 M; LK was dissolved in 70% ethanol to give a stock solution of 0.01 
M.  All stock solutions were diluted on the day using PSS. 
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4.3 Results 
4.3.1 Metabolic Parameters 
The average body weight of the male OZR (393 ± 17 g, n=5) was significantly greater than 
the male LZR (312 ± 11 g, n=7) (p<0.05, 1-way ANOVA).  Non-fasting blood glucose levels were 
significantly (p<0.5, 1-way ANOVA) higher in the male OZR (12.6 ± 1.6 mM, n=5) than the male 
LZR (6.2 ± 0.1 mM, n=7).  Insulin, cholesterol and triglyceride levels were also significantly higher 
in the male OZR rats compared with the LZR controls (p<0.05, 1-way ANOVA, n=5-7, Figure 
4.1). 
Non-fasting blood glucose levels were significantly (p<0.05, 1-way ANOVA) increased in 
the male OZR (12.6±1.6 mM, n=5) as compared with the female OZR (6.6±0.3 mM, n=22), with 
no significant (p>0.05, 1-way ANOVA) difference in weight between the female (391±5 g, n=22) 
and male (393±17 g, n=5) OZRs.  Male LZRs were significantly (p<0.05, 1-way ANOVA) heavier 
than the corresponding female LZRs, and cholesterol and insulin levels were significantly (p<0.05, 
student‟s t-test) higher in the male than the female LZRs.  Triglyceride levels were not significantly 
(p>0.05, 1-way ANOVA) different between the female and male LZRs. 
 
4.3.2 Vasodilatation Characterisation 
 All results have been normalised against the maximal (passive) diameters, which were not 
significantly different (p>0.05, Student‟s t-test) between LZR (176 ± 7 µm, n=7) and OZR (173 ± 
11 µm, n=5).  There was no significant difference (p>0.05, Student‟s t-test) in the absolute active 
diameters (LZR: 92 ± 5 µm, n=7; OZR: 90 ± 6 µm, n=5), or in the myogenic tone achieved by 
mesenteric arteries from the LZR (52.1 ± 1.3% of maximal diameter, n=7) and OZR (52.4 ± 1.8% 
of maximal diameter, n=5).   
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 Figure 4.2 and Figure 4.3 illustrate typical traces obtained for vasodilatation to ACh and LK 
respectively.  Concentration-response curves to ACh for the OZR (EC50 126.8 nM, 95% CI 76.9-
209.0 nM, n=5) showed a significant (p<0.05, Student‟s t-test) 2.8-fold rightward parallel shift 
compared to the LZR (EC50 44.7 nM, 95% CI 34.8-57.3 nM, n=7)(Figure 4.4a).  There was also a 
significant reduction (p>0.05, Student‟s t-test) in the maximal dilation caused by ACh between 
LZRs (98.1 ± 0.2% of maximal diameter, n=7) and OZRs (84.2 ± 2.1% of maximal diameter, n=5).  
Relaxation responses to LK were not altered in mesenteric arteries from the male LZRs or OZRs 
(Figure 4.4b).   
Responses to ACh were not changed (p>0.05, ANOVA) by L-NAME and ODQ in the 
male OZR (Figure 4.7a, n=4) or LZR (Figure 4.7b, n=4), but were abolished (p<0.05, ANOVA) by 
a combination of L-NAME, ODQ, TRAM-34 and apamin (Figure 4.7c, n=3).  Responses to LK in 
the male LZRs and OZRs were not altered (p>0.05, ANOVA) in the presence of L-NAME and 
ODQ (Figure 4.7b, n=4), nor were they altered (p>0.05, ANOVA) by the addition of L-NAME, 
ODQ, TRAM-34 and apamin (Figure 4.7d, n=4). 
Responses to ACh were not significantly different between male and female LZRs (p>0.05, 
ANOVA, n=6-14, Figure 4.5A).  ACh-induced relaxations were significantly reduced in mesenteric 
arteries from the male OZR, compared to the female OZR (p>0.05, ANOVA, n=5-21, Figure 
4.5B).  There was no significant difference in endothelium-independent responses to LK between 
mesenteric arteries from the female and male LZR or OZRs (p>0.05, ANOVA, n=5-21, Figure 
4.6).  Responses to ACh were not altered in the presence of NAME and ODQ (p>0.05, ANOVA) 
in the LZRs (Figure 4.8A) or OZRs (Figure 4.8B) from female or male rats, but were abolished in 
the presence of TRAM and apamin. 
Sulfaphenazole had no effect on responses to ACh or LK, in the lean or obese male Zucker 
preparations (p<0.05, ANOVA, n=4, Figure 4.9). 
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Figure 4.1:  Metabolic Parameters 
Metabolic parameter comparison of female and male lean (LZR) and obese (OZR) Zucker rats 
Data are expressed as mean ± SEM of n=5-7 animals. 
* p<0.05, significantly different from female LZR (1-way ANOVA, followed by Newman-Keuls). 
# p<0.05, significantly different from male LZR (1-way ANOVA, followed by Newman-Keuls). 
^ p<0.05, significantly different from female OZR (1-way ANOVA, followed by Newman-Keuls). 
Chapter 4 
4-14 
Chapter 4 
4-15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2:  Representative Acetylcholine–Induced Dilatations 
Typical traces illustrating responses to acetylcholine (10-9 to 10-5 M, cumulative additions indicated 
by arrows) in pressurised third-order mesenteric arteries from a male lean Zucker rat (LZR, A) 
and a male obese Zucker rat (OZR, B). 
 
B.    OZR
10-9
3x10-9
3x10-8
3x10-7
3x10-6
10-8
10-7
10-6
10-5
D
ia
m
et
er
 (

m
)









80
120
160
180
140
100
200
A.     LZR
80
120
160
D
ia
m
et
er
 (

m
)
3x10-6
3x10-7
10-6
10-7
3x10-8
10-8
3x10-9
10-9
180
140
100







2 min
200
2 min
10-5

D
ia
m
et
er
 (

m
)
D
ia
m
et
er
 (

m
)
 
Chapter 4 
4-16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3:  Representative Levcromakalim–Induced Dilatations 
Typical traces illustrating responses to levcromakalim (10-8 to 3x10-5 M, cumulative additions 
indicated by arrows) in pressurised third-order mesenteric arteries from a male lean Zucker rat 
(LZR, A) and a male obese Zucker rat (OZR, B). 
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Figure 4.4:  Male Zucker ACh- and Levcromakalim-Induced Dilatations 
Concentration-response curves for relaxations to acetylcholine (ACh, A) and levcromakalim (LK, 
B) in pressurised third-order mesenteric arteries from lean (●, n=11-14) and obese (●, n=12-18) 
male Zucker rats, in the presence of indomethacin (10 M).  Values are means ± SEM.  Note that 
error bars are smaller than the size of the symbols.  *p<0.05, Student‟s t-test, comparison of EC50 
and maximal responses. 
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Figure 4.5:  Female vs. Male Zucker Rats (Acetylcholine) 
Concentration-response curves for relaxations to acetylcholine (ACh) in pressurised third-order 
mesenteric arteries from A) lean female (●, n=22) and male (○, n=5) Zucker rats, B) obese female 
(●, n=22) and male (○, n=5) Zucker rats, in the presence of indomethacin (10 M).  Values are 
means ± SEM.  Note that in some instances error bars are smaller than the size of the symbols.  
*p<0.05, ANOVA. 
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Figure 4.6:  Female vs. Male Zucker Rats (Levcromakalim) 
Concentration-response curves for relaxations to levcromakalim (LK) in pressurised third-order 
mesenteric arteries from A) lean female (●, n=22) and male (○, n=5) Zucker rats, B) obese female 
(●, n=22) and male (○, n=5) Zucker rats, in the presence of indomethacin (10 M).  Values are 
means ± SEM.    Note that in some instances error bars are smaller than the size of the symbols.   
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Figure 4.7:  Male Zucker Vasodilatation Characterisation 
Concentration-response curves for relaxations to acetylcholine (ACh, A&C) and levcromakalim 
(LK, B&D) in pressurized third-order mesenteric arteries from lean (LZR, n=3-7) and obese 
(OZR, n=3-7) male Zucker rats before (● LZR, ● OZR) and after treatment with nitro-L-arginine 
methyl ester (L-NAME, 100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 M) 
(● LZR, ● OZR)  or treatment with L-NAME (100 M), ODQ (1 M), TRAM-34 (1 M) and 
apamin (1 M) (● LZR, ● OZR).   Values are means ± SEM.  Note that in some instances error 
bars are smaller than the size of the symbols.   
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Figure 4.8:  Female vs. Male Zucker Rats (NO and EDHF components) 
Concentration-response curves for relaxations to acetylcholine (ACh) in pressurised 
third-order mesenteric arteries from lean (A) and obese (B) female and male Zucker rats before (● 
female, ○ male) and after treatment with:  
Nitro-L-arginine methyl ester (L-NAME, 100 M) and 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ, 1 M) (● female, ○ male);  
TRAM-34 (1 M) and apamin (1 M) (● female, ○ male). 
Values are means ± SEM.  Note that error bars are smaller than the size of the symbols.  *p<0.05, 
ANOVA. 
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Figure 4.9:  Sulfaphenazole 
Concentration-response curves for relaxations to acetylcholine (ACh, A&C) and 
levcromakalim (LK, B&D) in third-order mesenteric arteries from male lean Zucker rats (LZR, 
n=3-5) and obese Zucker rats (OZR, n=3-5) before (● LZR, ● OZR) and after (● LZR, ● OZR)   
treatment with sulfaphenazole (300 M) in the presence of 10 M indomethacin.  Values are means 
± SEM.  Note that in some instances error bars are smaller than the size of the symbols.   
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4.4 Discussion 
In agreement with previous findings, the metabolic parameters measured in the male 
Zucker rats has confirmed that male OZRs are an acceptable model of type 2 diabetes, as 
confirmed by the presence of  overt hyperglycaemia (non-fasting glucose > 11.1 mM 
(International Diabetes Institute 2002)), hyperinsulinaemia, dyslipidaemia and obesity.   These 
characteristics are consistent with those seen by other research groups (Cox and Kikta 1992; 
Bohlen and Lash 1995; De Gennaro-Colonna, Rossoni et al. 2000; Brooks-Asplund, Shoukas et 
al. 2002; Burnham, Johnson et al. 2006; Schrijvers, Flyvbjerg et al. 2006).  It is important to note 
that glucose levels were also reported to be significantly higher in the male ZDF rats compared 
with age-matched females (Ajayi, Hercule et al. 2003).   
The findings from this set of experiments have identified for the first time, to the authors 
knowledge, the role of EDHF in endothelial function in the third-order mesenteric arteries from 
the male LZR and OZRs.  Responses to ACh were not altered in the presence of L-NAME and 
ODQ in either the LZR or OZR mesenteric preparations; this indomethacin/L-NAME/ODQ-
resistant response to ACh was abolished by the additional incubation with TRAM-34 and apamin.  
This confirmed that EDHF was the sole mediator of ACh-induced relaxation responses in the 
pressurised third-order mesenteric arteries from both male LZR and OZR.  The experiments in 
chapter 3 also identified EDHF to be the sole mediator of ACh-induced relaxation responses in 
third-order mesenteric arteries from female LZR and OZRs.  Therefore, gender does not appear 
to alter the relative contributions of EDHF and NO, in contrast to other studies which have 
reported changes in contributions between male and females (White, Rivera et al. 2000; Sakuma, 
Liu et al. 2002; Scotland, Madhani et al. 2005).  The reason for the contrasting findings is 
debateable, and may simply be due to the animal model being studied, given the contradictory 
findings were in studies using Sprague-Dawley rats (White, Rivera et al. 2000), Wistar rats 
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(Sakuma, Liu et al. 2002) or C57BL mice (Scotland, Madhani et al. 2005).  Another important 
difference is the vessel diameter.  Wire-mounted first-order mesenteric vessels were used in the 
Sakuma et al. study and although pressurised third-order mesenteric arteries were used in the 
White et al. study, the same as used in this study,  the average vessel diameter was ~260 m, which 
is considerable larger than the 140-170 m observed in this set of experiments.   The size of the 
vessels is important to the interpretation of these results, as EDHF is known to increase as the 
vessel size becomes smaller, and therefore a direct comparison between these studies must be 
done with caution.  It is possible that the gender-related differences in EDHF and NO 
contributions can only be observed in certain arterial sections. 
Another important finding from this set of experiments was the significantly reduced 
response to ACh in the male OZR mesenteric arteries compared with the male LZR vessels.   This 
reduced response was signified by a decrease in the maximal response as well as rightward parallel 
shift in the curve.  As responses to the endothelium-independent dilator LK were not altered, this 
attenuated response can be identified as endothelial dysfunction.  Furthermore, this degree of 
endothelial dysfunction was significantly greater than that observed in the female OZR, consistent 
with previous findings in the ZDF rats (Ajayi, Hercule et al. 2003).  The gender difference observed 
may be due to the more advanced stage of disease in the male OZR, i.e. female OZR is insulin-
resistant, male OZR is type 2 diabetic.  Similarly, the study in ZDF rats reported that the male 
ZDFs had a higher blood glucose level, and proposed that this advanced disease state might be the 
reason for the higher level of endothelial dysfunction seen in the male ZDFs compared with the 
age-controlled females (Ajayi, Hercule et al. 2003). 
This study has failed to identify the factor mediating EDHF relaxation responses, with 
sulfaphenazole having no effect on ACh-induced responses in male LZR or OZR mesenteric 
arteries.  This is consistent with the findings in the female LZR and OZR, and as discussed in 
chapter 3, this negative finding cannot be interpreted to mean that EETs are not involved in the 
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EDHF-mediated relaxations in these vessels.  Further investigation with other EET inhibitors are 
necessary in order to ascertain the role EETs do play in the EDHF relaxation responses in these 
preparations.  Aside from EETs, the role of gap junctions and other EDHF candidates also needs 
to be studied in the male LZR and OZR, in order to determine which characteristics of the EDHF 
response are attenuated in the OZR.  The limited availability of animals prevented us from 
undertaking these additional studies; furthermore, only one experiment can be done per day.   
In summary, this set of experiments has identified EDHF to be the primary mediator of 
ACh-induced relaxation responses in third-order mesenteric arteries from male LZR and OZRs, 
with ACh-induced responses being significantly reduced in the type 2 diabetic male OZR.  In 
regards to a gender difference between the female and male Zucker rats, there was no change in the 
relative contributions of EDHF and NO, with EDHF being the sole mediator in both females and 
males.  However, the level of dysfunction seen in the male OZR was significantly greater than that 
demonstrated in the insulin-resistant female OZR, possibly related to the advanced stage of disease 
seen in the male OZR.  Lastly, whilst sulfaphenazole had no effect on ACh-induced responses in 
the male Zucker arteries, further experiments are necessary in order to elucidate the mechanisms 
underlying the EDHF-mediated responses, in order to determine the pathways involved in the 
development of the EDHF-related endothelial dysfunction, which may be the target of future 
therapeutic strategies. 
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5. Connexin Expression in the Zucker 
Mesenteric and Renal Arteries 
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5.1 Introduction 
As mentioned in the the discussion of chapter 3, studies in our laboratory have 
demonstrated impaired EDHF-mediated relaxation in wire-mounted lobar arteries from the 
OZR, with a compensatoryincrease in NO (Reid, Roche et al. 2003).  Having determined that 
connexin 40-associated relaxations are reduced in the third-order mesenteric arteries (Chapter 3) 
and renal arteries (Reid, Roche et al. 2003) from the insulin-resistant 25-wk female obese Zucker 
rat (OZR), compared with the lean (LZR) littermate controls, we wanted to determine if this 
functional impairment is related to a decrease in protein or mRNA levels of connexin 40.   
Whilst changes in gap junctions and connexins have not been studied in this animal 
model, connexin protein and mRNA levels have been shown to be altered by hyperglycaemia.  A 
recent study in type 1 diabetic streptozotocin (STZ)-treated apoE-deficient mice, has 
demonstrated that connexin 37 mRNA expression is decreased in the small mesenteric artery 
from STZ-treated mice compared with the vehicle-treated apoE-deficient control mice (Ding, 
Hashem et al. 2005).  Additionally, the study found no change in connexins 40, 43 or 45 mRNA 
levels (Ding, Hashem et al. 2005).  In contrast, immunohistochemical analysis of connexins in the 
renal vasculature has demonstrated an increase in connexin 40 staining in STZ-treated rats, 
compared to the corresponding control rats (Zhang and Hill 2005). 
In cell culture studies, it has been demonstrated that exposure of vascular smooth muscle 
cells to high glucose results in impaired connexin 43 function, associated with increased 
phosphorylation and altered permeability (Inoguchi, Ueda et al. 1995; Kuroki, Inoguchi et al. 
1998; Inoguchi, Yu et al. 2001), without any reduction in protein or mRNA levels (Brink, Valiunas 
et al. 2006).  In microvessels from retinas isolated from STZ-treated rats, it has also been 
demonstrated that increased phosphorylation of connexin 43, associated with increased protein 
kinase C (PKC) activity, results in impaired gap junction function (Oku, Kodama et al. 2001).  
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Furthermore, a study in cultured rat microvascular endothelial cells exposed to high glucose levels 
has demonstrated a reduction in connexin 43 protein and mRNA levels, with no change in 
connexin 37 or 40 protein or mRNA levels (Sato, Haimovici et al. 2002).   
Given that a number of different factors may affect gap junction activity, it is important to 
determine the underlying mechanisms behind the changes in gap junction function observed in 
the third-order mesenteric and renal arteries from female OZRs.  The aim of the experiments 
described in this chapter was to investigate whether mRNA or protein levels of the vascular 
connexins (37, 40, 43 and 45) are altered in the mesenteric and renal arteries from the female 
OZR, compared to the LZR.   
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5.2 Methods and Materials 
5.2.1 Animals  
Female LZR and OZR of 25 wk of age were obtained from Monash Animal Services, 
Victoria, Australia.  All procedures involved were approved by the Animal Experimentation 
Ethics Committee (AEEC #0217 and #0530), and conformed to the Australian National Health 
and Medical Research Council Code of Practice for the Care and Use of Animals for Scientific 
Purposes.   The rats were killed by asphyxiation with carbon dioxide followed by decapitation.  
 
5.2.2 Western Blotting 
5.2.2.1 Rat Tissue Collection and Preparation 
The entire mesenteric bed and kidneys were removed from the body cavity and placed in 
physiological salt solution (PSS): 118 mM NaCl, 4.7 mM KCl, 0.45 mM MgSO4, 1.03 mM 
KH2PO4, 11.1 mM D(+) glucose, 25 mM NaHCO3 and 2.5 mM CaCl2 (gassed with 5% CO2, 
95%O2).  The mesenteric and renal arteries were isolated using fine forceps and scissors used to 
clear away layers of fat and connective tissue, under a dissecting microscope (Olympus SZX12, 
Olympus, Australia).  The tissues were then stored at -80oC until further use, with the tissue being 
frozen for no more than two months. 
 
5.2.2.2 Homogenate Preparation 
Renal arteries (including the primary and lobar arteries, and any other attainable branches) 
from two rats were pooled for testing and treated as one sample (n=1, ~50 mg).  First-, second- 
and third-order mesenteric arteries were isolated from each rat (n=1, ~150 mg). 
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Tissue samples were thawed on ice and finely minced with scissors prior to manual (glass) 
homogenisation (Dounce tissue grinder) for 5 min in lysis buffer (160 l for renals, 400 l for 
mesenterics: 1 mM NaHCO3, 10 mM ethylenediaminetetraacetic acid (EDTA), 10 mM 
iodoacetamide, 10 mM sodium pyrophosphate, 1 mM phenylmethylsulphonylfluoride (PMSF), 1 
U/ml aprotinin, 20 M pepstatin A, 20 M leupeptin, pH 7.4).  The homogenates were then 
incubated in the lysis buffer for 30 min at 4oC, vortexed for 2 min, and sonicated for 5 min, 
before centrifugation (Beckman Coulter, Allegra 64A centrifuge) for 10 min at 3,000 g at 4oC.   
 
5.2.2.3 Protein Content 
Protein content of the samples was quantified by using the Coomassie Protein Assay Kit 
(Bio-Rad Laboratories Pty Ltd, California, USA), based on the Bradford assay (Bradford 1976).  
Bovine serum albumin (BSA; Commonwealth Serum Laboratories, Australia) was used to prepare 
standard protein concentrations of 0.25–2 mg/ml.  Aliquots of the supernatant (5 l) were diluted 
1:10 with distilled water.  A ratio of 1 l diluted sample or standard: 100 l Coomassie reagent 
was analysed using the UV-visible spectrophotometer (Cintra5, GBC Scientific Equipment Pty 
Ltd, Illinois, USA) at a wavelength of 595 nM.  All standards and homogenate supernatants were 
measured in duplicate. 
 
5.2.2.4 Western Blot Procedure 
 The lysate protein content of each sample was adjusted with lysis buffer and reducing 
buffer (130 mM Tris HCl, 3% sodium dodecyl sulphate (SDS), 3% w/v glycerol, 20% w/v D,L-
dithiothreitol (DTT; Sigma, USA)) so that the protein in each lane was 25 g (connexin 37 and 
connexin 43) or 60 g (connexin 40) (for calculations see appendix (8.1)).  Samples were boiled at 
37oC for 60 min.  Once at room temperature, the samples were loaded onto a 10% acrylamide gel 
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and separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).  The 
size of the bands was determined using a wide-range (270,000–7,000 MW) molecular weight 
colour marker (Sigma, Australia), which was also loaded onto the gel.  The samples were run at 
200 V for approximately 45 min in running buffer (0.25 M Tris Base, 1.92 M glycine, 1% SDS) in 
a Bio-Rad Mini-PROTEAN II electrophoresis system (Table 5.1).  After electrophoretic 
separation, the proteins were transferred onto nitrocellulose membrane (Hybond-ECL, 
Amersham Pharmacia Biotech, Little Chalfont, UK) at 400 mA for 2 hr in blotting buffer (25 mM 
Tris base, 192 mM glycine, 20% methanol) in a Bio-Rad Mini Electrophoretic Transfer Cell 
System (Table 5.1). 
Nitrocellulose membranes were blocked with blocking buffer (5% skim milk, 0.1% 
Tween®-20 (Sigma), in Tris-buffered saline (TBS) (20 mM Tris base, 137 mM NaCl and 1 M HCl) 
for 4 hrs (connexin 40) or overnight (connexinx 37 and 43) at room temperature, to block non-
specific binding sites (Table 5.1).  The solution was replaced with fresh blocking buffer containing 
either polyclonal rabbit anti-mouse connexin 37 antibody (Jomar Diagnostics, Australia, 1:2000), 
polyclonal rabbit anti-mouse connexin 40 antibody (Jomar Diagnostics, Australia, 1:2000), or 
monoclonal mouse connexin 43 antibody (BD Transduction Laboratories, Australia, 1:2000), and 
incubated overnight (connexin 40) or for 6 hrs (connexins 37 and 43) (Table 5.1). 
Excess primary antibody was removed using a series of washes with TBS and TBS-Tween 
(0.01% Tween®-20): 10 min TBS, 15 min TBS-Tween, 10 min TBS, 10 min TBS.  The secondary 
antibodies (Cx 37 and 40: Swine anti-rabbit IgG, 10 g/ml, DakoCytomation, Australia; Cx 43: 
Goat anti-mouse IgG, 10 g/ml, DakoCytomation, Australia) were used 1:5000 in TBS and 
incubated for 1 hr (Table 5.1).  The secondary antibody was removed following thorough 
washings as described above.   
 
Chapter 5 
5-7 
5.2.2.5 Chemiluminescence 
Proteins were detected by enhanced chemiluminescence (Lumi-light Western Blotting 
Substrates; Roche Diagnostics, USA) for 5 min.  Detection of the proteins by Lumi-Light substrate 
solution using primary and secondary antibodies is illustrated in Figure 5.1.   
For connexin 43, membranes were then exposed to X-ray film (BioMaxTM MR film, 
Kodak, Australia) for 5 min and subsequent exposure times adjusted according to the result of the 
first exposure.   
For connexins 37 and 40, membranes were imaged using the Bio-Rad ChemiDoc XRS 
system (Bio-Rad Laboratories, Australia), which detects chemiluminescence using a charge-coupled 
device (CCD) camera, the image of which is automatically displayed, and is ready for analysis using 
Bio-Rad Quantity One software (Bio-Rad Laboratories, Australia).  
For all connexin types more than one band was visible on the gel, and the appropriate 
connexin band was identified using the wide-range molecular weight marker.   
 
5.2.2.6 Data and Statistical Analysis 
Densitometric analysis of band intensity and area was performed using the Bio-Rad 
Quantity One software for connexins 37 and 40.  Band area (measured as square mm) and intensity 
was automatically detected using this software. 
Scion Imaging (version 4.0.2, Scioncorp, USA) was used to perform densitometric 
analysis of band intensity and area for connexin 43.  Band area (measured as square pixels) was 
determined by manually tracing the outline of each band; band intensity was determined by 
highlighting the centre of the band (using the same box size for each band), and measuring the 
intensity within that area. 
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Data are presented as mean and standard error of the mean (SEM) with n indicating the 
number of samples.  Student‟s t-test was used to compare mean values between LZR and OZR.  A 
value of p<0.05 was regarded as statistically significant.  
 
5.2.2.7 Drugs and Chemicals 
All drugs were purchased from Sigma Chemicals unless otherwise stated.   
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5.2.3 Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
5.2.3.1 Microvessel Preparation 
 Female 25-wk LZRs and OZRs were asphyxiated with carbon dioxide inhalation 
followed by decapitation.  The kidneys and mesenteric bed were removed and placed in cold PSS: 
118 mM NaCl, 4.7 mM KCl, 0.45 mM MgSO4, 1.03 mM KH2PO4, 11.1 mM D
(+) glucose, 25 mM 
NaHCO3 and 2.5 mM CaCl2 (gassed with 5% CO2, 95%O2).   
 All obtainable orders of the mesenteric and renal arteries were isolated using fine forceps 
and scissors used to clear away layers of fat and connective tissue, under a dissecting microscope 
(Olympus SZX12, Olympus, Australia).  The tissues were then snap-frozen in liquid nitrogen and 
stored at -80oC until further use (no longer than 2 months). 
 
5.2.3.2 Ribonucleic acid (RNA) extraction 
RNA extraction from renal and mesenteric samples (20-30 mg) was completed using the 
Qiagen RNeasy Mini Kit (Qiagen, Australia).  This method results in total RNA isolation by 
combining guanidine-isothiocyanate lysis with silica-gel–membrane purification.  This process 
resulted in 50 l of RNA extract, which was stored at -80oC (used within a week of storage).  
 
5.2.3.3 Reverse transcription 
Reverse transcription (RT) was completed using the MJ Research PTC-200 Peltier thermal 
cycler DNA engine, using the protocol and solutions provided with the Qiagen Sensiscript RT Kit 
(Qiagen, Australia).  12 l of the RNA extract was heated at 65oC, and the master mix was added 
once the extract was cooled down to 4oC; the master mix consisted of: 2 l RT buffer (Qiagen);   
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2 l 5 mM deoxyribonucleotide triphosphate (dNTPs, Qiagen); 2 l Oligo (dT) 12-18 primer (100 
M, Invitrogen, Australia); 1 l sensi-script reverse transcriptase(Qiagen); 1 l RNasin (RNase 
inhibitor enzyme, 40 U/l, Promega, Australia).  The mixture was then heated to 37oC for 60 
min, 95oC for 5 min, and then cooled back down to 4oC to stop the reaction. 
 
5.2.3.4 Real-Time PCR 
Complementary DNA (cDNA, 1 l) was amplified in a 25-l reaction using the 
Quantitect Sybr Green Kit (Qiagen, Australia), containing 12.5 l Sybr green, 0.625 l forward 
primer, 0.625 l reverse primer and 11.25 l mQ water (See Table 5.2 for forward and reverse 
primer sequences designed by William Wiehler at the University of Calgary in Canada). 
To optimize reaction specificity, as determined by work carried out by William Wiehler at 
the University of Calgary in Canada, real-time PCR was performed on each primer set using 
SYBR-Green (Qiagen) and a range of annealing temperatures (52-62oC).  Based on melt-curve 
analysis, 1 l of each reaction product was placed on a DNA 500 lab chip and examined using an 
Agilent Technologies 2100 Bioanalyzer.  A separate aliquot of reaction product was 
electrophoresed on a 1.5% (w/v) agarose gel, extracted using a gel extraction kit (Qiagen) and 
subsequently sequenced to confirm product identity.  Having ascertained an ideal annealing 
temperature, real-time PCR reaction efficiency was determined for all primer sets by using serial 
dilutions of cDNA as template.   
The optimal real-time PCR reaction consisted of a hot start (95oC for 15 min) followed by 
40 cycles of 94oC for 15 sec, 60.1oC for 30 sec and 72oC for 30 sec, where optical data were 
collected during the extension phase.  A melt-curve analysis was performed on each reaction and 
threshold cycle was determined using software provided with the Bio-Rad iCycler.  The reaction 
efficiencies at an annealing temperature of 60.1oC for all messages are shown in Table 5.2. 
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β-Actin was used as the house-keeping gene, which has been shown to be unaffected by 
the diabetic state (Roy and Lorenzi 1996; Striker and Striker 1996; Wang and Gleichmann 1998).  
β-Actin has been shown to be a stable house-keeping gene in diabetes (Biederman, Yee et al. 
2004), and has been consistently used as an internal standard in diabetic studies (Roy and Lorenzi 
1996; Striker and Striker 1996; Wang and Gleichmann 1998; Hamaoui, Butt et al. 2004). 
 
5.2.3.5 Data and Statistical Analysis 
Data are presented as mean and standard error of the mean (SEM) with n indicating the 
number of experimental animals.  Student‟s t-test (unpaired) was used to compare mean values for 
LZR with OZR.  A value of p<0.05 was regarded as statistically significant.  
 The graphic and statistical software package GraphPad Prism version 4.00 for Windows 
(GraphPad, San Diego, California USA) was used to construct figures showing the data and 
analyses of the results.   
mRNA levels are expressed relative to β-actin ; the fold relative to β-actin for the mRNA 
of interest was calculated using the 2_DCT method (Livak and Schmittgen 2001), whereby: 
 
Fold relative to β-actin (x0.0001) = 2-average CT x 10,000 
 
Where CT = cycle threshold (refer to Figure 5.4:  PCR Representative Trace) 
 
5.2.3.6 Drugs and Chemicals 
All drugs were purchased from Sigma Chemicals unless otherwise stated.   
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Western Blotting Protocol 
SDS-PAGE 
10% SDS 
200 Volts 
45 min 
Transfer to Nitrocellulose Membrane 
400 mA 
2 hr 
  Connexin 37 Connexin 40 Connexin 43 
Blocking Time Overnight 4 hr Overnight 
Primary 
Antibody 
Antibody 
Polyclonal rabbit 
anti-mouse 
Polyclonal rabbit 
anti-mouse 
Monoclonal 
mouse 
Concentration 1:2000 1:2000 1:2000 
Incubation Time 6 hrs Overnight 6 hrs 
Secondary 
Antibody 
Antibody 
Horse Radish-
Peroxidase-
conjugated, 
swine anti-rabbit  
Horse Radish-
Peroxidase-
conjugated, 
swine anti-rabbit 
Horse Radish-
Peroxidase-
conjugated, goat 
anti-mouse 
Concentration 1:5000 1:5000 1:5000 
Incubation Time 1 hr 1 hr 1 hr 
Chemiluminescence 5 min 
Densitometric Analysis 1-5 min exposure 
 
Table 5.1:  Western Blot Protocol 
Homogenates prepared from renal and mesenteric arteries isolated from lean and obese Zucker rats 
were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred on to a nitrocellulose membrane.  Non-specific binding sites were blocked, prior to 
incubation with the primary and secondary antibodies.  Densitometric analysis was conducted 
following chemiluminescence. 
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Lumi-Light 
Substrate
Light
Primary Antibody
Secondary Antibody
HRP Conjugate
Antigen
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1:  Lumi-Light Chemiluminescence 
A diagram illustrating the chemiluminescent detection of antigens using primary and horseradish 
peroxidise (HRP) conjugated secondary antibodies by Lumi-Light substrate.  The primary antibody 
binds to the antigen on the membrane, followed by the binding of the secondary antibody to the 
primary antibody.  The HRP converts Lumi-Light substrate resulting in light emission.  This light is 
detected by exposition to X-ray film or exposure via the Bio-Rad ChemiDoc XRS System (Bio-Rad 
Laboratories, Australia). 
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Message  Primer Sequence 
Reaction 
Efficiency (%) 
β-actin 
Forward 
Reverse 
5‟ TATGAGGGTTACGCGCTCCC 3‟ 
5‟ ACGCTCGGTCAGGATCTTCA 3‟ 
95.0 
Connexin 37 
Forward 
Reverse 
5‟ TCATCTTCCGAATCCTCATCC 3‟ 
5‟ AAGCCTGGTCATAGCACAC 3‟ 
95.5 
Connexin 40 
Forward 
Reverse 
5‟ AGGTCCACAAGCACTCTAC 3‟ 
5‟ AATCAGCCTGCTCATCTCC 3‟ 
97.1 
Connexin 43 
Forward 
Reverse 
5‟ GGATTGAAGAGCACGGCAAGG 3‟ 
5‟ ACCACTGGATGAGCAGGAAGG 3‟ 
94.7 
Connexin 45 
Forward 
Reverse 
5‟ CTGTGTTTGAGGTGGGCTTTC 3‟ 
5‟ TGAGGACAAGGAAGTCTGCTG 3‟ 
93.8 
 
 
Table 5.2:  PCR primer sequences and reaction efficiencies 
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5.3 Results 
5.3.1 Western Blotting 
5.3.1.1 Mesenteric Arteries 
Comparison of Western blot band intensity and area values indicated a significant 
reduction (p<0.05, Student‟s t-test) in connexin 37 (Figure 5.2, n=8) and connexin 40 (Figure 5.2, 
n=8) protein levels in vascular homogenates from the OZR compared with the LZR.  In contrast, 
there was no significant difference (p>0.05, Student‟s t-test) in connexin 43 area or intensity 
between the LZR and OZR (Figure 5.2, n=8). 
 
5.3.1.2 Renal Arteries 
Both the band intensity and band area showed a significant reduction (p<0.05, Student‟s t-
test) in connexin 40 protein levels in vascular homogenates from the OZR compared with the 
LZR (Figure 5.3, n=6).   There was no significant difference (p>0.05, Student‟s t-test) in connexin 
37 (Figure 5.3, n=6) or connexin 43 band area or intensity between the LZR and OZR (Figure 
5.3, n=6). 
 
5.3.2 Real-Time PCR 
5.3.2.1 Mesenteric Arteries 
Figure 5.4 shows a representation of real-time PCR traces obtained using mesenteric 
homogenates.  Quantitative analysis of mesenteric connexin mRNA levels (Figure 5.5) showed a 
significant (p<0.05, Student‟s t-test) 78% decrease in connexin 40 expression in mesenteric 
arteries from the OZR (n=6) compared with the LZR (n=7), and a 68% decrease in connexin 37 
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expression in the OZR (n=6) compared with the LZR (n=5).  There was no change in connexin 
43 or connexin 45 mRNA expression, which were present at low levels (n=4-6).   
 
5.3.2.2 Renal Arteries 
There was a significant (p<0.05, Student‟s t-test) 65% decrease in connexin 40 mRNA 
expression in renal arteries from the OZR (Figure 5.6, n=8) compared with the LZR (n=8), and a 
72% decrease in connexin 37 expression in the OZR (Figure 5.6, n=6) compared with the LZR 
(Figure 5.6, n=5).   There was also a significant reduction in connexin 45 mRNA, with no change 
in connexin 43 mRNA expression, both of which were present at low levels (Figure 5.6, n=4-6).   
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Figure 5.2:  Western Blot Analysis: Mesenteric Arteries 
A)  A typical result of Western Blot analysis of connexin 37, 40 and 43 in mesenteric arteries from the lean (LZR) and obese (OZR) Zucker rat.  Mean data of the B) area 
and C) intensity of Western Blot bands for connexin 37, 40 and 43 protein content in mesenteric arteries from LZRs and OZRs.  Each value represents the mean ± SEM 
of 8 preparations.  *p<0.05 Student‟s t-test.   
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Figure 5.3:  Western Blot Analysis: Renal Arteries 
A)  A typical result of Western Blot analysis of connexin 37, 40 and 43 in renal arteries from the lean (LZR) and obese (OZR) Zucker rats.  Mean data of the B) area and 
C) intensity of Western Blot bands for connexin 37, 40 and 43 protein content in renal arteries from LZRs and OZRs.  Each value represents the mean ± SEM of 6 
preparations. *p<0.05 Student‟s t-test.   
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Figure 5.4:  PCR Representative Trace 
Typical trace illustrating threshold levels for mRNA levels of connexins 37 (Cx37) and 40 (Cx40) and β-actin in mesenteric arteries from a female lean Zucker rat (LM3) 
and a female obese Zucker rat (OM3).  Results were obtained by the Sybr green method of Real-Time PCR. 
 
Cycle threshold 
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Figure 5.5:  Real-Time PCR, Mesenteric Artery 
Comparison of connexin mRNA expression in mesenteric artery homogenates from lean 
() and obese () Zucker rats.  Levels are expressed relative to beta-actin (x 0.0001) and are shown 
as means ± SEM (n=4-8).  (*p<0.05, Student‟s t-test) 
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Figure 5.6:  Real-Time PCR, Renal Artery 
Comparison of connexin mRNA expression in renal artery homogenates from lean () 
and obese () Zucker rats.  Levels are expressed relative to beta-actin (x 0.0001) and are shown as 
means ± SEM (n=4-8).  (*p<0.05, Student‟s t-test) 
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5.4 Discussion 
The findings from the experiments described in this chapter indicate that connexin 40 
protein and mRNA levels are reduced in the mesenteric and renal arteries from the OZR, 
compared with the LZR controls.  Connexin 37 protein and mRNA levels were also reduced in 
OZR arteries, with connexin 45 mRNA expression being reduced in the renal OZR arteries.  
Connexin 43 protein and mRNA levels were not altered in mesenteric or renal arteries from the 
OZR.  As the mRNA levels of connexin 43 and 45 were present in such low levels, this 
statistically significant reduction in connexin 45 mRNA may not be clinically significant. 
The decrease in connexin 40 protein and mRNA expression in the renal and mesenteric 
arteries from the OZR supports the observation of decreased connexin 40-related EDHF-
mediated relaxation in these arteries.  Whilst connexin 37 protein and mRNA levels were also 
found to be decreased in these arteries, this appears to be unrelated to the functional attenuation 
of EDHF-mediated responses partly attributed to impaired gap junction function, as connexin 37 
mimetic peptides had no effect on ACh-induced responses in either the third-order mesenteric 
artery (Chapter 3) or the renal artery (Lau and Reid, unpublished) from LZRs or OZRs.  Ding et 
al. (2005) found no change in connexin 40 mRNA expression in mesenteric arteries from STZ-
treated apoE-deficient mice, but did find a reduction in connexin 37 mRNA levels.  Although this 
contrasts with the study reported in this chapter, different models of diabetes were used (i.e. STZ-
treated type 1 diabetic mice compared with insulin-resistant OZRs), and hence can not be directly 
compared.  Furthermore, the reduction in connexin 37 mRNA levels found by Ding et al. (2005) 
was associated with a decrease in EDHF-mediated vasodilatation, however no studies were 
conducted to determine if the attenuation in EDHF-mediated vasodilatation was specifically 
associated with a decrease in connexin 37 activity.  The results from the studies reported in this 
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thesis have shown that reduced connexin 37 mRNA and protein levels in the mesenteric OZR 
arteries is not related to the attenuated EDHF-mediated vasodilatation.   
In regards to the specificity of the connexin antibodies used for the Western Blotting 
protocol, the antibodies were commercially available and were specific for that connexin subtype, 
although several bands could be seen on the blots, with the specific connexin band very clear.  
The Western blotting protocol used in our experiments is unable to differentiate the 
phosphorylated from the non-phosphorylated forms of each connexin.  It has been demonstrated 
that an increase in the non-phosphorylated form correlates with gap junction activity (Sato, 
Haimovici et al. 2002; Lampe and Lau 2004; Warn-Cramer and Lau 2004).  Exposure to high 
glucose in cultured aortic smooth muscle cell has been shown to increase the ratio of 
phosphorylated/non-phosphorylated connexin 43, through excessive phosphorylation by protein 
kinase C, and subsequently gap junction activity was shown to be decreased (Kuroki, Inoguchi et 
al. 1998; Inoguchi, Yu et al. 2001).  Connexin phosphorylation sites can be studied in a variety of 
ways including SDS-PAGE electrophoresis which shows a mobility shift with phosphorylation 
(Cooper, Solan et al. 2000), and may be a worthwhile follow-up study.  It should be noted that the 
state of phosphorylation may also be an important factor with connexin 37 and 40, and may be 
part of the reason why connexin 37-related gap junction function (see chapter 3) is not altered 
despite the decrease in protein and mRNA levels. 
The findings suggest that the impaired function of connexin 40-associated gap junctions 
in third-order mesenteric and renal arteries from the OZR is associated with a reduction in 
connexin 40 protein and mRNA levels.  However, since the vascular homogenates used for the 
measurement of protein and mRNA expression contain both endothelial and smooth muscle 
cells, the data do not allow any conclusions to be drawn concerning the cellular location of the 
gap junctions, which may be heterocellular (myoendothelial) or homocellular (endothelial-
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endothelial or smooth muscle-smooth muscle).  Immunohistochemical analysis of these arteries is 
required in order to study the localisation of the gap junctions and connexins.  Protein and 
mRNA analysis suggests that the number of heterocellular and/or homocellular gap junctions 
may be decreased in third-order mesenteric arteries and renal arteries from OZRs.  Please refer to 
Chapter 7 (7.3.2) for further discussion of connexin localisation. 
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6. Characterisation of Vasodilatation in 
the Mesenteric Artery of the Insulin-
Resistant Fructose-Fed Rat 
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6.1 Introduction 
Chapters 2-5 have focussed on EDHF and gap junctions in the female and male Zucker 
rats, with endothelial dysfunction, associated with EDHF, being demonstrated in both the male and 
female obese Zucker rats (OZR).  In the female OZR, this dysfunction was further attributed to an 
impairment in connexin-40 gap junctions.  Given these results, it is important to determine if the 
changes in the OZRs are due to the state of insulin resistance or type 2 diabetes, or due to 
characteristics specific to the Zucker rat.  The objective of the work described in the present 
chapter was therefore to study EDHF, and the role of gap junctions, in an alternative model of 
insulin resistance or type 2 diabetes. 
There are not many animal models of insulin resistance or type 2 diabetes available, and 
these are discussed in chapter 1 (section 1.8).  These animal models can be split into two groups, 
being the genetic models of disease and the diet-induced models of disease.  The genetic models of 
type 2 diabetes include: Zucker diabetic fatty rat (ZDF); Otsuka Long-Evans Tokushima Fatty 
(OLETF) rat; C57BL/KsJ-db/db mouse; and Tally Ho mouse.  In regards to diet-induced insulin 
resistance, the fat-fed and fructose-fed rats are the most established models (Katakam, Ujhelyi et al. 
1998; Katakam, Ujhelyi et al. 1999; Ye, Doyle et al. 2001; Youngren, Paik et al. 2001).  A review of 
the literature shows that the fat-fed model is a popular model of insulin resistance and type 2 
diabetes for the study of skeletal muscle and metabolism (Ye, Doyle et al. 2001; Youngren, Paik et 
al. 2001), however very few studies have investigated endothelial function; endothelial dysfunction 
has been demonstrated in third-order mesenteric arteries from insulin-resistant high fat-high 
sucrose fed rats (Naderali and Williams 2003).  There are however, numerous studies in fructose-
fed (FF) rat models of insulin resistance investigating endothelial function.  Endothelial dysfunction 
has been demonstrated in third-order (Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999) 
and superior mesenteric arteries (Verma, Bhanot et al. 1996), perfused kidneys (Kamata and 
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Yamashita 1999), cerebral arteries (Erdos, Miller et al. 2002) and coronary arteries (Miller, Katakam 
et al. 1999) from  FF rats fed a high fructose diet for 4 weeks.  Impaired endothelium-dependent 
relaxations were associated with a defect in EDHF-mediated relaxations in coronary (Miller, 
Katakam et al. 1999; Katakam, Ujhelyi et al. 2000) and small mesenteric arteries (Miller, Hoenig et 
al. 1998; Katakam, Hoenig et al. 2000), and in one study decreased EDHF activity in the small 
mesenteric artery was also associated with a compensatory increase in NO (Miller, Hoenig et al. 
1998).   The FF model was chosen for the present study as it is the same species as the Zucker (i.e. 
rat), and other genetic rat models of insulin resistance or type 2 diabetes are not readily available in 
Australia.   
There are several differences between the studies that have utilised FF rats.  Both 
Sprague-Dawley (Verma, Bhanot et al. 1996; Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 
1999; Miller, Katakam et al. 1999) and Wistar  (Kamata and Yamashita 1999; Miatello, Risler et al. 
2002; Renna, Risler et al. 2005) rats have been used, and feeding periods of 3-4 wk (Verma, Bhanot 
et al. 1996; Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999; Miller, Katakam et al. 1999) 
or 8 (Kamata and Yamashita 1999; Miatello, Risler et al. 2001; Miatello, Risler et al. 2002) wk have 
been used.  Interestingly, although the FF rat is reported as a model of insulin resistance, only the 
Miatello et al. (2001, 2002) studies have conducted glucose tolerance tests, which did demonstrate 
glucose intolerance following an 8-wk high-fructose diet period.  Non-fasting glucose levels, which 
are routinely measured, are inconsistent between studies with some showing no change (Verma, 
Bhanot et al. 1996; Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999; Miller, Katakam et al. 
1999), and others reporting elevated glucose levels (Kamata and Yamashita 1999; Miatello, Risler et 
al. 2001; Miatello, Risler et al. 2002) in FF rats following 4- or 8- week dieting periods compared 
with the control rats.  All of the studies demonstrated hyperinsulinaemia, hypertension (excluding 
Miatello et al. 2001) and no change in weight. 
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Whilst impaired EDHF-mediated vasodilatation has been consistently reported in the FF 
rat, none of these studies has investigated the involvement of gap junctions.  The aim of the 
experiments described in this chapter was to conduct a small pilot study, to confirm that insulin 
resistance can be induced in the Sprague-Dawley (SD) rat via high-fructose feeding.  As this model 
of insulin-resistance had not previously been employed in our laboratory, we needed to ensure that 
the state of insulin resistance and accompanying endothelial dysfunction could be replicated.  Once 
this model of insulin resistance had been validated, the endothelial dysfunction could then be 
investigated in depth, and the role of gap junctions in EDHF-mediated dilatation could be 
identified.   
Ideally, endothelial function would be studied in pressurised third-order mesenteric 
arteries so the results could be compared to those from the obese Zucker rat.  However, as this was 
a small pilot study, wire-mounted renal lobar arteries were chosen to optimise the use of the 
animals, i.e. four sets of wire-myograph experiments can be conducted per animal, compared with 
one set of pressurised experiments.  Furthermore, previous experiments in our laboratory 
conducted by Winnie Lau ((Lau and Reid 2000), have demonstrated endothelial dysfunction in 
renal lobar arteries from the obese Zucker rat.  These experiments identified a decrease in EDHF-
mediated relaxation, with a compensatory increase in NO. 
More specifically the experiments described in this chapter served to answer the following 
questions: 
1. Do male SD rats develop insulin resistance following a 4- or 8-wk feeding period of high-
fructose chow, as determined by measuring glucose tolerance, insulin, non-fasting glucose 
and lipid levels?   
2. In the instance that insulin resistance has developed, is endothelial function of the renal 
artery altered following a 4- or 8-wk feeding period of high-fructose chow? 
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3. Are there differences in the relative contributions of NO and EDHF in renal lobar 
arteries between the control and fructose-fed rats? 
4. Do gap junctions play a role in the EDHF-mediated vasodilatation, and is this altered in 
following a 4- or 8-wk feeding period of high-fructose chow? 
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6.2 Methods and Materials 
6.2.1 Animals 
Male Sprague-Dawley rats of 4 wk of age were obtained from Monash Animal Services, 
Victoria, Australia.  The use of the animals was approved by the Animal Experimentation Ethics 
Committee (AEEC #0403), and conformed to the Australian National Health and Medical 
Research Council Code of Practice for the Care and Use of Animals for Scientific Purposes.  At 4 
wk of age the rats were separated into groups, with the control group being fed normal chow for 4 
or 8 wk, and the FF group being fed high fructose feed (66% fructose, 22% casein, and 12% lard, 
plus essential vitamins and minerals; Specialty Feeds, Stepney, SA) for 4 or 8 wk.  All rats were 
weighed weekly, and all food consumption was monitored, but not restricted.  As rats were housed 
in groups, food consumption was measured for the two separate groups rather than individual 
animals. 
The rats were killed by asphyxiation with carbon dioxide followed by decapitation.  All 
animals were weighed prior to culling.   
 
   Metabolic Parameters 
An oral glucose tolerance test was performed on all rats.  Rats were administered a 70% 
glucose solution (2.5 mg/kg) by oral gavage.  Blood from the tail vein was then sampled over 90 
mins (baseline, followed by 10, 15, 30, 60 and 90 min post-gavage).  Glucose levels were analysed 
using the MediSense

2 glucometer with Precision Plus

 blood glucose electrodes (MediSense, 
Australia).   
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Plasma for glucose, lipid and insulin analysis was obtained by centrifugation of blood (1-2 
ml), taken by exsanguination at the time of killing, and stored at -20oC until assayed.  Non-fasting 
glucose levels were measured as described above.  Insulin levels (8-wk groups only) were 
measured using an Ultra-sensitive Rat Insulin ELISA (Mercodia AB, Uppsala, Sweden).  Lipid 
levels (triglyceride, cholesterol and HDL) were measured on the Roche Modular analyser 
(Roche, Sydney, Australia).   
8-wk group rats were placed in a metabolic cage the day before culling in order to obtain 
an overnight urine collection, which was used to measure the albumin/creatinine ratio (ACR).  
The ACR was measured on the Roche Cobas Integra 800  analyser (Roche, Sydney, Australia). 
 
6.2.2 Wire Myography   
Renal Artery Isolation 
 The kidneys, with the renal pedicles attached, were removed and placed in ice-cold 
physiological salt solution (PSS) of the following composition: 118 mM NaCl, 4.7 mM KCl, 0.45 
mM MgSO4, 1.03 mM KH2PO4, 11.1 mM D(+) glucose, 25 mM NaHCO3 and 2.5 mM CaCl2 
(gassed with 5% CO2, 95%O2).  The kidney was cut in half in a „butterfly‟ fashion and the lobar 
branches of the renal artery (Figure 6.1 and Figure 6.2) were isolated under a dissecting microscope 
(Olympus SZ-30, Olympus, Australia).  Care was taken not to damage the endothelium.  Each 
section had a diameter of 300-400 μm and was cut into four 1.5-2 mm segments with no side 
branches.   
 
Chapter 6 
6-8 
 
Wire Myography 
Wire myography experiments were carried out using the myograph (model 610M) 
manufactured by Danish Myo Technology by J.P Trading I/S in Denmark (Figure 6.3). Two 
parallel stainless steel wires of 40 μm diameter were threaded through the lumen of the vessel 
segment.  Each wire was mounted on a jaw holder (Figure 6.3).  One holder was fixed to an 
isometric force transducer.  The other holder was attached to a micrometer that adjusted the 
distance between the two wires in order to control the passive tension loaded on the tissue.  The 
preparation was immersed in a chamber containing 6 ml of PSS.  The myograph consisted of an 
internal heating system, thus maintaining the PSS at a temperature of 37 ± 1oC and was 
continuously aerated with 95% O2 and 5% CO2.   
After an initial equilibration period of 15 min, the preparations were stretched for 
normalization (Mulvany and Halpern 1977), using a software program developed by G.A. 
McPherson (McPherson 1992).  This program calculated the resting tone corresponding to 90% 
of the vessel diameter, which the vessel would reach when relaxed at 100 mmHg transmural 
pressure.  This setting represents a resting tension of approximately 2-3 mN for the renal artery 
preparations. 
The isometric tension of the vessel was recorded with a data acquisition system 
(MacLab/4 Chart Software, model MKIIII, AD Instruments Pty Ltd, Australia).  Each 
preparation was equilibrated for 45 min before commencing the experiment. 
All responses were obtained in the presence of 10 M indomethacin to block prostanoid 
production.  Vessels were primed with 10 M phenylephrine (PE) for 5 min followed by 10 M 
acetylcholine (ACh) to ensure endothelium viability.  Following a 15-min wash-out period a 
concentration-response curve to PE (10 nM–10 M) was conducted.  From this curve the 
concentration of PE required for the vessel to obtain 70-80% constriction was determined, and 
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this concentration was used to preconstrict the vessels prior to concentration-response curves 
obtained for relaxation responses.  Endothelial function was determined by studying responses to 
the endothelium-dependent dilator ACh (1 nM–10 M) and the endothelium-independent dilator 
levcromakalim (10 nM–30 M).  Concentration-response curves were obtained by the cumulative 
addition of the drug directly into the chamber.  Two concentration-response curves for ACh or 
levcromakalim were obtained in the same preparation.  Time-control experiments, as shown in 
Figure 6.13, demonstrated that responses to ACh and levcromakalim did not change when 2 
concentration-response curves were obtained in the same mesenteric artery preparation without 
addition of inhibitor drugs.    
Specific inhibitors were added to the chamber 20-30 min before, and remained present 
during the concentration-response curve to ACh or levcromakalim.  The contribution of NO to 
the vasodilator response was examined by incubation with nitro-l-arginine methylester (L-NAME, 
100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 M).   
 
6.2.3 Data & Statistical Analysis 
Data are presented as mean and standard error of the mean (SEM) with n indicating the 
number of experimental animals.  Student‟s t-test (unpaired unless otherwise stated) and two-way 
analysis of variance (two-way ANOVA) followed by Student-Newman-Keuls test were used to 
compare mean values.  A two-way repeated measures ANOVA followed by Student-Newman-
Keuls test was used when comparing concentration-curves obtained in the same vessel.  A value 
of p<0.05 was regarded as statistically significant.   
 The graphic and statistical software package GraphPad Prism version 4.00 for Windows 
(GraphPad, San Diego, California USA) was used to construct figures showing the data and 
analyses of the results.  Typical traces were obtained using MacLab.   
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EC50 values were interpolated from the regression lines, and correspond to a 
concentration producing 50% of the maximal response.  EC50 values are shown with the 95 % 
confidence interval (CI) ranges, and were considered to be significant if the ranges did not 
overlap. 
 Contractions were measured at equilibrium as increases in resting tone and are presented as 
force in absolute mN.  Relaxations were measured at equilibrium as a percentage of tone (% 
preconstriction) induced by PE.  The relaxation was calculated using the following formula: 
 
Relaxation (%) = 100 – (R/T x 100) 
 
where R is the value of tension difference between the resting tension prior to preconstriction and 
the tension at the given concentration of the vasodilator; and T is the value of the tension 
difference between the resting tone prior to preconstriction and the preconstricted tension. 
 
6.2.4 Drugs and Chemicals 
All drugs were purchased from Sigma chemicals.  All drugs were dissolved in distilled water 
with the exceptions of indomethacin which was dissolved in 0.1 M Na2CO3 and levcromakalim 
which was dissolved in 70% ethanol, to give stock solutions of 0.01 M.   All stock solutions were 
diluted on the day of the experiment using PSS. 
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Figure 6.1:  Lobar Artery 
Illustration of the renal vascular system, identifying the lobar artery used for functional 
wire myograph experiments (Cheetham 2000). 
 
Lobar Artery 
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Figure 6.2:  Isolation of the Lobar Artery 
A:  The kidney is cut in half in a “butterfly” fashion, and is pinned out.   
B:  Sections of the lobar artery, located underneath the connective tissue, are isolated and cleared of 
surrounding tissue.  
A. B. 
 
 
Lobar Arteries 
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Figure 6.3:  Wire Myography  
A: The chambers on the 4-channel wire myograph are filled with physiological salt solution.   
B: A 1.5-2.0 mm segment of lobar artery is attached to the transducer using two 40-m wires. 
A. 
B. 
 
 
Stainless Steel Wires 
Isometric Force Transducer 
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6.3 Results 
6.3.1 Weight and Metabolic Parameters 
Rate of growth over the 4-wk dieting period was significantly higher (p<0.05, student‟s t-
test, Figure 6.4a) in the 4-wk FF group (180.6 ± 6.0%, n=4), compared with the corresponding 4-
wk control group (164.4 ± 2.1%, n=4) despite a significantly different starting weight (p<0.05, 
student‟s t-test, n=4).  In contrast, rate of growth over the 8-wk dieting period was significantly less 
(p<0.05, student‟s t-test, n=4, Figure 6.4b) in the 8-wk FF group (348.5 ± 6.1%, n=8), compared 
with the corresponding 8-wk control group (387.4 ± 9.8%, n=8).  The FF groups weighed 
significantly less than their corresponding 4-wk (p<0.05, Student‟s t-test, n=4, Table 6.1) and 8-wk 
(p<0.05, Student‟s t-test, n=8, Table 6.1) control group at the end of the diet period.   
Average weekly food intake was comparable between both 4 and 8 wk control and FF 
groups (Figure 6.4C).   
There was no significant difference in glucose, cholesterol and HDL levels between the 4-
wk groups (p>0.05, Student‟s t-test, n=4, Table 6.1) or the 8-wk groups (p>0.05, Student‟s t-test, 
n=8, Table 6.1).  Triglyceride and insulin levels were significantly higher in the 8-wk FF group 
compared with the 8-wk control group (p<0.05, Student‟s t-test, n=8, Table 6.1).   
There was no significant difference in oral glucose tolerance test results between and 4-
wk FF and control groups (p>0.05, ANOVA, n=4, Figure 6.5).  The 8-wk FF group showed 
significantly reduced oral glucose tolerance compared to the 8-wk control group (p<0.05, ANOVA, 
n=8, Figure 6.5). 
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6.3.2 Wire Myography 
 As the oral glucose tolerance test demonstrated that the 4-wk FF group had not 
developed insulin resistance, wire myograph experiments were only conducted on the 8-wk control 
and FF lobar arteries.    
 There was no significant difference (p>0.05, Student‟s t-test, n=7) between the maximum 
internal diameters of the lobar arteries from control (407 ± 24 m) and FF (383 ± 12 m) rats.  
The concentration-response curves to PE were not significantly different between control and FF  
rats (p>0.05, ANOVA, n=7), as illustrated by the typical traces in Figure 6.6 and shown in Figure 
6.7.  To obtain relaxation responses, lobar arteries were preconstricted with 0.1-1 M PE.  The 
level of PE-induced precontraction achieved, as shown in Figure 6.8, was not significantly different 
(p<0.05, Newman-Keuls multiple comparison test, n=7) between the control and FF groups, prior 
to any concentration-response curve to ACh or LK, before or after the incubation with 100 M L-
NAME and 1 M ODQ. 
Typical relaxation responses to ACh and LK are illustrated in the traces shown in Figure 
6.9 and Figure 6.10 respectively.  Relaxations induced by ACh or LK were not significantly altered 
in the 8-wk FF group compared with the control group (p>0.05, ANOVA, n=7, Figure 6.11).  
Responses to ACh were abolished in the presence of L-NAME and ODQ in both the control and 
FF groups (Figure 6.12).  Responses to LK were not altered in the presence of L-NAME and 
ODQ (p>0.05 ANOVA, n=5-7). 
In time-control experiments, relaxations to ACh and LK did not significantly change over 
time following 2 successive concentration-response curves to ACh or LK (Figure 6.13). 
 
Chapter 6 
6-16 
 
4 5 6 7 8
0
100
200
300
400
500
Age (weeks)
W
e
ig
h
t 
(g
)
4 6 8 10 12
0
100
200
300
400
500
Age (weeks)
W
e
ig
h
t 
(g
)
0
500
1000
1500 4 wk 8 wk
A
v
e
ra
g
e
 F
o
o
d
 I
n
ta
k
e
 (
g
 p
e
r 
w
e
e
k
)
 
 
A) 
 
 
 
 
 
 
 
 
 
 
 B) 
 
 
 
 
 
 
 
 
 
 C) 
 
 
 
 
 
Figure 6.4:  Growth and Diet  
Body weights of control () and fructose-fed () rats in A) 4-wk and B) 8-wk protocols.   
C) Average weekly food intake for 4- and 8- wk control () and fructose-fed () groups.  Note that 
in A) and B) error bars are smaller than the size of the symbols.   
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Table 6.1: Metabolic Parameters 
Metabolic parameter comparison of control and fructose-fed rats after A) 4-wk and B) 8-
wk of controlled diet.   
 
A) 4 wk 
 
 Control Fructose-Fed 
Weight (g) 352 ± 1.4 294 ± 9.7* 
Glucose (mM) 5.75 ± 0.18 5.23 ± 0.20 
Cholesterol (mM) 2.35 ± 0.18  2.76 ± 0.24 
Triglyceride (mM) 2.68 ± 0.39 4.02 ± 0.61* 
HDL (mM) 1.70 ± 0.15 1.86 ± 0.27 
 
B) 8 wk 
 
 Control Fructose-Fed 
Weight (g) 412 ± 8 380 ± 8.0* 
Insulin (pM) 647 ± 42 1118 ± 81* 
Glucose (mM) 6.4 ± 0.4 6.2 ± 0.2 
Cholesterol (mM) 2.42 ± 0.12  2.68 ± 0.13 
Triglyceride (mM) 2.43 ± 0.26 4.14 ± 0.36* 
HDL (mM) 1.71 ± 0.10 1.60 ± 0.10 
Albumin Creatinine Ratio 0.88 ± 0.15 0.80 ± 0.14 
 
 
Data are expressed as mean ± SEM of n=4-8 animals. 
 
* p<0.05, significantly different from corresponding control values (Student‟s t-test). 
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Figure 6.5:  Oral Glucose Tolerance Tests 
 
Oral glucose tolerance tests in the control () and fructose-fed () rats after A) 4-wk or B) 8-wk of 
monitored diet.  Blood glucose levels were measured at times: 0, 10, 15, 30, 60 and 90 min after an 
oral gavage of glucose (2.5 g/kg body weight).  Each value represents the mean ± SEM of 3-8 
animals.  * p<0.05, two-way ANOVA.  Note that in some instances error bars are smaller than the 
size of the symbols. 
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Figure 6.6:  Representative Phenylephrine-Induced Constrictions  
Typical traces illustrating the constrictions induced by phenylephrine (10-8 to 10-5 M, cumulative 
doses indicated by arrows) in lobar arteries from control and fructose-fed (FF) rats after 8 wk of 
monitored diet.   
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Figure 6.7:  Phenylephrine Concentration-Response Curves   
Concentration-response curves for constrictions to phenylephrine (PE) in lobar arteries from 
control (, n=7) and fructose-fed (, n=7) rats after 8 wk of monitored diet, in the presence of 10 
M indomethacin.  Values are expressed as a percentage of the response to 0.3 mM.  Each value 
represents the mean ± SEM of 7 preparations.   
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Figure 6.8:  Precontractions   
Level of phenylephrine-induced precontractions (0.1-1 M) prior to concentration-response curves 
to A) acetylcholine (ACh) or B) levcromakalim (LK), before and after exposure to nitro-l-arginine 
methylester (L-NAME, 100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 M), 
in lobar arteries from control ( before,  after, n=7) and fructose-fed (FF,  before,  after, 
n=7) rats after 8 wk of monitored diet, in the presence of 10 M indomethacin.  Each value 
represents the mean ± SEM of 7 preparations.   
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Figure 6.9:  Representative Acetylcholine-Induced Relaxations 
Typical traces illustrating the relaxations induced by acetylcholine (10-9 to 10-5 M, cumulative doses 
indicated by arrows) in lobar arteries from control and fructose-fed (FF) rats after 8 wk of 
monitored diet, preconstricted with phenylephrine (PE, 0.1-1 M).   
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Figure 6.10:  Representative Levcromakalim-Induced Relaxations 
Typical traces illustrating the relaxations induced by levcromakalim (10-8 to 3x10-5 M, cumulative 
doses indicated by arrows) in lobar arteries from control and fructose-fed (FF) rats after 8 wk of 
monitored diet, preconstricted with phenylephrine (PE, 0.1-1 M).   
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Figure 6.11:  Acetylcholine and Levcromakalim Concentration-Response 
Curves   
Concentration-response curves for relaxations to A) acetylcholine (ACh) and B) levcromakalim 
(LK) in lobar arteries from control (, n=7) and fructose-fed (, n=7) rats after 8 wk of controlled 
diet, in the presence of 10 M indomethacin.  Each value represents the mean ± SEM of 7 
preparations.   
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Figure 6.12:  Characterisation of the NO Contribution of Vasodilation 
Responses 
Concentration-response curves for relaxations to acetylcholine (ACh) in lobar arteries, after 8 wk of 
controlled diet, before ((control (, n=7); fructose-fed (, n=7)), and after exposure to nitro-l-
arginine methylester (L-NAME, 100 M) and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 
1 M) ((control (, n=7); fructose-fed (, n=7)).  Values are mean ± SEM.     
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Figure 6.13:  Time Controls   
Time-control concentration-response curves for relaxations to acetylcholine (ACh, A & C) and 
levcromakalim (LK, B & D) in lobar arteries from control ( 1st curve,  2nd curve, n=7) and 
fructose-fed ( 1st curve,  2nd curve, n=7) rats after 8 wk of monitored diet, in the presence of 10 
M indomethacin.  Each value represents the mean ± SEM of 7 preparations.   
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Log [ACh, M]
%
 R
e
la
x
a
ti
o
n
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Log [LK, M]
%
 R
e
la
x
a
ti
o
n
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Log [ACh, M]
%
 R
e
la
x
a
ti
o
n
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Log [LK, M]
%
 R
e
la
x
a
ti
o
n
A) B)
C) D)
 
Chapter 6 
6-27 
 
6.4 Discussion  
The metabolic parameters studied following 4- and 8- wk diet periods demonstrated that 
the 4-wk feeding period was not long enough to induce insulin resistance, given that oral glucose 
tolerance was not altered.  Although aspects of insulin resistance were evident following the 8-wk 
feeding period (glucose intolerance and hyperinsulinaemia), the FF rats failed to demonstrate 
hyperglycaemia, proteinuria and dyslipidaemia, although there was a significant increase in 
triglycerides.  This is in contrast to studies conducted in Wistar rats fed a high-fructose diet for 8 
wk, in which hyperglycaemia, dyslipidaemia as well as glucose intolerance and hyperinsulinaemia 
were reported (Kamata and Yamashita 1999; Miatello, Risler et al. 2001; Miatello, Risler et al. 2002).   
Studies in which Sprague-Dawley rats have been fed high-fructose diets for 4 wk have 
demonstrated normoglycaemia, hyperinsulinaemia, hypertension and an increase in triglyceride 
levels.  Even at this early stage of disease, vascular function in these arteries has consistently been 
shown to be impaired, as demonstrated in third-order (Katakam, Ujhelyi et al. 1998; Katakam, 
Ujhelyi et al. 1999) and superior mesenteric arteries (Verma, Bhanot et al. 1996), perfused kidneys 
(Kamata and Yamashita 1999), cerebral arteries (Erdos, Miller et al. 2002) and coronary arteries 
(Miller, Katakam et al. 1999).  As the 4-wk FF rats in this study were not insulin-resistant, 
endothelial function of the lobar arteries was not studied.  It should be noted however, that 
vascular function was studied in small mesenteric arteries by a colleague, who showed that 
endothelial function was not altered in the small mesenteric arteries (Hashem, unpublished).  The 
contradictory findings in our 4-wk study, in comparison to those conducted in other laboratories 
(Verma, Bhanot et al. 1996; Katakam, Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999; Miller, 
Katakam et al. 1999; Erdos, Miller et al. 2002), are unclear.  Whilst the nutritional level of the high-
fructose feed was closely matched to that described in the other studies, the feeds were purchased 
from different sources, with our feed supplied by Specialty Feeds in South Australia, whilst the 
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other studies obtained normal and fructose-feed from Teklad Laboratories in Wisconsin (United 
States). Similarly, all studies used male Sprague-Dawley rats, however our rats were from an 
Australian breeder, whilst the other studies used Sprague-Dawley rats from the United States.  
Therefore, differences in feed and breed may have contributed to the fact that insulin resistance did 
not develop in most vessels after 4 wk of high-fructose feed in this set of experiments.  
Additionally, it is difficult to compare the level of insulin resistance between this study and the 
studies mentioned above (Verma, Bhanot et al. 1996; Katakam, Ujhelyi et al. 1998; Kamata and 
Yamashita 1999; Katakam, Ujhelyi et al. 1999; Miller, Katakam et al. 1999; Erdos, Miller et al. 
2002), as none of these studies conducted oral glucose tolerance tests, although hyperinsulinaemia 
was reported in all studies.   
The experiments carried out the in the 8-wk FF rats demonstrated similar characteristics 
to the 4-wk FF, however glucose intolerance was now evident.  As the lobar arteries were 
preconstricted with PE, concentration-response curves to PE were generated so that the vessels 
could be preconstricted to 70-80% prior to conducting concentration-response curves to ACh or 
LK.  Responses to PE were not significantly different between the control and FF rats.  Responses 
to ACh and LK were also not significantly different between the control and FF rats.  There was 
therefore no indication of endothelial dysfunction in lobar arteries from the 8-wk FF.  The small 
mesenteric arteries were studied by a colleague, who also demonstrated no change in vasodilatation 
responses to ACh (Hashem, unpublished).   
Vasodilatation responses were then studied in the additional presence of L-NAME and 
ODQ to block the NO component, which abolished responses to ACh in both the control and 8-
wk FF groups, indicating that relaxation responses to ACh are solely mediated by NO, with no 
EDHF contribution.  This was unexpected as EDHF has been identified as the predominant 
endothelium-derived relaxing factor in this vessel in Zucker rats (Lau and Reid 2000), wistar rats 
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(Jiang and Dusting 2001) and Sprague Dawley rats (Karagiannis, Rand et al. 2004).  Since there was 
no endothelial dysfunction, and responses to ACh were mediated by NO, there was no benefit in 
studying the role of gap junctions as was outlined in the initial aims.   
It should be noted that the results of these two pilot studies were unexpected, particularly 
in light of the studies reported in the literature.  Firstly, we were expecting to see glucose 
intolerance from 4 wk of high-fructose feed; secondly, we expected to observe endothelial 
dysfunction in the lobar artery as well as the gracilis and third-order mesenteric arteries being 
studied by colleagues; and thirdly, we expected EDHF to play some role in the endothelial function 
of the lobar artery (as it does in the lobar artery from the Zucker rat).  As outlined in the 
introduction, it is vital to determine if the vascular changes detailed in the female and male OZR are 
associated with the development of insulin resistance and type 2 diabetes, respectively, or if the 
changes are specific to the Zucker rat animal models.  The two small pilot studies outlined in this 
chapter suggest that, firstly, the lobar artery is not suitable for this study as there was no EDHF 
component; third-order mesenteric arteries may be a better artery to study given that EDHF was 
shown to mediate relaxation in these arteries from the Zucker rats (see chapters 3 and 4).  Secondly, 
the 4- or 8-wk fructose-fed models may not be the most suitable model, as a more advanced stage 
of disease is required to observe endothelial dysfunction under the experimental conditions used in 
this project.  It could be argued that the high fat/high-fructose diet may be more suitable, given 
that animals fed this diet are consistently reported to be insulin resistant (Barnard, Youngren et al. 
1995; Chalkley, Hettiarachchi et al. 2002).  Alternatively, the genetic mouse models of type 2 
diabetes (Tally Ho and db/db) could also be considered, as endothelial dysfunction has been widely 
reported in the db/db mouse  (Lagaud, Masih-Khan et al. 2001; Didion, Lynch et al. 2005; Ding, 
Howarth et al. 2005). 
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This set of experiments has established that under the experimental conditions described, 
a 4-wk diet of high-fructose feed induces hyperinsulinaemia but not insulin resistance.  Insulin 
resistance can be demonstrated following an 8-wk dieting period; however endothelial function 
was not compromised.  Furthermore, endothelium-dependent vasodilatation in the lobar artery is 
solely mediated by NO.  These were therefore disappointing results, and due to the lack of 
endothelial dysfunction and the finding that EDHF was not involved in these responses, the role 
of gap junctions was not studied.   
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7.1 Interpretation of  Findings: An Overview 
 
It was the aim of this project to study EDHF and gap junctions in animal models of 
insulin resistance, being the obese Zucker rat (OZR) and the fructose-fed Sprague-Dawley rat 
(see chapter 1.9).  The experimental aims were designed to firstly determine if endothelial 
dysfunction was present in the third-order mesenteric artery from the OZR, and the lobar artery 
from the fructose-fed Sprague-Dawley rat, compared with the corresponding controls lean 
Zucker rats (LZR) and normal chow-fed Sprague-Dawley rats respectively.  Furthermore, we 
wanted to investigate the role of EDHF and gap junctions in the development of endothelial 
dysfunction. 
In order to study EDHF, which is the main endothelium-dependent vasodilator in small 
resistance arteries, a pressure myography method was developed to allow us to study endothelial 
dysfunction in third-order mesenteric arteries under physiological conditions (see chapter 2).  As 
discussed in chapter 2, it has been suggested that pressure myography can stimulate in vivo 
conditions more closely than wire myography (VanBavel, Mooij et al. 1990; VanBavel, Giezeman 
et al. 1991). 
Using the developed pressure myograph technique, third-order mesenteric arteries from 
female and male Zucker rats were studied (chapters 3 and 4).   The obese Zucker rat model of 
insulin resistance was chosen as it is an established model of insulin resistance that displays all of 
the abnormalities associated with human insulin resistance syndrome, including 
hyperinsulinaemia, mild hyperglycaemia, enlarged fat cells, hyperphagia, insulin resistance, 
hypertension, hyperlipidaemia and proteinuria (Kasiske, O'Donnell et al. 1992; McCaleb and 
Chapter 7 
7-3 
 
Sredy 1992).  Furthermore, as detailed in chapter 1.7.3, endothelial dysfunction has been 
consistently reported in this animal model  (Zanchi, Delacretaz et al. 1995; Wu, Makynen et al. 
1996; Walker, Dores et al. 1997; Duarte, Martinez et al. 1999; Brooks-Asplund, Shoukas et al. 
2002; Laight, Anggard et al. 2002). 
The relative roles of NO and EDHF were characterised, in which EDHF was found to 
be the sole mediator of endothelium-derived vasodilatations to acetylcholine (ACh) in third-order 
mesenteric arteries from both male and female LZRs and OZRs under the experimental 
conditions used (chapters 3 and 4).  These studies also demonstrated that endothelial dysfunction 
was present in third-order mesenteric arteries from both the female and male OZRs, compared 
with the sex/age-matched lean control Zucker rats (LZRs).  Furthermore, endothelial 
dysfunction was shown to be greater in the male OZR than the female OZR, which was 
associated with the severity of the disease status, i.e. male OZRs were insulin-resistant and 
diabetic, whilst female OZRs were insulin-resistant only with glucose levels not elevated 
sufficiently to be classified as type 2 diabetes.  Our finding related to the nature of endothelial 
dysfunction was consistent with other reports of EDHF dysfunction in rat animal models of 
insulin resistance, including coronary arteries (Miller, Katakam et al. 1999), renal arteries (Kamata 
and Yamashita 1999), epineurial arteries (Coppey, Gellett et al. 2003), middle cerebral arteries 
(Erdos, Miller et al. 2002) and superior (Verma, Bhanot et al. 1996) and third-order (Katakam, 
Ujhelyi et al. 1998; Katakam, Ujhelyi et al. 1999) mesenteric arteries.   
Due to the limited availability of male rats, further experimentation was carried out with 
female rats only, in order to identify the role of gap junctions in the vasodilatation responses, 
which was completely mediated by EDHF in the LZRs and OZRs.  This study, as detailed in 
chapter 3, determined that gap junctions associated with connexin 40 do play a role in the 
EDHF-mediated responses in the female LZR, but not the OZR. This suggested that impaired 
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EDHF-mediated responses in the OZR may be related to a reduction in connexin 40-associated 
gap junction activity.  This was further correlated with the studies detailed in chapter 5, in which 
western blotting and real-time polymerase chain reaction (PCR) were used to identify and 
compare connexin protein and mRNA levels respectively, in mesenteric homogenates from 
female LZRs and OZRs.  These experiments showed a significant reduction in connexin 40 
protein and mRNA levels in the OZR mesenteric artery, as well as a reduction in connexin 37 
protein and mRNA levels.   Whilst the reduction in connexin 40 protein and mRNA levels is 
reflected by the absence of connexin 40-associated gap junction activity in the EDHF-mediated 
responses in third-order mesenteric arteries from the OZR, the importance of the reduced 
connexin 37 protein and mRNA levels isn‟t clear, as connexin 37-associated gap junctions were 
not found to play a role in EDHF-mediated responses in the female LZRs or OZRs, at least 
under our experimental conditions. 
Although the 40gap27 peptide (a gap junction inhibitor that specifically targets connexin 
40) significantly attenuated responses to ACh in third-order mesenteric arteries from the female 
LZR, there was still a substantial EDHF response that was not sensitive to the connexin 40-
mimetic peptide.  Furthermore, 40gap27 had no effect on responses to ACh in the third-order 
mesenteric arteries from the female OZR.  The remaining EDHF components in the LZR and 
the entire EDHF component in the OZR therefore still needs to be characterised.   A small 
number of experiments were conducted using the cytochrome P450 (CYP) 2C/3A inhibitor 
sulfaphenazole, which is a commonly used inhibitor of epoxyeicosatrienoic acids (EETs) 
(Fleming, Michaelis et al. 2001; Earley, Pastuszyn et al. 2003).  Sulfaphenazole had no effect on 
responses to ACh in the male or female LZR or OZR third-order mesenteric arteries.  However, 
as discussed in chapter 3, other studies which have failed to show inhibition with sulfaphenazole 
have demonstrated inhibition with clotrimazole, a general CYP inhibitor (Adeagbo 1997), and 
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hence the involvement of EETs in the EDHF-attributed responses in the third-order mesenteric 
arteries from the Zucker rats cannot be ruled out. 
The studies in the Zucker rats demonstrate that endothelial dysfunction is associated with 
impaired EDHF activity, which was further attributed to gap junctions in the female OZRs.  
However, it is still not clear whether this impairment is attributable to the state of insulin 
resistance, or due to specific phenomena in the OZRs.  Hence, a pilot study was undertaken to 
determine if these findings could be replicated in an alternative model of insulin resistance, for 
which the fructose-fed rat model was chosen.  As detailed in chapter 6, Sprague-Dawley rats 
developed insulin resistance following an 8-wk diet of high-fructose feed, however endothelial 
function in the lobar arteries was not altered, compared with control (normal-chow) rats.  The 
results of this study were disappointing, and unfortunately still leave us questioning if the Zucker 
findings are general to the state of insulin resistance, or are specific to this animal model. 
The impairment of EDHF-mediated vasodilatation in the third-order mesenteric arteries 
from the female and male OZRs identifies EDHF as a potential therapeutic target, in the effort 
to prevent the onset of endothelial dysfunction, and ultimately vascular complications.  
Furthermore, the female Zucker rat study of gap junctions identifies connexins and gap junctions 
as an additional therapeutic target, with a reduction in connexin 40-associated gap junctions 
accompanying the impaired EDHF-mediated responses in the OZR. 
 
 
7.2 Diabetic Therapeutic Strategies 
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Current therapeutic strategies aim to normalise glucose levels in diabetic patients by 
targeting mechanisms such as insulin secretion (e.g. sulphonylureas), insulin sensitisation (e.g. 
peroxisome proliferator-activated receptor-γ (PPARγ) agonists) and hepatic glucose regulation 
(e.g. biguanides) (Moller 2001; Xu 2004), in an indirect effort to reduce the onset of diabetic-
related vascular complications.  
Sulphonylureas, such as glibenclamide, and other related insulin secretagogues, are used 
to increase insulin secretion from pancreatic β-cells, by targeting adenosine triphosphate (ATP)-
sensitive potassium channels (KATP) on the β-cell membrane (Xu 2004).  The benefit of 
sulfonylureas were highlighted in the United Kingdom Prospective Diabetes Study (UKPDS), in 
which glibenclamide was shown to significantly reduce microvascular, but not macrovascular, 
complications in type 2 diabetic patients (UKPDS 1998).   
PPARγ agonists such as thiazolidinediones  (TZDs) enhance insulin action, by altering 
the transcription of several genes involved in glucose and lipid metabolism and energy balance 
(Hauner 2002; Boden and Zhang 2006).  The three main TZDs are troglitazone, rosiglitazone, 
and pioglitazone.  Pioglitazone is an effective treatment option as it acts by increasing hepatic and 
peripheral insulin sensitivity, is well tolerated, has few adverse effects and has no known 
interaction with other drugs  (Waugh, Keating et al. 2006).  The large randomised PROspective 
pioglitAzone Clinical Trial In macroVascular Events (PROactive) found that pioglitazone reduces 
the risk of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 
diabetes who have a high risk of macrovascular events (Dormandy, Charbonnel et al. 2005).   
The biguanide metformin reduces glucose levels by reducing hepatic glucose production, 
improving hepatic insulin sensitivity and increasing glucose clearance (Natali and Ferrannini 
2006).  In the UKPDS, intensive glycaemic control with metformin was found to decrease the 
risk of microvascular and macrovascular endpoints (UKPDS 1998).   
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The limitation of the current therapeutic strategies is that they have limited efficacy, 
limited tolerability and significant side effects, many increasing the risk of weight gain and 
hypoglycaemia (Moller 2001).  Furthermore, the results of the UKPDS and Diabetes Control and 
Complications Trial (DCCT) have shown that intensive glycaemic control, which can be achieved 
via currently available therapies, can be successful in reducing, but not totally preventing the 
onset of diabetic complications (DCCT 1993; UKPDS 1998).   
It is important to note that the therapeutic strategies mentioned above treat 
hyperglycaemia rather than targeting the mechanisms which cause vascular complications (see 
chapter 1.5).  Hence, new therapeutic strategies have focussed on the pathogenesis of diabetic 
vascular complications, such as endothelial dysfunction (see chapter 1.5 and 1.6).   
 
7.2.1  Treatments Targeting Endothelial Dysfunction 
Emerging therapeutic strategies have focussed on targeting the pathways which are 
related to the development of endothelial dysfunction (see chapter 1.6), including the polyol 
pathway, advanced glycation end-product (AGE) formation, oxidative stress, protein kinase C 
(PKC) activation and the altered renin-angiotensin system (RAS)(Figure 7.1).  These are discussed 
in detail below.  It should be noted that many of these therapeutic strategies/drugs are still in 
early experimental stages, and the clinical efficacy is still yet to be established. 
 
7.2.1.1 Targeting the polyol pathway 
As discussed in chapter 1.6.1, the increased flux of glucose through the polyol pathway in 
states of hyperglycaemia can contribute to diabetic vascular complications (Ahmad, He et al. 
2005).  Aldose reductase inhibitors aim to reduce the amount of glucose fluxing through the 
polyol pathway.  Clinical trials involving aldose reductase inhibitors have failed to identify 
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significant benefits of treatment, however the aldose reductase inhibitor minalrestat has been 
used to improve reduced microvascular reactivity in mesenteric arteries from alloxan-induced 
diabetic rats (Akamine, Hohman et al. 2003).  Furthermore, zopolrestat, another aldose reductase 
inhibitor, has also been shown to restore endothelial function in aortae from alloxan-induced 
diabetic rats (Tesfamariam, Palacino et al. 1993).  In contrast, the aldose reductase inhibitor 
ponalrestat had no effect on impaired relaxations to acetylcholine in perfused mesenteric arteries 
from streptozotocin (STZ)-induced diabetic Charles River rats (Taylor, Wickenden et al. 1994).   
 
7.2.1.2 Targeting oxidative stress 
Oxidative stress is a state in which increased levels of reactive oxygen species (ROS) are 
generated in the diabetic vasculature (see chapter 1.6.3), contributing to the development of 
endothelial dysfunction through DNA damage, PKC activation and increasing AGE formation.   
The antioxidants vitamins C and E have been shown to be effective in improving 
endothelial function in aorta from STZ-induced diabetic rats (Cinar, Ulker et al. 2001; Alper, 
Olukman et al. 2006).  Early vitamin E supplementation has been used to improve endothelial 
function in mesenteric resistance arteries from STZ-treated diabetic rats, possibly due to an 
inhibitory effect on PKC (β2 isoform) (Wigg, Tare et al. 2004).  Vitamin E has also shown 
beneficial effects on forearm blood flow in female type 2 diabetic patients (Regensteiner, 
Popylisen et al. 2003).   Vitamin C has been shown to improve angiotensin II-mediated 
endothelial function in human forearm vessels (Ting, Timimi et al. 1996; Hirooka, Eshima et al. 
2003).  However, treatment with vitamin C for three weeks was ineffective in improving 
oxidative stress, blood pressure or endothelial dysfunction in type 2 diabetic subjects (Darko, 
Dornhorst et al. 2002).   
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Alpha-lipoic acid has been used in conjunction with fidarestat, an aldose reductase 
inhibitor with antioxidant properties (Obrosova, Pacher et al. 2005), to successfully treat 
diabetes-induced vascular and neuronal dysfunction in STZ-treated diabetic rats (Yorek, Coppey 
et al. 2004).  A reduction of oxidative stress has also been achieved with the water-soluble 
antioxidant raxofelast which has been shown to improve forearm blood flow, following one week 
of treatment in type 2 diabetic males (Chowienczyk, Brett et al. 2000).   
The formation of peroxynitrite, a damaging ROS in diabetes, can be prevented with 
tetrahydrobiopterin (BH4), which is a rate-limiting cofactor in endothelial nitric oxide synthase 
(eNOS) conversion of arginine to citrulline.  A decrease in BH4 has been demonstrated in 
diabetic animal models, which purportedly leads to eNOS uncoupling and increased peroxynitrite 
formation (Channon 2004).  Administration of BH4 has been shown to correct endothelial 
function in alloxan-diabetic female rats (Akamine, Kawamoto et al. 2006).  Coenzyme Q10 
(CoQ) is also thought to provide potent antioxidant activity by recoupling eNOS, resulting in 
improved endothelial function (Chew and Watts 2004).  Additionally, CoQ has been used in 
conjunction with fenofibrate, an anti-lipaemic agent, to improve endothelial function in forearm 
microvessels (Playford, Watts et al. 2003), and has been used alone to improve endothelial 
function in brachial arteries from type 2 diabetic subjects (Watts, Playford et al. 2002). 
 
7.2.1.3 Targeting AGE formation 
The formation of AGEs leads to endothelial dysfunction by altering intracellular protein 
function, disrupting the cellular matrix and impairing the uptake of low-density lipoproteins and 
apoprotein B which results in foam cell formation and atherosclerosis (Ahmad, He et al. 2005) (see 
chapter 1.6.4).  The AGE inhibitor aminoguanidine has been shown to prevent diabetes-induced 
endothelial dysfunction in STZ-induced diabetic Wistar rats (Ozyazgan, Unlucerci et al. 2000). 
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7.2.1.4 Targeting PKC activation 
PKC isoform-specific inhibitors (particularly β2) provide another therapeutic strategy to 
combat the development of endothelial dysfunction by preventing PKC activation which results in 
altered cell signalling, decreased NO production, angiogenesis and increased vessel permeability 
(Ahmad, He et al. 2005)(see chapter 1.6.2).  LY290181 has been shown to prevent diabetes-induced 
vascular dysfunction by inhibiting transcription factor binding to specific PKC-regulated genes 
involved in vascular function (Birch, Heath et al. 1996).  The β-selective PKC inhibitor LY333531 
has also been shown to potentiate endothelial function in mesenteric arteries from insulin-resistant 
db/db mice (Lagaud, Masih-Khan et al. 2001). 
 
7.2.1.5 Targeting the renin-angiotensin system 
The RAS is an important regulator of blood volume, arterial pressure and vascular 
function (Ahmad, He et al. 2005).  The RAS involves the conversion of angiotensinogen to 
angiotensin I by renin, which is then converted to angiotensin II by angiotensin converting 
enzyme (ACE).  Angiotensin II has many physiological roles, including vasoconstriction, pro-
coagulation, inflammation and vascular remodelling (Ahmad, He et al. 2005).  In the diabetic 
state, the effects of angiotensin II are exacerbated by hyperglycaemia, resulting in decreased 
insulin sensitivity and accelerated development of diabetic vascular complications (Ahmad, He et 
al. 2005).  Losartan, an inhibitor of type 1 angiotensin II receptors has been shown to improve 
endothelial function in the forearm of type 2 diabetic patients (Cheetham, Collis et al. 2000; 
Cheetham, O'Driscoll et al. 2001). 
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7.2.2 EDHF and Gap Junctions as Possible Therapeutic 
Targets 
 
Whilst the therapeutic strategies discussed above certainly look promising, there has been 
little attention directed at targeting EDHF and gap junctions in developing new therapies.  
EDHF is crucial in maintaining vascular function in resistance vessels, and the loss of EDHF has 
been suggested to be involved in the development of diabetes-related microvascular 
complications (Fitzgerald, Kemp-Harper et al. 2005).  The results presented in chapters 3 and 4 
of this thesis show that EDHF is the primary endothelium-dependent vasodilator in the third-
order mesenteric arteries from both the female and male LZR and OZR, and EDHF-impaired 
vasodilatation is impaired in the insulin-resistant female and the type 2 diabetic male OZR.  
These findings indicate that EDHF may be an important therapeutic target in preventing the 
development of endothelial dysfunction in insulin resistance and type 2 diabetes.   
Furthermore, the results presented in chapter 3 showed that the impairment in EDHF-
mediated vasodilatation in the third-order mesenteric arteries was linked with the absence of 
connexin 40-associated gap junction activity in the female OZR.  Further investigation in the 
female mesenteric arteries correlated this impairment with a reduction in connexin 40 mRNA and 
protein levels (chapter 5).  As discussed in chapters 1.3 and 1.8, gap junctions have been 
consistently found to be important in EDHF-mediated responses (Griffith 2004), and a reduction 
in gap junction activity may, at least in some cases, account for the reduced EDHF activity 
demonstrated in insulin resistance and type 2 diabetes.  Therefore, therapeutically targeting 
EDHF or gap junctions may be beneficial in preventing or delaying the onset of endothelial 
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dysfunction and ultimately diabetic-related cardiovascular complications.  This is discussed in 
detail below. 
 
7.2.2.1 Drugs targeting EDHF 
As the nature of EDHF is not completely understood, there have only been a limited 
number of studies investigating treatments that may restore an attenuated EDHF-mediated 
vasodilatation.  However there have been several reports of pharmaceutical agents that indirectly 
improve EDHF activity.  The antioxidant eugenol has been shown to not only improve NO-
mediated vascular function, but also EDHF-mediated vascular function in the sciatic nerve, gastric 
fundus and renal arteries from STZ-induced diabetic rats (Nangle, Gibson et al. 2006).  Evening 
primrose oil has also been used to prevent the development of EDHF-associated endothelial 
dysfunction in mesenteric arteries from STZ-induced diabetic rats (Jack, Keegan et al. 2002). 
The ACE inhibitor temocapril was shown to improve EDHF-mediated vasodilatation in 
mesenteric arteries from eNOS knockout mice.  This improvement was abolished by catalase, 
suggesting the temocapril-induced increase in EDHF activity was due to an increase in hydrogen 
peroxide (H2O2)(Fujiki, Shimokawa et al. 2005).    
A new potential drug shown to upregulate EDHF is 2,5-dihydroxybenzenesulfonate 
(calcium dobesilate).  Calcium dobesilate, which acts via an unknown mechanism (Ruiz, Lorente et 
al. 1997), has been used to fully reverse endothelial dysfunction in human penile resistance arteries 
by potentiating EDHF activity (Angulo, Cuevas et al. 2003; Angulo, Cuevas et al. 2003).  Calcium 
dobesilate is also registered as a treatment for diabetic retinopathy, which has been associated with 
antioxidant properties (Ruiz, Lorente et al. 1997), but may also improve EDHF-mediated 
vasodilatation (Garay, Hannaert et al. 2005). 
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At this time, the underlying mechanism behind therapeutic agents that do benefit EDHF-
associated vascular function in diabetes is unclear, and as the EDHF mechanism of action becomes 
better understood, therapeutic strategies will become more specific.  
 
7.2.2.2 Drugs targeting gap junctions 
Whilst there are many potential EDHF targets, depending on the mechanism of action 
involved (see chapter 1.2.1), gap junctions are consistently found to be involved in EDHF-
mediated vasodilatation, and may provide the „unifying‟ factor, therefore making potentially suitable 
therapeutic target for restoring EDHF activity (Griffith 2004).  The regulation of connexin 
expression, and hence gap junctions as potential therapeutic targets is discussed in chapter 1.3.3.  
To the author‟s knowledge, there are no published studies in the literature describing therapeutic 
agents that target gap junctions for the specific purpose of improving endothelial function in 
diabetes.   
One recent study in rabbit iliac arteries demonstrated that impaired NO-independent 
vasodilatations can be improved with 5-methyltetrahydrofolate (5-MTHF) or BH4 by restoring 
defective myoendothelial electronic signalling (Griffith, Chaytor et al. 2005).   
Rotigaptide (ZP123) was recently developed as an anti-arrhythmic agent, with successful 
results (Haugan, Kjolbye et al. 2005; Clarke, Thomas et al. 2006; Guerra, Everett et al. 2006; 
Hennan, Swillo et al. 2006).  Rotigaptide increases gap junction communication via phosphorylation 
of connexin 43 (Axelsen, Stahlhut et al. 2006), and whilst this drug may not be beneficial in 
improving EDHF function associated with connexin 40 (as found in the experiments presented in 
this thesis), it does provide evidence that modulating gap junction activity can be beneficial in 
treating disease states.  Certainly, the finding that connexin-40 knockout mice demonstrate drastic 
vascular abnormalities (see chapter 1.3.1), identifies a clear potential therapeutic target. 
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Another important study found that cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, 
improves EDHF function in mesenteric arteries from STZ-induced diabetic rats (Matsumoto, 
Kobayashi et al. 2005).  This study followed the finding that impaired EDHF activity in STZ-
treated rats is associated with a decrease in cyclic adenosine monophosphate (cAMP) levels and 
subsequent protein kinase A (PKA) activity, and an increase in PDE3 activity (Matsumoto, 
Wakabayashi et al. 2004).  It is possible that this improvement in EDHF function is related to the 
upregulation of gap junctions through the cAMP/PKA pathway (see chapter 1.3.3.5). 
It is interesting to note that the insulin-sensitising PPARγ agents pioglitazone and 
troglitazone have been shown to ameliorate tumour necrosis factor α (TNFα)-associated insulin 
resistance in hyperlipidaemic mice and OZRs (Okuno, Tamemoto et al. 1998; Iwata, Haruta et al. 
2001).  As discussed in chapter 1.3.3.3, increases in TNFα have been associated with the down-
regulation of connexins 37 and 40 (van Rijen, van Kempen et al. 1998), and hence it is possible 
that the restorative effect may involve restitution of gap junction activity.   
In regards to gap junctions, the ultimate goal would be to find a specific therapeutic 
system, which will target the biosynthesis, assembly, degradation or the transcriptional and 
translational controls of specific connexins (Beyer and Berthoud 2002; Brink 2002; Lagaud, 
Davies et al. 2002).  It should also be noted that the therapeutic strategies targeting PKC 
activation (see 7.2.1.4) may also be beneficial in improving gap junction activity, as PKC is 
involved in the regulation of connexins (see 1.3.3.6). 
 
7.3 Future Directions 
The findings presented in this thesis lead to many potential avenues of investigation: 
1. EDHF characterisation 
2. Gap junction localisation 
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3. Vasoconduction 
4. Gender comparison of EDHF and gap junctions in the LZR and OZR 
5. Alternative models of insulin resistance 
6. Regulation of connexins and gap junctions 
These are discussed in detail below. 
 
7.3.1 Characterisation of  EDHF in the Zucker Rat 
As discussed in chapter 1, EDHF is characterised by the hyperpolarisation and 
vasodilatation of the smooth muscle cells (Feletou and Vanhoutte 1996).  The experiments 
described in this thesis have identified EDHF functionally by using the calcium-activated potassium 
channel inhibitors apamin and charybdotoxin or apamin and 1-[(2-chlorophenyl)diphenylmethyl]-
1H-pyrazole (TRAM-34) to block the vasodilatation response.  However these experiments have 
failed to identify or study the hyperpolarisation action of EDHF.  The use of electrophysiology to 
measure changes in polarisation of the smooth muscle cells, and also endothelial cells, would have 
contributed greatly to the understanding of EDHF in the blood vessels studied, and could have 
been used to support the functional data presented in this thesis.   
Another area of EDHF characterisation to be further investigated relates to the role of gap 
junctions.  As discussed in section 7.1, gap junction inhibitors failed to fully inhibit EDHF 
responses in third-order mesenteric arteries from female LZRs and OZRs, although they do 
significantly reduce responses in the LZRs.  It should also be noted that out of the three connexin-
mimetic peptides studied only the 40gap27 peptide has any effect on EDHF-mediated responses.  It 
would be interesting to study EDHF-mediated responses in the presence of a combination of these 
inhibitors.  Studies have shown that some vessels require a combination of gap peptides to cause 
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significant attenuation of the relaxation response, in which individual peptides have either no or 
negligible effects (Chaytor, Martin et al. 2001).   
In addition to gap peptides, sulfaphenazole was used to determine if EETs played a role 
in EDHF-mediated relaxations in third-order mesenteric arteries from Zucker rats.  Whilst 
sulfaphenazole had no effect on responses to ACh in the male or female LZR or OZR third-
order mesenteric arteries, the use of other EET-specific CYP inhibitors are required to confirm if 
EETs are involved in EDHF-mediated relaxations.  Aside from alternative CYP inhibitors such 
as proadifen, fluconazole, clotrimazole or 17-Octadecynoic acid (17-ODYA), there are also 
specific EET competitive antagonists available.  EET antagonists such as 14,15-epoxyeicosa-
5(Z)-enoic acid (EEZE) and 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonylimide (EEZE-mSI)  
have been used successfully to inhibit EDHF responses in porcine (Weston, Feletou et al. 2005) 
and bovine (Gauthier, Deeter et al. 2002; Gauthier, Jagadeesh et al. 2003) coronary arteries, mice 
gracilis arteries  (Krummen, Falck et al. 2005), and rabbit renal arteries (Wang, Borrego-Conde et 
al. 2003).  The limited number of Zucker rats available precluded the conduct of experiments 
with alternative EET inhibitors. 
Apart from gap junctions and EETs there are several other EDHF candidates to 
investigate.  Two possibilities, as discussed in chapter 1.2.1, include reactive oxygen species 
(ROS) and C-Natriuretic Peptide (CNP).  Whilst evidence suggests that ROS are not involved in 
EDHF responses under normal physiological conditions, it has been suggested that ROS, 
especially H2O2, may play a role in EDHF responses in certain disease states (Shimokawa and 
Morikawa 2005).  As insulin resistance and type 2 diabetes are associated with an increase in ROS 
(Giugliano, Ceriello et al. 1996; Son, Whalin et al. 2004; Ceriello 2006; Jay, Hitomi et al. 2006), 
there is a possibility that H2O2 may be involved in EDHF responses.  In order to determine if 
H2O2 is involved in EDHF responses, inhibitors such as catalase, superoxide dismutase (SOD) or 
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tiron can be used.  Catalase has been shown to inhibit EDHF-attributed relaxations and 
hyperpolarisations in small mesenteric arteries from eNOS knockout mice (Matoba, Shimokawa 
et al. 2000), canine small coronary arteries (Yada, Shimokawa et al. 2003), and human mesenteric 
and coronary arteries (Matoba, Shimokawa et al. 2002; Miura, Bosnjak et al. 2003; Yada, 
Shimokawa et al. 2003).  SOD or the SOD-mimetic tiron can also be used to dismutate H2O2, 
although these compounds have been largely unsuccessful in blocking EDHF responses 
(Pomposiello, Rhaleb et al. 1999; Ellis, Pannirselvam et al. 2003; Tanaka, Kanatsuka et al. 2003; 
Hatoum, Binion et al. 2005).   
 
7.3.2 The localisation of  connexins within the vasculature 
in the Zucker rat 
A limitation of the studies described in this thesis relates to the lack of morphology data to 
support the findings of reduced connexin 37 and 40 protein and mRNA levels in the mesenteric 
arteries.  Whilst the protein and mRNA studies showed a reduction in connexin 37 and 40 protein 
and mRNA levels (Chapter 4), the localisation of those connexins within the vessel wall cannot be 
determined by these methods.  Immunohistochemistry analysis of the third-order mesenteric 
arteries is vital in understanding the type of gap junctions affected by the reduction in these 
proteins.  Connexins 37 and 40 are largely associated with endothelial homocellular coupling as well 
as myo-endothelial heterocellular coupling, connexin 43 being associated with smooth muscle cell 
homocellular coupling as well as myo-endothelial heterocellular coupling (van Kempen and 
Jongsma 1999; Severs, Rothery et al. 2001; Ujiie, Chaytor et al. 2003).   The use of electron 
microscopy would also be beneficial in identifying the size and the density of gap junctional 
plaques. 
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7.3.3 The effect of  insulin resistance and type 2 diabetes 
on vasoconduction in the Zucker rat 
The importance of gap junctions in vasoconduction was discussed in detail in chapter 1 
(1.3.2).  Briefly, these studies involve using microiontophoresis to deliver ACh to a localised area 
of an arteriole, a defined distance (up to 2000 m) from the recording sites (Figueroa, Paul et al. 
2003; Crane, Neild et al. 2004).  Connexin 37- and 40-associated gap junctions has been 
demonstrated to be involved in the conduction of vasodilatation along the endothelium of mouse 
cremaster arterioles (Looft-Wilson, Payne et al. 2004) and hamster feed arteries (Segal, Welsh et 
al. 1999; Emerson and Segal 2000).  Additionally, vasodilatation conductance in hamster cheek 
pouch arterioles have been shown to involve both endothelial and smooth muscle layers (Welsh 
and Segal 2000; Sandow, Looft-Wilson et al. 2003), associated with gap junctions consisting of 
connexins 37, 40 and 43 (Sandow, Looft-Wilson et al. 2003).   Studies in connexin 40-deficient 
mice have also identified the importance of connexin 40 in the propagation of vasodilatation and 
vasoconduction responses (de Wit, Roos et al. 2000; de Wit, Roos et al. 2003; de Wit 2004). 
The vasodilatation responses observed in the experiments described in chapter 3 followed 
the superfusion of ACh; this form of administration masks any level of propagation, as it 
stimulates each individual endothelial cell.  Therefore, although only connexin 40 was identified 
to play a role in EDHF-mediated responses, other connexins may play a role in the propagation 
of the EDHF response.   Therefore, whilst the reduction in connexin 37 protein and mRNA 
levels didn‟t appear to be involved in the EDHF-mediated vasodilatation responses to ACh in the 
third-order mesenteric arteries, it is possible that connexin 37 is involved in the propagation of 
the EDHF response along the vessel wall, either through the endothelial or smooth muscle layer. 
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7.3.4 Gender comparison of  EDHF and gap junctions in 
LZRs and OZRs 
The experiments described in chapter 4 formed the beginning of an interesting 
investigation, by demonstrating that endothelial dysfunction is more advanced in the type 2 
diabetic male OZR, compared with the insulin-resistant female OZR.  The next step would be to 
identify the role of gap junctions in the male LZR and OZR preparations, and compare these 
results with those seen in the females.  Protein and mRNA comparisons would also be beneficial 
in determining if the reduction in connexin levels is greater in the male OZR than the female 
OZR.   
 
 
7.3.5 Alternative animal models of  insulin resistance and 
type 2 diabetes 
The aim of the experiments described in chapter 6 was to establish an alternative model 
of insulin resistance (fructose-fed rats), and compare the vascular characteristics with those 
demonstrated in the OZR.  The small pilot study detailed in chapter 6 showed that whilst an 8-
wk feeding period of a high-fructose diet led to the development of insulin resistance, endothelial 
function was not compromised.  Whilst a longer feeding period may see the development of 
endothelial dysfunction associated with a more advanced stage of insulin resistance, it may be 
more beneficial to feed a high fat/high fructose diet which has been reported to induce insulin 
resistance (Barnard, Youngren et al. 1995; Chalkley, Hettiarachchi et al. 2002).  This diet is also a 
Chapter 7 
7-20 
 
closer match to the „fast-food‟ diets that increase the risk of developing insulin resistance in 
humans.  There are several other models of insulin resistance and type 2 diabetes, including the 
Otsuka Long-Evans Tokushima Fatty (OLETF) rat, C57BL/KsJ-db/db and Tally-Ho mice and 
diet-induced rat models of insulin resistance and type 2 diabetes, which were discussed in chapter 
1 (see chapter 1.7), and would be a possible avenue for further investigation.   
 
7.3.6 The regulation of  gap junctions and connexins 
This study has demonstrated that connexin 37 and 40 protein and mRNA levels are 
decreased in mesenteric and renal arteries from the female OZR (Chapter 3), however the 
mechanism behind this decrease in mRNA and protein levels is not known.  As discussed in 
chapter 1 (1.3.3) the regulation pathways of connexins have not been studied in depth, especially 
in regards to connexins 37 and 40.  Tumour necrosis factor α (TNFα) has been shown to 
downregulate connexins 37 and 40 mRNA levels in cultured cells, associated with a 40% decrease 
in dye transfer (van Rijen, van Kempen et al. 1998).  This study is of particular interest, as TNFα 
is known to be over-expressed in insulin resistance (Halle, Berg et al. 1998; Peraldi and 
Spiegelman 1998; Hotamisligil 1999; Hotamisligil 1999; Borst 2004) and type 2 diabetes (Argiles, 
Lopez-Soriano et al. 1994; Moller 2000).    Hyperhomocysteinaemia has also been correlated with 
the down-regulation of connexin 40 in renal arteries from hyperhomocysteinaemic (HHcy) rats, 
which was accompanied by a decrease in EDHF-mediated vasodilatation (Heil, De Vriese et al. 
2004).  This is also a relevant study, as high homocysteine levels in type 2 diabetes can increase 
the risk of developing cardiovascular complications (Brown 2000; Huijberts, Becker et al. 2005).  
An investigation into the association between TNFα, homocysteine and other possible 
regulating factors, such as tyrosine kinase, protein kinases and vascular endothelial growth factor 
(VEGF) (see chapter 1.3.3), would open up an entirely new area of research, and would provide 
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important information regarding the gap junctional changes in insulin resistance.  By 
understanding the underlying mechanisms, the optimal therapeutic target can be identified. 
 
7.4 Conclusion 
The findings from this thesis have demonstrated that EDHF-attributed endothelial 
dysfunction in OZR mesenteric arteries are associated with a reduction in connexin 40 protein and 
mRNA levels.  These data complement the functional data showing that connexin 40-associated 
gap junctions contribute to EDHF-derived responses to ACh in third-order mesenteric arteries 
from the LZR, but not the OZR.  This suggests that gap junctions may be a suitable target for 
emerging therapeutic strategies. 
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AR inhibitors Aminoguanidine
Diabetic Vascular Complications
Altered activity of the intracellular molecules, gene expression and protein function
Vascular dysfunction
Antioxidants PKC inhibitors
RAS
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Figure 7.1: Therapeutic strategies 
Derived from (Ahmad, He et al. 2005) 
AR=aldose reductase, AGE=advanced glycation end product, PKC=protein kinase C, RAS=renin-angiotensin system, ACE=angiotensin converting enzyme
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8. Appendices 
8.1 Appendix 1 
 
 
Example calculation of the final volume of microvessel lysate sample required to load 30µg of protein into each well. 
1. Determine the volume of diluent to add to sample lysate (Vd) 
 Vd = [Pi x Vs/Pr] - Vs 
 where, 
Pi = initial protein concentration, µl/mg (obtained from spectrophotometer readout of 
protein assay) x dilution factor. 
  Vs = starting volume of sample lysate, µl 
   Pr = required protein concentration x 100 
 Example:   
    Pi= 2116 µl/mg x 10 
  Vs = 10 µl 
   Pr = 30 x 100 
 So, Vd = [21160 x 10/3000] – 10 
           = 60.53 µl of diluent to add to the 10 µl lysate sample 
2. Determine the volume of reducing buffer to add to sample lysate (Vr) 
  Vr = (Vs + Vd) x 0.5 
 Example:   
  Vr = (10 + 60.53) x 0.5 
       =35.26 µl 
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3. Determine final protein concentration in sample after the diluent and reducing buffer are 
added (Pf) 
  Pf = [((Vs+Vd)/(Vf)) x Pr]/100 
  where, 
  Vf = final volume of sample lysate (Vs + Vd + Vr) 
 Example:   
  Pr = [((10+60.53)/(105.79)) x 3000]/100 
      =19.99 
4. Determine volume of sample to load into well (Vl) 
  Vl = [Pr/Pf] x 10  
  Example:  
  Vl = [30/19.99] x 10 
       =15 µl 
  So, 
  In order to load 30 µg of protein into wells, 15 µl is required of a microvessel lysate sample 
with an initial protein concentration of 2116 µl/mg which has been treated with diluent and 
reducing buffers. 
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